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There are a subset of cancers that since their initial discovery and early efforts to develop 
treatments, still have a poor prognosis. These include Small cell lung cancer, Neuroblastoma 
and Glioblastoma and together they contribute to a large percentage of human cancer 
deaths. Efforts now focus on identifying novel targets that drive the initiation and 
development of these cancers to advance therapeutics in an advance towards personalised 
cancer therapies. 
Aberrant post-transcriptional gene regulation has been implicated in numerous diseases 
including Neurodegeneration and Cancer. The family of Hu proteins consists of the neuronal 
HuB, HuC and HuD and ubiquitously expressed HuR. They are proto-type RNA-binding 
proteins functioning in all aspects of RNA processing including RNA stability, alternative 
splicing, polyadenylation, localisation and nuclear export. Hu proteins that are ectopically 
expressed or overexpressed in Small cell lung cancer (SCLC), Neuroblastoma and 
Glioblastoma have been linked to tumour progression. 
Little research has been done to analyse how Hu proteins contribute to the development 
and progression in the described cancers. Silencing Hu proteins using siRNA interference 
provides an opportunity to analyse the effect of decreased Hu expression on cellular 
properties and the change in post-transcriptional regulation of target RNA that may play a 
role tumour formation and progression. 
Effects of cell migration and cell viability were assessed in vitro and revealed HuB and HuC 
proteins to be key regulators of these processes.  A decrease of HuB gene expression by 
RNA interference resulted in an increase in migration, in Glioblastoma cells U87-MG and the 
Neuroblastoma cell lines SH-SY5Y and SK-N-AS. Whilst a decrease in HuB and HuC gene 
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expression showed an increase in viability and migration of the Neuroblastoma cells SH-
SY5Y and Glioblastoma cells U87-MG suggesting these proteins act to control these factors 
in the cancers. 
Individual and combined Hu gene knockdowns with siRNA also revealed regulatory and 
compensatory interactions of the Hu family members. HuR protein was found to positively 
regulate the expression of HuC in all cell models. In SH-SY5Y Neuroblastoma cells and U87-
MG Glioblastoma cells, additional similarities were observed. HuR protein positively 
regulated HuD mRNA and HuC negatively regulated HuR mRNA. The HuR and HuC 
interactions suggests they can regulate each other’s protein levels ensuring an abundance of 
each protein in cells. 
Molecular screening of a set of mRNA targets that have been described to contribute to the 
development of each cancer revealed many changes. From the array of targets that changed 
after knockdowns, genes with a high expression fold-change and influenced by more than 
one Hu protein were chosen to confirm the regulation by Hu proteins. Many of these targets 
were identified as members of the MAPK signalling pathway. 
Further analysis including a complete knockout of the Hu proteins is needed to confirm the 
role of Hu proteins in regulating members of the MAPK signalling pathway and how the 
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1.1 Gene regulation  
The human genome encodes approximately 25,000 genes, organised into 23 chromosome 
pairs, made of over three billion deoxyribonucleic acid (DNA) base pairs. Whilst humans have 
the same sequence homology as plants and animals, there is greater diversity in appearance, 
properties and functions between organisms and within species due to differential ways 
genes are regulated (Phillips 2008).  
The enormous complexity and dynamic structure of the human genome emphasises the 
need for its regulation.  Regulation of eukaryotic gene expression is fundamental for 
synchronised synthesis, assembly and localisation of cells structure (Orphanides and 
Reinberg 2002). It is a multi-step process regulated at every level, from DNA to ribonucleic 
acid (RNA) and to protein. These processes begin in the nucleus and then continue in the 
cytoplasm following mRNA export.  
These events regulate processes including transcription, RNA processing, mRNA transport, 
turnover, storage, and translation. Proteins also undergo post-translational regulatory 
mechanisms during modification events including phosphorylation, ubiquitination and 
methylation (Maniatis and Reed 2002).  




Figure 1.1. Gene regulation from DNA to protein. DNA is regulated at a transcriptional level, to ensure 
the quality and number of mRNA transcripts. The pre-mRNA is subjected to capping, splicing and 
polyadenylation during post-transcriptional control. The mature mRNA is then transported to the 
cytoplasm where it sustains translational regulatory events during protein production and further 
post-translational modifications. 
 
In the nucleus, transcription factors recruit RNA polymerase II that bind upstream of a 
promoter in a gene sequence regulating RNA synthesis. The produced messenger RNA 
(mRNA) is processed by a large amount of RNA-binding proteins (RBPs) through post-
transcriptional events which prepares the mRNA for export through nuclear pores. In the 
cytoplasm, the mRNA is localised to regions consistent with its fate. mRNA can be destined 
for exonuclease-mediated degradation or when colocalised to translation factors and 
ribosomes, is used as a template for protein synthesis. Following translation, proteins still 
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endure further modifications such as phosphorylation and methylation. These processes 
combined, allows cells to respond to physiological stimuli (Glisovic et al. 2008, Yao et al. 1993). 
1.2 Post-transcriptional gene regulation 
Post-transcriptional gene regulation is a highly-coordinated process controlled by multiple 
mechanisms to ensure cellular homeostasis and contribute to organismal complexity (Glisovic 
et al. 2008). Pre-mRNA produced from RNA synthesis undergoes post-transcriptional gene 
regulatory events including 5′ capping, 3′ polyadenylation, cleavage, pre‐mRNA splicing, 
export, mRNA decay, and translation, ultimately increasing the diversity of a single gene. 
Several ubiquitous molecules and cell-specific trans-acting factors participate in the processes 
including RNA-binding proteins (RBPs), non-coding RNAs (ncRNAs) and microRNAs (miRNAs) 
(Khabar 2017). Modified pre-mRNA is then transported to the cytoplasm and translated into 
a protein (Glisovic et al. 2008). 
1.2.1 5′ capping  
The first modification the pre-mRNA experiences is 5'-capping where a 7-
methylguanosine cap (5′ m7G cap) is added to the beginning of the RNA transcript. The 5′ 
m7G cap is evolutionarily conserved in eukaryotic mRNA. It allows the recruitment of cellular 
proteins that regulate pre-mRNA processing and nuclear export including c-myc, involved in 
cell proliferation (Ramanathan et al. 2016). 
26 
 
1.2.2 Alternative splicing 
Alternative splicing occurs in all eukaryotes and is crucial for the development, differentiation 
and complexity of a cell. This diverse process determines the binding potential, intracellular 
localisation, enzymatic activity and protein stability of many proteins (Stamm et al. 2005). 
Alternative splicing allows the production of cell specific isoforms from a single gene in 
response to external stimuli (Roméria da Silva et al. 2015). A schematic diagram of this is 
shown in Figure 1.2. 
All genes are composed of long non-protein coding sequences called introns and shorter 
untranslated/coding sequences called exons. Alternative splicing joins exons or portions of 
exons by removing intronic sequences in a pre-mRNA transcript. The diverse isoforms can 
differ in composition and function determined by which exons are spliced together and 
translated (David and Manley 2010).  
Selection of alternative splice sites is determined by the spliceosome (Pagliarini et al. 2015). 
The spliceosome is a functionally dynamic, multi-megadalton ribonucleoprotein composed of 
small nuclear RNA (snRNA) and ribonucleoproteins (RNPs). cis-sequence transcripts in the 
core spliceosome bind to trans-acting RBPs that enlist factors and enzymes to initiate the 




Figure 1.2: Alternative splicing of proteins. During transcription, a copy of DNA is made producing a pre-mRNA transcript. Alternative splicing of this transcript 




Polyadenylation is a complex mechanism to regulate gene expression in all eukaryotic mRNAs 
except histones. Polyadenylation occurs at the 3’ end of pre-mRNA in the nucleus. It is a 2-
step reaction involving the cleavage of the 3’ end and addition of the poly (A) tail to the newly 
generated 3’ end (Erson-Bensan 2016). Polyadenylate, also known as the poly(A) tail is around 
100-200 nucleotides long and acts to protect the mRNA from degradation by phosphatases 
and nucleases (Ray and Fry 2015).  
The process involves a multiprotein machinery consisting of subunits of cleavage factors; 
polyadenylation stimulatory factor (CPSF), cleavage stimulatory factor (CSTF) and several 
other cleavage factor complexes. CPSF is the main regulator of poly(A) signal selection, a 15-
30 nucleotide sequence upstream of the cleavage site. The poly(A) signal sequence, AAUAAA, 
is highly conserved in mammals and present in 70% of human genes (Erson-Bensan 2016, 
Derti et al. 2012). Differential selection of poly(A) sites by polyadenylation and/or splicing 
factors can alter gene expression and implement significant physiological changes. RBPs play 
a crucial role in polyadenylation as they regulate the stability of the mRNA transcript during 
the process (Zhu 2009).  
1.2.4 mRNA export 
Transport of mRNA from the nucleus to the cytoplasm is crucial for the further processing of 
mRNA. The synthesised mature mRNA associates with various proteins forming a messenger 
ribonucleoprotein (mRNP) particle. The mechanism of nuclear mRNA export involves 
principal transport factors that allow only complete, functional mRNA to be transported to 
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the cytoplasm (Katahira 2015). Once in the cytoplasm, mRNA is either translated into 
protein, stored or recognised by degradation machinery depending on cell environmental 
signals (Zhu 2009). 
1.2.5 mRNA stability 
mRNA transcript stability is detrimental in the control of gene expression. It is mostly 
governed by AU-rich instability elements (AREs) and cis-acting elements located in the 3’ 
untranslated region and their interactions with trans-acting factors including RBPs. These 
interactions are initiated by specific intra-cellular and extra-cellular signals. AREs are 
destabilised thereby increasing the stability and half-life of the mRNA (Caput et al. 1986). 
Stability can also be affected by polyadenylation, mRNA primary and secondary structure, 
rate of translation and intracellular location (Bolognani et al. 2012).  Mutations in the coding 
region or nonsense mutation in 5’-UTR of mRNAs can result in truncated mRNAs that then 
contain an instability determinant affecting mRNA half-life (Ross 1995).  
1.2.6 mRNA localisation 
Eukaryotic cells contain various organelles that implement different functions. The 
localisation of mRNA depends on the transcript and its proteins function in certain specialised 
roles that relate to specific subcellular compartments (Martin and Ephrussi 2009). Some types 




1.2.7 mRNA decay 
RNA decay rate is dependent upon the mRNA sequence or structural elements within it. Poly-
A tail protects mRNAs from rapid or indiscriminate degradation as the first step in mRNA 
decay is deadenylation. cis-acting regulatory sequences, like GU-rich elements can regulate 
RNA decay in a similar manner trans-acting sequences (Halees et al. 2011). 
There are multiple RNA decay pathways and together they control the quality of gene 
expression. Pathways assesses properties crucial for functionality such as structural integrity 
or the presence of complete open reading frames. Upon initiation of mRNA decay, transcripts 
are degraded rapidly (Ghosh, Shubhendu and Jacobson 2010). 
1.3 Aberrant gene regulation in the development of human disease  
Maintenance of cell homeostasis including cellular growth, proliferation and differentiation 
are tightly managed processes activated when biological events occur including wound 
healing, blood cell formation, immune cell expansion and tissue regeneration (Campos-Melo 
et al. 2014). The intricate processes of cell homeostasis, the complex nature of gene 
regulation and its impact on cellular physiological development is rationale for the increased 
possibility for deleterious mutations, polymorphisms and deregulation to occur (Faustino et 
al. 2003). Mutations can lead to aberrant function of the gene expression regulators RBPs, 
microRNAs (miRNAs) and non-coding RNAs (ncRNAs). This results in altered gene expression 
levels and abnormal protein aggregation that impacts cellular function as displayed in Figure 
1.3 (Fredericks et al. 2015, Lukong et al. 2008, Gerstberger et al. 2014). Aberrant gene 
regulation is implicated in the pathophysiology of diseases, including neurodevelopmental 
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disorders, neurological diseases and cancer (Cooper et al. 2009, Wurth 2012, Yano et al. 
2016).  
Aberrant splicing, a process controlled by RBPs, produce differential mRNA transcripts that 
translate to proteins with aberrant function. This allows inhibited cell death, uncontrolled 
proliferation and decreased response to anti-apoptotic factors in cancer, or excessive 
neuronal cell death in neurodegenerative diseases (Driver 2012, Zaharieva et al. 2012).  
Alternative splicing contributes to functional complexity in normal cell homeostasis and 
influences tumour cell progression in cancer. Of all the post-transcription regulatory events, 
alternative splicing produces the most diverse outcomes. Whilst proto-oncogenes are largely 
associated with spontaneous mutation, activation of such genes can also occur through 
splicing events. The flexibility of remodelling the proteome is advantageous to cancer cells by 
producing proteins with antagonistic functions or excess expression levels that contribute to 
the growth and spread of the tumour (David and Manley 2010). Exon skipping produces 
truncated proteins with reduced or no function. Intron retention results in non-coding regions 
being translated, whilst use of alternative splice sites gives rise to a change in the protein 
composition or alteration to the proteome (Fredericks et al. 2015).  





Figure 1.3: Deregulation of alternative splicing factors influences tumorigenesis. Aberrant changes 
in the regulation of alternative splicing can influence overexpression or aberrant function of splicing 
factors promoting the common traits of cancer formation and progression, angiogenesis, invasion, 
metastasis and evasion of cell death. Key: E-exon; RBP-RNA-binding protein. 
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Apoptosis is a result of many normal cellular pathways that many cancer cells are able to 
evade (Letai 2008). Alternative splicing of apoptosis-associated genes is regulated by RBPs. 
This results in isoforms with differentiated roles that are pro-apoptotic or anti-apoptotic 
proteins. A balance of these proteins achieves a regulatory mechanism for maintaining cell 
death in normal cells. In cancer cells, aberrant splicing patterns can result in fewer pro-
apoptotic isoforms causing prolonged survival (Schwerk and Schulze-Osthoff 2005). 
FOX-2 (RBM9) is an RBP paralog of the brain- and muscle-specific splicing factor FOX-1 
(A2BP1). FOX-2 is an upstream master regulator of splicing regulators. In ovarian tumours, 
FOX-2 is down regulated three-fold compared to normal ovarian tissues resulting in disrupted 
splicing events. Consequently, this leads to increased cell proliferation. In breast cancer, FOX-
2 influences 50% of splicing events particularly of genes involved in EMT (Venables et al. 
2009).  
Cyclin D1 is a key regulator of G1 phase progression of the cell-cycle. Cyclin D1 endures 
alternative splicing to produce Cyclin D1a and D1b, of which D1a is localised in the nucleus 
and the cytoplasm but D1b is found only in the nucleus (Betticher et al. 1995). Cyclin D1b is 
upregulated in breast and prostate cancer where nuclear Cyclin D1b expression is indicative 
of a more oncogenic form (Burd et al. 2006, Alt et al. 2000). 
Caspase-2 is a highly conserved cysteine protease and regulator of apoptosis initiation and 
execution (Puccini et al. 2013). It is alternatively spliced to produce a proapoptotic isoform 
called exon 9-lacking caspase-2L, and a antiapoptotic isoform exon 9-containing caspase-2S. 
Aberrant splicing patterns lead to an imbalance of these two factors and in some cases, it 
favours the cancers growth  (Iwanaga et al. 2005). Caspase 2 is often seen depleted in 
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Leukaemia, resulting in an increased survival of cells, particularly in response to 
chemotherapeutic agents (Ho et al. 2009). 
The B-cell lymphoma (BCL2) family of proteins are responsible for the regulation of the 
mitochondrial or intrinsic apoptotic response. Increased expression of anti-apoptotic BCL-2 
family proteins is observed in many cancers including breast and prostate cancer. 
Overexpression occurs due to chromosomal translocations, gene amplification, increased 
gene transcription, and/or altered post-translational processing (Hata et al. 2015). Alternative 
splicing of Bcl-x produces two distinct variants, Bcl-xL and Bcl-xS. Bcl-xL has a longer sequence 
and inhibits apoptosis, whilst Bcl-xS has a shorter sequence and activates apoptosis (Boise et 
al. 1993). Bcl- xL is overexpressed in colorectal cancer (Scherr et al. 2016). 
1.4 RNA-binding proteins 
The family of RNA-binding proteins (RBPs) diversely function as primary regulators of gene 
expression, playing essential roles in RNA splicing, export to the cytoplasm, translation and 
stability ultimately controlling the fate of RNAs (Glisovic et al. 2008). Until 2014 1542 RBPs 
were documented in the mammalian genome (Gerstberger et al. 2014). 
RBPs contain various structural motifs where RNA molecules interact directly with specific 
sequences or structures. There are several types of motifs, including K homology domain, Sm 
domain and zinc finger domain. The most abundant protein domain in eukaryotes is the RNA 
recognition motif (RRM) (Maris et al. 2005). The human genome has 497 genes coding for 
proteins containing RRMs. RRMs consist of 80-90 amino acid residues and can be present in 
single or multiple copies within a protein. RRMs are arranged specifically to achieve diverse 
functionality through their versatility and structural flexibility. This allows RBPs to control the 
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diversity of many different transcripts (Pereira et al. 2017). The target specificity of RBPs is 
influenced by the sequence length and type of ARE, the cellular environment and any 
posttranslational modifications to the RBP itself (Khabar 2017).   
The localisation of the RBPs in the cell is also crucial to their regulatory role in post 
transcriptional gene regulation (Zaharieva et al. 2015a). RBPs can be found in the nucleus or 
cytoplasm and translocate by shuttling between the two (Fan and Steitz 1998). In the nucleus, 
RBPs exist as heterogeneous ribonucleoprotein particles (hnRNPs) that form complexes with 
pre-mRNA. In the cytoplasm, RBPs influence mRNA stability and turnover allowing cells to 
adapt to environmental changes and increase cell survival (Bronicki and Jasmin 2013).  
RBPs can translocate between the nucleus and cytoplasm as a result of cellular stress 
including UV irradiation and hydrogen peroxide (H2O2) both of which induce oxidative stress 
(Wang et al. 2000), heat shock (Gallouzi et al. 2000), nutrient deficiency (Yaman et al. 2002) 
or energy depletion (Jeyaraj et al. 2005).  
Proteins including importins and exportins facilitate the export of macromolecules including 
RNA and proteins across the nuclear membrane to the cytoplasm. Protein sequences can 
contain nuclear localisation signals. Importins and Exportins can bind to these sequences 
initiating translocation to or from the nucleus in a GTP-dependent reaction against a 
concentration gradient. This mechanism could explain the ability of RBP to shuttle between 
the nucleus and cytoplasm although further research would be required to clarify this (Lange 
et al. 2007). 
miRNAs are a conserved family of about 22 nucleotide-long noncoding RNAs. In the human 
genome over 2000 miRNAs have been discovered. They regulate broad target networks and 
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influence diverse biological roles controlling one third of the genes in the genome (Hammond 
2015). Like RBPs, miRNA bind directly to adenylate/uridylate-rich elements (AREs), controlling 
mRNA decay and translating RBPs (Agami 2010, Khabar 2017). RBPs and miRNAs interact with 
each other to cooperate in a complex or compete for specific binding sites on mRNA 
transcripts. This cooperation or antagonism regulates PTGR processes (Khabar 2017).  
Another role of RBPs is as regulators of miRNA biogenesis (Fig. 1.4). RBPs function in every 
stage of miRNA formation from primary miRNA processing to formation of RNA-induced 
silencing complexes (RISC) (Loffreda et al. 2015).  
RNA Polymerase II consists of 12 RBP subunits and is responsible for the synthesis of the 
primary-miRNA (pri-mRNA) (Ha and Kim 2014). The stem-loop structure of the pri-miRNA is 
cleaved by p68, a dimer composed of two subunits, the RNase III enzyme DROSHA and its 
essential cofactor DGCR8 (Denli et al. 2004). The released hairpin called precursor-miRNA 
(pre-miRNA) is exported to the cytoplasm by Exportin-5 (Yi et al. 2003). DICER converts the 
pre-miRNA into a mature 22nt miRNA of which one strand is integrated into the RNA-induced 
silencing complex (Hutvágner et al. 2001). RISCs are a family of ribonucleoprotein complexes 






Figure 1.4: Biogenesis of canonical microRNAs. In the nucleus, pri-miRNA is cleaved by p68 aided by 
RNA polymerase II and RBPs. The pre-miRNA is then transported to the cytoplasm by Exportin 5. The 





1.4.1 RNA-binding proteins implicated in disease 
Human neurological disorders are often related to irregular function of RNA-binding proteins. 
For example, Fragile X syndrome is caused by a trinucleotide repeat (CGG) expansion in the 
5′ UTR of the fragile X mental retardation (FMR1) gene. This gene codes for the RNA-binding 
protein, FMR1 protein in which the mutation results in the loss of protein function (Chelly and 
Mandel 2001).  
Similarly, Myotonic dystrophy is caused by a trinucleotide repeat (CTG) in the 3′UTR of the 
DMPK gene, coding for myotonic dystrophy protein kinase. In vitro experiments have shown 
that once the expanded trinucleotide repeat is transcribed, it folds into very stable and long 
RNA hairpin structures, that then accumulate in the nucleus.  This alters the function of RBPs 
including Muscle blind-like protein 1 (MBNL) and CUG binding protein 1 (CUGBP1). MBNL was 
shown to have a loss of function (Lee and Cooper 2009), whilst the mutation causes hyper-
phosphorylation and stabilisation of  CUGBP1 initiating aberrant activation of the Protein 
kinase C pathway (Kuyumcu-Martinez et al. 2007).  
NOVA-1 RBP has been implicated in paraneoplastic neurodegenerative disorders 
(Buckanovich and Darnell 1997). NOVA-1 expression is restricted to the brain. Therefore 
abnormal expression causes an immune response where auto-antibodies attack NOVA-1 in 
the normal expression areas of the brain and spinal cord (Yang et al. 1998).  
Aberrant transcriptional events, deregulation of RBPs, abnormal gene amplifications and 
alterations to signalling events contribute towards cancer progression (Croce 2008, Wang et 
al. 2015). Gene regulatory events including splicing, polyadenylation, translation, mRNA and 
protein stability are altered during the development of cancers and can influence the diseases 
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initiation and progression. PTGR events are therefore considered a ‘convergence point of 
oncogenic signalling’ (Yan and Higgins 2013).  
Several studies have highlighted correlation between aberrant RBP expression and cancer 
development. RBPs function as RNA regulatory factors in gene regulation is pathologically 
disrupted in cancer. Due to RBPs structurally flexible binding domains, they can regulate a 
wide range of mRNA sequences controlling their stability. Some of these transcripts can code 
for tumour-related proteins (Wang et al. 2015). They can therefore contribute to the complex 
network that enables tumour development (Eberhardt et al. 2016). Defects in RNA regulation 
include altered protein expression levels, abnormal aggregation, gene mutations and 
translocations and gain-of-function (oncogene). These changes deregulate important 
developmental pathways that drive cell proliferation, survival and differentiation, instead 
influencing invasion, metastasis and angiogenesis and avoiding cellular apoptosis 
(Abdelmohsen 2010, Wang et al. 2015, Wurth 2012). 
The examples discussed below highlight the importance of identifying RBPs role in cancers 
also emphasising the significance of alternative mRNA processing in cancer (López de Silanes 
et al. 2005). 
Musashi1 coded by the gene MSI1 is an RBP. Sam68 belongs to a family of RBPs called Signal 
Transduction and Activation of RNA. Both these factors have been shown to target hundreds 
of genes, forming networks that control all aspects of homeostasis particularly ensuring a 
balance between self-renewal and differentiation (Glazer et al. 2012). Musashi1 and Sam69 
have been shown to be upregulated in Glioblastoma, Breast and Colon cancer. In cancers, 
they regulate mRNA expression of oncogenic targets involved in cell adhesion, proliferation, 
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apoptosis, migration and invasion (Vo et al. 2012, Glazer et al. 2012, Plateroti et al. 2012, Busà 
et al. 2007, Richard et al. 2008).  
Quaking I (QKI) is an RNA-binding protein essential for myelination of the central nervous 
system implicated in promoting oligodendrocyte lineage development (Chen et al. 2007). At 
a cellular level, QKI protein supresses cell proliferation and transformation thus their 
downregulation in lung cancers is associated with larger tumour growth (Zong et al. 2014). 
1.5 Embryonic lethal abnormal vision 
The Drosophila melanogaster (D. melanogaster) Embryonic lethal abnormal vision (Elav) gene 
was the first member of neuronal RNA-binding proteins to be identified and is a paradigm for 
a gene family present in all metazoans. The mammalian homolog of elav is therefore referred 
to as ELAV-like (ELAVL) more recently referred to as Hu. In D.melanogaster, elav resides in a 
family of three genes alongside RNA-binding protein-9 (Rbp9) and found in neurons (Fne) (Yao 
et al. 1993). The three genes share 59-68% sequence homology (Samson 2008).  
Elav is one of the first neuronal proteins expressed during neurogenesis in Drosophila and 
continues to be expressed in all neurons throughout adulthood. It is essential for the 
differentiation, development and maintenance of post-mitotic neurons as well as and the 
development of the eyes (Robinow 1988). Fne also found exclusively in neurons but occurs 
later in D. melanogaster development than Elav. Fne is expressed in the cytoplasm suggesting 
a role in protein shuttling. Elav and Fne have been shown to interact with each other (Samson 
and Chalvet 2003). Rbp9 is predominantly expressed in nerve cells. Rbp9 is expressed mainly 
in the nuclei of neuronal cells but has also been located in the cytoplasm of cystocytes during 
the production and development of ovum (Kim-Ha et al. 1999). A number of other proteins 
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homologous to elav have been identified in other species including Xenopus laevis, Danio rerio 




Figure 1.5: Sequence homology of D. melanogaster elav protein in other species. The elav family is  
conserved in 11 species. In Homo sapiens, the Drosophila melanogaster elav protein shares 55% 
sequence similarity with HuB, HuD and HuR whilst HuC shares 54% similarity. Elav in C. elegans called 
EXC-7 shares 47% protein identity. A. gambiae has three elav-like proteins called Ag-1, Ag-2 and Ag-3 
that share 74%, 60% and 65% elav protein similarity. Like C. elegans, P. humanus corporis elav-like 




In mice, the Hu homologue, ELAVL proteins, are expressed in neurons and shown to play a 
role in neuronal differentiation (Okano and Darnell 1997, Akamatsu et al. 2005). Studies have 
shown the direct binding of the mouse Hu homologues to target RNAs. Crosslinking 
immunoprecipitation and high-throughput sequencing of RNA (CLIP-seq), along with 
transcriptome profiling of ELAVL3/4 knockout mice, showed that ELAVL binds to the U-rich 
elements with dispersed purine residues in 3’UTRs and introns within the mouse brain (Ince-
Dunn et al. 2012). Knockout of ELAVL3 and ELAVL4 in mice causes problem in neuronal 
maturation as well as motor and sensory defects. Haploinsufficiency of ELAVL3 results in 
cortical hyper-synchronisation. These studies highlight the importance of ELAVL in mouse 
development but also a role in post-transcriptional events (Akamatsu et al. 2005, Ince-Dunn 
et al. 2012).  
1.6 The human ‘Hu’ proteins  
Human Hu proteins are a family of four RNA-binding proteins, HuB, HuC, HuD and HuR. They 
are highly conserved throughout evolution and the four human proteins share 74–91% 
identity (Samson, 2008). In humans, they were discovered due to their aberrant expression in 
paraneoplastic neurological syndromes (Darnell 1996). ‘Hu’ describes the first initials of the 
patient in which they were identified (Bronicki and Jasmin 2013). In the disease, 
autoantibodies are released by the immune system in response to the tumour that. These 
autoantibodies cross the blood-brain barrier and target healthy tissue causing severe 
neurological defects defined as paraneoplastic syndrome (Szabo et al. 1991, Darnell 2010, 
DeLuca et al. 2009). More on this topic is discussed in Section 1.8.   
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The HuB gene is located on chromosome 9p21.3 and contains 20 exons. This was determined 
by chromosome microdissection polymerase chain reaction (PCR) and fluorescence in situ 
hybridization (FISH) (Han et al. 1996).  
The HuB gene encodes a protein of 39.60kDa (D’Alessandro et al. 2008). In older studies, HuB 
is often referred to as Hel-N1. It has three transcript variants encoding two different isoforms. 
Alternative 5' splicing of HuB mRNA containing 20 exons, creates two isoforms Hel-N1 (HuB) 
and Hel-N2. Hel-N2 is characterised by the insertion of a 91-bp exon and has a larger N-
terminal region of 29 amino acids than Hel-N1. Both isoforms are predominantly localised to 
the cytosol although they can be in the nucleus too. The Hel-N2 isoform is expressed in 
different cell lines including neuronal precursors however, it is absent in mature neurons (Gao 
et al. 1994, King, 1994). Two isoforms also exist in rat neural tissue, Rel-N1 and Rel-N2 and 
share 96% nucleotide conservation between the two isoforms (King 1994).  
The HuB protein is localised in the cytoplasm of gonadal tissue and undifferentiated neurons. 
In neurons HuB co-localises with ribosomes facilitating mRNA metabolism and neuronal 
differentiation, ultimately influencing mRNA homeostasis in the dendrites of maturing 
neurons (Gao and Keene 1996). If the HuB-bound mRNAs associate with microtubules of the 
cytoskeleton, the complex binds with polysomes forming large β complexes that associate 
with the microfilament framework of the cytoskeleton (Antic and Keene 1998).  
Van Tine et al. (1998) used the tyramide signal amplification (TSA)-FISH technique, a 
molecular tool for visualising specific amplified DNA sequences in chromosome preparations, 
and radiation hybrid mapping of chromosomes for HuC localisation studies. HuC is localised 
to chromosome 19p13.2. 
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HuC encodes a protein of 39.55kDa (D’Alessandro et al. 2008). It is expressed in the cytoplasm 
of differentiated neurons. Four alternatively spliced transcript variants encode for two 
protein isoforms of HuC. The first is 367 nucleotides and the second is 360 nucleotides in 
length, the loss of nucleotides from RRM3 (Hinman et al. 2013, Kasashima et al. 1999). 
HuD was found to be located on 1p34 by Fluorescent in-situ hybridisation (FISH) (Muresu et 
al. 1994). The HuD gene spans 146kb of DNA and has eight coding exons, E1 to E8, each 
containing 44kb of DNA (Sekido et al. 1994, Inman et al. 1998, Bronicki et al. 2012). HuD gene 
contains multiple promoters that may provide considerable variation and complexity, further 
supporting its ability to be ectopically expressed in some cancers (Bronicki et al. 2012).  
HuD encodes a protein of 40.50kDa(D’Alessandro et al. 2008). HuD is alternatively spiced 
producing three isoforms called as HuD, HuDmex and HuDpro, with HuD being the more 
prominent transcript (Sekido et al. 1994). HuDpro is the largest variant due to the inclusion of 
an additional 42 nucleotides from the HuD isoform whilst, HuDmex is the smallest isoform 
characterised by a deletion of 13 amino acids (Liu et al. 1995).  
In mature neurons, HuD protein is present in axons and dendrites including pre- and post-
neurite terminals (Aronov et al. 2002). It is localised to the cytoplasm in neurons (Kasashima 
et al. 1999). Contrary to previous thoughts that HuD protein was only expressed in neurons, 
immunohistochemical analysis of HuD expression in a human tissue arrays reveals traces of 
HuD in in several non-neuronal tissues including lung, testes, liver, heart, pituitary gland and 
skeletal muscle (Abdelmohsen et al. 2010). Additionally, HuD is located in Beta-cells of the 
pancreas facilitating insulin expression (Lee et al. 2012).  
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Like HuC, HuR is also localised to chromosome 19p13.2. HuR and HuC each have distinct loci 
with HuC centromeric to HuR (Van Tine et al. 1998, Ma and Furneaux 1997). 
HuR encodes a protein of 36.00kDa (D’Alessandro et al. 2008). HuR exists as three isoforms 
which differ in 3′ UTR length. Each variant has differential AU-rich element involvement and 
stability. Each variant differs in size and in their tissue distribution. The 2.4kb transcript is 
ubiquitously expressed, the 1.5kb variant is localised in the testes with minor expression in 
heart and spleen, whilst the rarer, less-stable 6.0kb isoform is induced during neuronal 
differentiation and is expressed only in neurons (Mansfield and Keene 2012). The RNA binding 
specificity of HuR is similar to that of HuD and Hel-N1 (Ma et al. 1996).  
HuR protein is expressed ubiquitously including in the adipose tissue, intestines, spleen and 
testes (Wang et al. 2013). Its expression is predominantly seen in the nucleus of cells (Good 
1995). 
1.6.1 Structure of Hu proteins  
Th Hu protein family range between 326 and 380 amino acids with the sequence similarity 
between 74–91%. Thus, the four Hu proteins are of a similar size (Samson 2008). Hu proteins 
belong to the RNA recognition motif (RRMs) superfamily. Hu proteins have three, RRM1, 
RRM2 and RRM3, as shown in Fig 1.6, with each RRM containing 60-100 amino acid residues 
(Lunde et al. 2007). The RRM are structurally flexible allowing the binding of a large range of 
transcripts. Sequence alignment indicates that all three RRMs have the same canonical 
β1α1β2β3α2β4 fold (Maris et al. 2005). All three RRMs are highly conserved in vertebrates 
with the hinge domain less conserved. The N-terminal fragment is the most diverse domain 
among the ELAVL proteins (Liu et al. 1995). It is 117-amino acids long and carries RRM1 (Pulido 
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et al. 2016). HuR’s N-terminus has a small sequence homology to HuB, HuC or HuD. However, 
HuR’s N-terminus is most similar to the Xenopus homologue, elrA (Good 1995). 
RRM1 and RRM2 are consecutively arranged near the N-terminus followed by a hinge domain 
and RRM3 near the C-terminus (Fig 1.6) (Antic and Keene 1997). A nucleocytoplasmic 
shuttling sequence (HNS) is in the hinge region of Hu proteins. It is around 60-residues long 




Figure 1.6: Structure of Hu Proteins. The generalised structure of Hu proteins displays three RNA 
Recognition Motifs (RRMs). RRM1 and RRM2 are separated from RRM3 by a hinge region.  
 
RRM1 and RRM2 of Hu proteins have been shown to specifically bind to the cis-acting 
elements, typically in the 3’UTR (Uren et al. 2011). RRM3 functions to block polyadenylation 
and binds with high specificity to long poly(A) tails stabilising RBP-mRNA complexes (Zhu et 
al. 2007, Brennan and Steitz 2001). RRM3 assembles HuR oligomers on RNA transcripts to 
support stabilisation (Fialcowitz-White et al. 2007). HuR’s RRM3 preferably binds to Uracil-
rich sequences rather than AUUUA motifs (Scheiba et al. 2014). 
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The first two RRMs of HuD interact with the primary general mRNA export receptor complex, 
nuclear RNA export factor 1 (NXF1) also called tip-associated protein (TAP) in humans. HuD 
therefore acts as a regulator for efficient export of ARE-containing mRNAs in neuronal cells 
(Saito et al. 2004). HuD has also been shown to bind and regulate cell cycle regulator p21 
(Joseph et al. 1998), neuronal mRNAs including N-myc (Lazarova et al. 1999) and growth-
controlling proteins including c-fos (Fig. 1.7) (Chung et al. 1996). 
 
 
Figure 1.7: Interaction of c-fos mRNA with HuD. This ribbon diagram displays an 11 nucleotide 
fragment of c-fos 3’UTR binding with the β-sheets (green) of the first two RRM’s of HuD. Α-helix of the 




The versatility and flexibility of Hu proteins’ structure allows them to bind to many RNA 
targets and regulate their fate through different mechanisms (Wurth 2012, López de Silanes 
et al. 2004).  
1.7 Function of Hu proteins  
The family of Hu proteins are part of an intricate network where they are collaboratively 
responsible for many biological functions including the regeneration and development of the 
nervous system, neuronal specific RNA processing, differentiation, synaptic plasticity and 
learning and memory (Akamatsu et al. 2005, Deschênes-Furry et al. 2007). It also plays a 
crucial role in neuronal plasticity controlling the response to axonal injury and increasing 
learning and memory (Bronicki and Jasmin 2013).  
Both in vitro and tissue culture studies have shown that neuronal Hu proteins regulate gene 
expression at a post-transcriptional level typical of RNA-binding proteins. They influence all 
aspects of RNA processing including RNA stability, alternative splicing, polyadenylation, 
localisation and nuclear export as displayed in Fig 1.8. They are therefore essential in 




Figure 1.8 Hu proteins influence on gene regulation. Hu proteins mediate many aspects of core-
transcription and post-transcriptional events. In the nucleus, Hu proteins regulate 5′ capping, alternative 
splicing, 3’ poly-A tail addition and mRNA export. In the cytoplasm, they regulate mRNA  localisation, 
stability and degradation.  
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miRNAs have been shown to regulate RBP expression. Abdelmohsen et al. (2008) reported 
miR-519 binds directly to HuR mRNA decreasing HuR-regulated gene expression. HuR 
contains two binding sites for miR-519, one located in the coding regions and the other in its 
3′UTR. By measuring HuR translation and HuR mRNA association with polysomes, in several 
cancers over expressing miR-519 including, cervical, colon and ovarian, it was found that miR-
519 does not alter HuR mRNA abundance but decreases HuR biosynthesis. This thereby 
reduces HuR translation, HuR-regulated gene expression and cell division. 
Hu RNA-binding proteins promote skipping of alternative exons by inducing local histone 
hyperacetylation through interactions with pre-mRNAs and alternative exons (Wang et al. 
2010). The neuronal proteins, HuB, HuC and HuD are mostly implicated in alternative splicing, 
which allows cells to adapt to different stimuli by altering protein compositions (Wurth 2012). 
This significantly impacts neurophysiological mechanisms including neurotransmission, cell 
recognition and receptor specificity (Zhu 2009).  
Another role that Hu proteins regulate is polyadenylation. During this process, cleavage of the 
3’ end of the sequence and addition of the poly (A) tail to the newly generated 3’ end occurs 
producing mature mRNA as previously described in Section 1.2.3 (Erson-Bensan 2016). Hu 
proteins bind directly to sequence in cleavage sites preventing polyadenylation signals being 
transmitted. Hu proteins particularly target poly(A) sites that contain U-rich sequences near 
cleavage sites and the third RNA-recognition motif of Hu proteins is required to block 
polyadenylation. Interplay between Hu proteins and two poly(A) factors, the multiprotein 
cleavage and polyadenylation specificity factor (CPSF160) and the Cleavage stimulation factor 
(CstF64) is known. CPSF160 interacts with poly(A) polymerase initiating cleavage and poly(A) 
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addition whilst CstF64 is directly involved in binding to pre-mRNAs on 3’ non-coding sites (Zhu 
et al. 2007). 
Neurofibromatosis type I or von Recklinghausen neurofibromatosis is one of the most 
common dominant inherited autosomal disorders affecting 1 in 3,500 individuals worldwide. 
Neurofibromin 1, (NF1) gene codes for neurofibromin protein. This protein acts a tumour 
suppressor. NF1 gene mutations result in multiple abnormalities, including development of 
neurofibromas and gliomas and abnormal distribution of melanocytes (Bernards 1995). Exon 
23a of the NF1 gene is an in-frame exon that is included during alternative splicing. In the 
presence of HuC protein, exon23a of NF1 is skipped by binding to AU-rich sequences located 
either side of the regulated exon. This results in a defective NF1 protein. Deletions of HuC 
proteins RRMs resulted in exon 23a inclusion in NF1, whilst deletion of the hinge region only 
reduced NF1 exon 23a inclusion. This confirms HuC’s role as a polyadenylation regulator (Zhu 
et al. 2008). 
Hu proteins are essential in the cytoplasm for regulating mRNA stability by binding to AU-rich 
elements (AREs) of many short-lived mRNAs. AREs are typically found in non-coding regions 
of the transcripts, particularly the introns and the 3’ untranslated regions (UTR). By binding 
directly to AREs, Hu proteins influence the translation rate of targets RNA, preventing their 
degradation and enhancing protein production (Zhu et al. 2007). Hu proteins target an array 
of RNA transcripts coding for transcription factors, cytokines, growth factors and proto-
oncogenes (Wang et al. 2015). 
Jain et al. (1997) show that overexpression of HuB in preadipocytes elevated the expression 
of endogenous glucose transporter (GLUT1) protein 10-fold. This resulted in increased the 
uptake of glucose. HuB binding occurred directly to the U-rich region of GLUT1 mRNAs 3’-UTR 
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increasing GLUT1 at both translational and post-transcriptional levels confirming a role of HuB 
in mRNA stabilization and accelerated formation of translation initiation complexes.  
Although most neurons express HuC with HuB and/or HuD proteins, cerebellar Purkinje cells 
and hippocampal granule cells express only HuC protein. Studies in mice showed that HuC 
protein deficiency caused progressive motor deficits resulting in severe cerebellar ataxia 
and eventual axonal degeneration. This demonstrates that HuC protein is required for the 
maintenance of Purkinje neuron axons (Ogawa et al. 2018). 
HuD plays a critical role in Protein kinase C (PKC)-mediated neurite outgrowth through 
stabilising growth-associated protein-43 (GAP-43) mRNA. HuD protein binds to GAP-43 mRNA 
regulating its transcript. GAP-43 regulates axon growth in neurons (Beckel-Mitchener et al. 
2002). Overexpression of HuD results in delayed degradation of GAP-43 due to decrease in 
the rate of mRNA de-adenylation. PKC phosphorylates GAP-43, regulating neurite formation, 
regeneration and synaptic plasticity (Mobarak et al. 2000). 
p21 gene is highly regulated enabling cells to progress through the cell cycle. HuD protein 
binds with high affinity to a 42-nucleotide sequence within a U-rich region of the 3’UTR of 
cyclin-dependent kinase inhibitor 1 (p21waf1) mRNA. p21waf1 causes cell cycle arrest at the 
transition from G1 to S phase of the cell cycle through inhibition of cyclin-dependent kinases 
and proliferating cell nuclear antigens. G1 to S phase is essential in cell differentiation (Joseph 
et al. 1998). HuR was also shown to bind in the same manner to p21waf1 (Giles et al. 2003). 
Binding of Hu proteins enhances the transcripts stability. This example indicates how Hu 
proteins role in binding to targets involved in the regulation of the cell cycle, influences cell 
differentiation, mRNA stability, and the termination of the cell cycle. 
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HuR was first discovered in 1997 and is the most broadly studied in the Hu protein family (Ma 
and Furneaux 1997). Many of HuR mRNA targets encode proteins responsible for cell growth, 
proliferation, the immune response and the cellular response to stress and embryonic 
development and survival (Mansfield and Keene 2012, Hinman and Lou 2008).  Specific mRNA 
targets are discussed in more detail in Chapter 1.10.  
HuR functions in energy depletion through interactions with the mRNA target V-ATPases. 
These are multi-subunit membrane proteins that use ATP binding and hydrolysis to pump 
protons across cellular membranes against a concentration gradient. They also function in 
acidification of internal components in mechanisms including endocytosis and are therefore 
are required by all eukaryotes. V-ATPases are regulated at a post-transcriptional level. When 
ATP depletion is caused by cellular stress, HuR binds directly to AREs within the V-ATPase 
mRNA and stabilises the transcript, ultimately protecting the cell from loss of V-ATPase 
protein (Jeyaraj et al. 2005). 
1.7.1 Hu protein expression during development 
HuB, HuC and HuD proteins are expressed at different levels in embryonic neurons in 
comparison to adult neurons. HuB proteins are initially expressed in neurogenic progenitor 
cells and stays continuously expressed in mature neurons (Marusich et al. 1994, Yano et al. 
2016). HuC and HuD expression begins slightly later in development during cortical neuron 
development (Yano et al. 2016). In developing neurons, HuD is found in the growth cones of 
extending neurites (Aranda-Abreu et al. 1999).  
Akamatsu et al. (2005) showed that a triple knockdown of the neuronal Hu genes is lethal in 
mice. A single knockdown of HuC and HuD gene showed mice survive to adulthood but they 
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do display some neurological defects including poor hind-limb reflexes and decreased 
proliferative activity in the neural progenitor cells (Akamatsu et al. 2005). Interestingly, a 
knockdown of HuR in mice resulted in death of progenitor cells in the bone marrow, thymus, 
and intestine, loss of intestinal villi and obstructive inflammation of the small intestine and 
the colon. Death occurred within 10 days showing that in mice, HuR is required for organism 
survival (Ghosh et al. 2009).  
1.7.2 Homo- and hetero-dimerisation of Hu proteins 
Hu proteins are known to bind to themselves and other Hu protein family members to form 
complex assemblies (Kasashima et al. 2002). In situ chemical crosslinking assays revealed HuB 
can form dimers but not trimers. It also found HuD forms dimers, trimers and multimers in 
cells. The multimer maintains its ability to regulate mRNA transcripts and bind with additional 
Hu proteins. Additionally, HuR can form dimers but not trimers (Kasashima et al. 2002). 
Using immunoprecipitation and RT-PCR, it was found that the hinge region and the first 24 
amino acids of RRM3 of HuC are required for HuC homo-dimerisation. All four splice variants 
of the HuC hinge region were able to form HuC-self interactions highlighting alternative 
splicing does not affect homodimerization (Hinman et al. 2013). 
Similar to HuC, the third RRM and the hinge region of HuR play a role in homo-multimerization 
(Fialcowitz-White et al. 2007). HuR binds the 2.4kb ubiquitously expressed transcript of HuR 
mRNA sequences containing an ARE and stabilises its own transcript. This results in increased 
HuR expression (Pullmann et al. 2007, Al-Ahmadi et al. 2009).  
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1.7.3 Hu proteins participate in nucleo/cytoplasmic shuttling 
The subcellular location of Hu proteins determines the role in which they function. Hu 
proteins must become localised in the nucleus for pre-mRNA splicing to occur (Zhu 2009).  
HuR has been shown to shuttle between the nucleus and cytoplasm and can therefore be 
assumed the neuronal proteins HuB, HuC and HuD could have the same ability. The 
cytoplasmic trafficking of HuR and mRNA cargo is poorly understood although there are many 
proposed mechanisms. HuR contains nucleo-cytoplasmic shuttling sequences (HNS) in the 
hinge region of the protein spanning residues 205–237. It is thought this region is responsible 
for translocation (Fan and Steitz 1998). The HNS is phosphorylated by kinases including 
protein kinase Cα (Doller et al. 2007), protein kinase Cβ (Amadio et al. 2010), protein kinase 
Cδ (Doller et al. 2008), checkpoint kinase 2 (Abdselmohsen et al. 2007), cyclin dependant 
kinase 5 (Filippova et al. 2012) and cyclin dependent kinase 1 (Kim et al. 2008).  
The binding activity of HuR and its localisation is dependent on the kinase phosphorylating 
the HNS but also the position within the HNS that is phosphorylated (Kim and Gorospe 2008). 
For example, protein kinase C phosphorylates HuR at serine 158 and serine 221 and increasing 
its cytoplasmic expression (Doller et al. 2007). Cyclin dependent kinase 1 phosphorylates HuR 
at serine 202 (S202) ensuring HuR remains in the nucleus where it regulates polyadenylation 
and splicing. Unphosphorylated HuR-S202 complex is actively transported to the cytoplasm 
confirming phosphorylation of the complex changes its cellular location (Kim et al. 2008). 
Doller et al. (2013) proposed the involvement of actin-myosin in HuR mRNA trafficking. 
Angiotensin II initiates translocation of protein-kinase Cδ, which in turn phosphorylates 
nuclear HuR at serine 318 located within RRM3. This process increases HuR’s binding potential 
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to mRNAs. The HuR-bound mRNA complex interacts with motile transport ribonucleoproteins 
and cytoskeleton bound polysomes to translocate to the cytoplasm through myosin-driven 
transport along filamentous actin. HuR-bound mRNA is protected from degradation by 
exonucleases increasing the transcript stability. Once in the cytoplasm, HuR releases itself 
from the bound mRNA and returns to the nucleus (Fan and Steitz 1998a). 
Translocation of Hu proteins is modulated by cellular stress induced by UV-light, heat shock 
and nutrient deficiency derived translocation are described here.  
P21 protein is an inhibitor of cyclin-dependent kinase and known target of HuR protein. 
Human colorectal carcinoma, RKO cells were stimulated by Ultraviolet C-irradiation. HuR 
cytoplasmic localisation was enhanced, more HuR-p21 complexes were observed resulting in 
enhanced stability of p21 mRNA and its consequential upregulation. In the same study, 
western blot confirmed that when treating RKO cells with damaging agents including 
actinomycin D, hydrogen peroxide, an alkylating agent, and a cyclopentenone, p21 protein 
and cytoplasmic protein HuR levels increased (Wang et al. 2000).  
Immunofluorescence and cell fractionation studies revealed that following a heat-shock of 
HeLa cells, cytoplasmic HuR expression increased. Although cytoplasmic HuR is usually 
associated with upregulation of mRNA transcripts containing AREs, this was not observed and 
instead the only function of cytoplasmic HuR was sequestration of mRNA transcripts in the 
nucleus (Gallouzi et al. 2000). This highlights that a large cytoplasmic presence of HuR is not 
necessarily functioning to upregulate transcripts expression that would disrupt the 
homeostasis of the cell. 
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1.7.4 Self-regulation of Hu proteins 
Similar to its Drosophila homologue, members of the Hu family can bind their own mRNA and 
auto-regulate themselves or other Hu proteins (Bolognani et al. 2009, Mansfield and Keene 
2012). HuR protein has been shown to auto-regulate its own expression through a negative 
feedback loop. Nuclear HuR protein binds HuR mRNA sequences containing a GU-rich element 
that overlaps the HuR major polyadenylation signal, PAS2. Increased expression of HuR 
protein initiates the expression of the 2.4KB HuR mRNA that contains an ARE to destabilize 
the HuR mRNA and therefore reduce its protein production. Reduced recruitment of the 
Cleavage stimulating factor CstF-64 in the GU-rich region on HuR mRNA, resulted in activated 
PAS2. This mechanism results in a definite expression of HuR protein and allows a stable 
nucleocytoplasmic distribution and HuR homeostasis in proliferating cells (Dai et al. 2012) 
Hu proteins can also function as splicing enhancers on their own family transcripts. An 
example is their ability to promote the inclusion of an alternative exon, called exon 6 of the 
HuD pre-mRNA. This exon contains an ARE in which HuD and other Hu proteins can bind to 
resulting in an abundance of HuD protein expression (Wang et al. 2010). All three HuC RRMs 
are critical for the regulation of reporter HuD exon 6 inclusion (Kasashima et al. 2002). This 
confirms Hu proteins role as splicing regulators of their own transcripts but also allows them 
to self-regulate their own expression. 
1.8 Hu Proteins Implicated in Disease 
Since Hu proteins regulate many aspects of RNA regulation and the complex nature of the 
processes involved, there are many opportunities for deregulation to occur. This then causes 
disease in humans (Bronicki and Jasmin 2013). 
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Paraneoplastic encephalomyelitis and/or a sub-acute sensory neuropathy (PEM/SN) are 
collectively known as paraneoplastic neurological diseases (Anderson et al. 1987). These are 
disorders caused by an elicit Hu-specific humeral immune system response to Hu antigens 
produced ectopically by a primary tumour or metastasis in the brain. The body recognises 
these as foreign and releases autoantibodies that target all Hu proteins for degradation, this 
includes those that occur naturally in the body and those that are oncogenic, ectopically 
expressed. Normal tissue as well as cancerous tissue is targeted for degradation (Fisher et al. 
1994, Graus et al. 1997). This produces systemic symptoms resulting in dementia, cerebellar 
degeneration, brainstem encephalitis, or myelitis. The presence of paraneoplastic disorders 
has shown a more promising cancer-related prognosis due to the body destroying the Hu 
proteins in the tumour. However, the patients quality of life remains diminished as they suffer 
non-reversible, debilitating neurological syndromes (Manley et al. 1995, Dalmau, Josep and 
Furneaux 1992, Graus et al. 1997). The presence of these neuropathies is considered symbolic 
of a Small cell lung cancer tumour or Neuroblastoma (Szabo et al. 1991, Fisher et al. 1994).  
HuD was originally discovered by Szabo et al. (1991) due to its presence in patients with both 
Small cell lung cancer and paraneoplastic diseases. Patient’s antiserum was screened against 
a cerebellar expression library and found to have Hu autoantibodies present. This disorder 
was later described as the ‘Hu syndrome,’ after the name of the patient in which the 
antibody was first discovered (Graus et al. 1997). All SCLC tumours aberrantly expressed 
neuronal HuD protein and the tumour-initiated immune response can be detected in up to 
20% of those patients however PEM/SN is thought to develop in 1% of SCLC patients (Dalmau, 
Josep and Furneaux 1992, DeLuca et al. 2009). Posner and Dalmau (1997) determined the 
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other neuronal members of the Hu family, HuB and HuC were also autoimmune antigens of 
the Hu syndrome.  
A study by Dalmau and Furneaux (1992) of patients with PEM/SN and a raised level of Hu-
antibodies had tumours that were localised and small and this remained unchanged until 
death. Hu-autoantibodies are protective against tumour development and may aid 
eradication of tumour cells or at least improve patient survival (Graus et al. 1997). Research 
by Darnell and DeAngelis (1993) showed patients positive for anti-Hu antibodies showed 
spontaneous regression of Small cell lung cancer. This finding suggests the HuD-antigen might 
provide a molecular target for immunotherapy against HuD positive tumours but also 
provides a potential target for screening as a biomarker (Ehrlich et al. 2014). However, current 
efforts with systemic immunotoxin therapy and solid tumours is relatively unsuccessful due 
to poor penetration into the tumour mass because of large molecular size of the therapy, 
chemical instability or immunogenicity (Shan et al. 2013). 
Some Neuroblastoma patients also present with anti-HuD antibodies that initiate neuronal 
apoptosis resulting in enteric nervous system impairment underlying paraneoplastic gut 
dysmotility (De Giorgio et al. 2003). In one of the first reported cases, a child with 
Neuroblastoma, showed paraneoplastic symptoms of progressive hearing loss, areflexia, and 
seizures following removal of the tumour. Analysis of serum and cerebrospinal fluid 
discovered anti-Hu antineuronal antibodies (Fisher et al. 1994).  
Whilst aberrant expression of antigens by tumours can initiate an immune response, it is 
unusual for it to develop into a paraneoplastic disease therefore understanding the 
mechanism at which this occurs could be of value in the development of tumour detection, 
60 
 
diagnosis and new treatments, including immunotherapy (Kazarian, Meleeneh and Laird-
Offringa 2011).  
A recent study by Pulido et al (2016), identified isoaspartylation as a potential mechanism. 
Isoaspartylation is a naturally-occurring post-translational modification generating 
immunogenic protein damage. Isoaspartyl compounds are normally processed in the body 
causing no harm however abnormal isoaspartylation is implicated in several autoimmune 
diseases. Antibodies against isoaspartylated Hu would cross-react eliciting an immunological 
stimulus and an autoimmune response. Isoaspartyl linkages in proteins have been linked to 
aging and arise under physiological condition causing cellular stress (Mamula et al. 1999). HuD 
contains four canonical isoAsp-prone sites. The N-terminal region containing RRM1 contains 
three of those isoAsp conversion sites suggestive of RRM1’s role in the auto-immune response 
of paraneoplastic disease in SCLC (Pulido et al. 2016, Manley et al. 1995, Graus et al. 1997). 
Additionally, the deregulated expression of neuronal protein in non-neuronal cell types, like 
that of the neuronal Hu proteins in the lung, can induce isopartylated proteins (Pulido et al. 
2016). 
Neurofibromatosis type I or von Recklinghausen neurofibromatosis is one of the most 
common dominant inherited autosomal disorders affecting 1 in 3,500 individuals worldwide. 
Neurofibromin 1, (NF1) gene codes for neurofibromin protein. This protein acts a tumour 
suppressor. NF1 gene mutations result in multiple abnormalities, including development of 
neurofibromas and gliomas and abnormal distribution of melanocytes (Bernards 1995). Exon 
23a of the NF1 gene is an in-frame exon that is included during alternative splicing. In the 
presence of HuC protein, exon23a of NF1 is skipped by binding to AU-rich sequences located 
either side of the regulated exon. This results in a defective NF1 protein. Deletions of HuC 
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proteins RRMs resulted in exon 23a inclusion in NF1, whilst deletion of the hinge region only 
reduced NF1 exon 23a inclusion. This confirms HuC’s role as a polyadenylation regulator (Zhu 
et al. 2008). 
Aberrant expression of Hu proteins is also thought to play a role in Neurodegeneration 
(Doxakis 2014, Okano and Darnell 1997). Within the nervous system, the role of RBPs in brain 
function is essential for the architectural complexity of the neurons (Campos-Melo et al. 
2014). Hu proteins have been shown to play important roles in neurite outgrowth, synapse 
formation and plasticity. HuD’s role in neural development and regeneration means its 
aberrant role results in  in multiple neurological disorders including Parkinson’s disease, 
Alzheimer’s disease, schizophrenia, epilepsy and spinal muscular ataxia (Perrone-Bizzozero 
and Bird 2013). HuD was shown to bind to mRNA transcripts of APP encoding amyloid 
precursor proteins and BACE1 encoding β-site APP-cleaving enzyme 1, connected to 
Alzheimer’s disease pathogenesis. HuD upregulated transcript stability by binding to the 3’ 
UTR enhancing production of Aβ peptides that are related to the neurotoxicity of Alzheimer’s 
disease (Kang et al. 2014). Genome-wide association study (GWAS) of Japanese and Chinese 
populations found SNPs in HuB to contribute to the pathogenesis of schizophrenia (Yamada 
et al. 2011). 
Neurodegeneration is caused by disruptions of pathways involved in cell survival, cell death 
and the cell cycle resulting in a decrease in regulatory functions that impact on progressive 
neuronal cell death in neurodegenerative diseases (Driver 2012). A homeostatic balance 
between cell survival and cell death is dependent on the preservation of DNA integrity and 
repair. Additionally, deregulation to RNA metabolism is also considered a key feature in 
Neurodegeneration since it is essential for the molecular processes of RNA transcription, 
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maturation, transport, stability, degradation and translation in normal cells (Campos-Melo et 
al. 2014). HuR stabilises the mRNAs transcripts coding for cyclins D1, E1, A2, B1 each of which 
favour cell cycle progression. Therefore deregulation of HuR protein may influence 
neurodegeneration progression (Wurth 2012).  
Commonly seen in neurodegenerative diseases is the ectopic expression of proteins and 
accumulation of cytoplasmic protein aggregates that initiates cell death and neurotoxicity due 
to protein inspecificity (Zaharieva et al. 2012). Hu proteins are reportedly ectopically and 
overexpressed in many cancers and therefore their role in neurodegeneration should be 
further analysed. 
1.9 Cancer  
Cancer is a heterogeneous group of diseases characterised by growth, invasion and metastasis 
defined through changes at cellular, genetic, and epigenetic levels and abnormal cell division. 
In the process of cancer development, normal cells evolve progressively to a neoplastic, 




Figure 1.9: Hallmarks of cancer development. Normal cells evolve into oncogenic cells through a 
series of mechanisms that ultimately results in mutated cells and formation of tumours. 
 
Inflammation and energy metabolism also play an extensive role in cancer progression. 
Ultimately cancer is caused by an activation of oncogenes or decreased expression of tumour 
suppressors (Hanahan and Weinberg 2011). Tumours develop from cell populations including 
64 
 
inflammatory cells, vascular cells and support cells. Interactions between these cells is critical 
for the cancers maintenance and survival from the body’s immune defences and any 
additional treatments (Bissell and Labarge 2005). Cancer initiation and development is 
dependent on the reprogramming of cellular metabolism networks. This occurs through 
oncogenic mutations that allow the cancer cells to access nutrients from a nutrient-enriched 
environment and use them to sustain growth and vitality. Ultimately changes occur to glucose 
uptake, nutrient retrieval, glycolysis, nitrogen demand, gene regulation, and metabolic 
interactions with the microenvironment (Pavlova and Thompson 2016). 
For normal homeostasis, cells experience regulated cell death called apoptosis. Cancer cells 
that become mutated due to DNA damage, form a secondary tumour in an extrinsic area or 
are targeted by cancer therapy, should go through apoptosis as a method to supress tumour 
formation. Unfortunately cancer cells are able to evade apoptosis following these events 
(Lopez and Tait 2015). Apoptosis is triggered through two pathways; the extrinsic and intrinsic 
pathways. The extrinsic pathway is induced when tumour necrosis factors (TNF) bind to cell 
surface death receptors which initiates the death-inducing signalling complex (DISC) and the 
apical caspase 8.  The intrinsic pathway is started by interference with the mitochondrial outer 
membrane function and is the most common deregulated pathway involved in cancer 
apoptosis. It is regulated by a balance of pro- and antiapoptotic members of the Bcl-2 family 
of proteins (Reed 2000). 
Another cellular process affected in cancer is the epithelial to mesenchymal transition (EMT). 
This is a dynamic set of processes during which cells transition from a polarised epithelial cells 
into migratory, invasive mesenchymal phenotypes and was first described by Hay and Zuk 
(1995). In the human body it is essential for the formation of the body plan and differentiation 
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of tissues and organs as well as processes including tissue repair. During cancer, EMT is 
stimulated in epithelial-derived cancer cells allowing cells to dissociate from the primary 
tumour, invade blood vessels and initiate the formation of a secondary tumour (Thiery et al. 
2009, Goossens et al. 2017). EMT is controlled by a series of transcription factors including 
the families of Snail, Zeb and Twist, as well as microRNAs and epigenetic and post-
transcriptional gene regulators. During cancers, these factors and process can be aberrantly 
affected also contributing to a carcinogenic phenotype. 
Despite huge advances in our understanding into the mechanisms by which metastatic cells 
arise from primary tumours and the reasons that certain tumour types tend to metastasize to 
specific organs, it still accounts for around 90% of all cancer-related deaths. This mechanism 
was first described by an English surgeon called Stephen Paget in 1889. He hypothesised that 
metastasis relies on homeostatic interactions between the cancer cells, ‘the seeds’, and the 
organ microenvironment, ‘the soil’. Research has continued to evolve this theory (Fidler 
2003).  
1.10 Hu proteins, their presence and function in carcinogenesis 
Hu proteins interact and stabilise many mRNA targets that code for proto-oncogenes, 
cytokines and lymphokines each of which influence carcinogenesis. Regulation consists of 
multiple tightly controlled processes, consequently the complexity of each step increases the 
chance for deregulation to occur. Modifications to expression levels and function of RBPs and 
their mRNA targets can augment the effects of cancer driver genes by accelerating tumour 
progression and promoting aggressiveness (Bronicki and Jasmin 2013).  
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Radio-labelled transcripts and binding studies revealed HuB interacts and forms multimers 
with c-myc. This binding occurs directly to AUUUG, AUUUA, and GUUUUU sequences in the 
3’ UTR of c-MYC mRNA. Deletion analysis determined HuB’s RRM3 binds to those sequences 
(Levine et al. 1993). c-Myc functions as a transcription factors in many cancers, activating 
autonomous proliferation and growth, increasing DNA replication, upregulating cellular 
metabolism and has therefore been considered a molecular hallmark of cancer (Gabay et al. 
2014). c-FOS is also a target of HuB (Levine et al. 1993). c-Fos functions in proliferation and 
differentiation of normal tissue as well as in oncogenic transformation and tumour 
progression (Mahner et al. 2008).  
Each Hu proteins are known to have complementary mRNA target that once bound effects 
their stability. Brennan and Steitz (2001) have shown that HuR achieves stabilisation by 
competing with destabilizing ARE-binding proteins for the same mRNA binding sites or 
through actively protecting the mRNA transcript from degradation. HuR’s stabilising function 
correlates with its cytosolic presence which is often seen overexpressed in high grade 
tumours (Brennan and Steitz 2001, Bolognani et al. 2012). HuR binds to mRNA transcripts 
coding for proto-oncogenes, cytokines, growth factors and invasion factors increasing 
stability and translation. The corresponding proteins then influence various stages of tumour 
development including over-proliferation through c-Myc upregulation, evasion of apoptosis 
via apoptosis factors p27, p21, Bcl-2, sustained angiogenesis by upregulating VEGF and tissue 
invasion and metastasis by affecting the expression of MMP-9 and Snai1 (Wang et al. 2013, 
Vo et al. 2012, Wurth 2012, Filippova et al. 2011, Dong et al. 2007, 2014). Further details of 




Cancer Hallmark mRNA Target Hu protein Expression 
change 
Reference 
Tumour Formation ER HuR Upregulated (Calaluce et al. 2010) 
 GLUT1 HuB Upregulated (Jain et al. 1997) 
 Wnt5a HuR Downregulated (Leandersson et al. 2006) 
Proliferation BCL-2 HuR Upregulated (Filippova et al. 2011) 
 p21 HuD 
HuR 
Upregulated (Joseph et al. 1998) 
(Wurth 2012) 
 p27 HuR Upregulated (Wang et al. 2013) 
 Msi-1 HuR Upregulated (Vo et al. 2012) 
 c-fos HuD 
HuR 
HuB 
Upregulated (Chung et al. 1996) 
(Nabors et al. 2001) 
(Levine et al. 1993) 
 Cyclin A HuR Upregulated (Guo and Hartley 2006) 
 Cyclin B1 HuR Upregulated (Cho et al. 2006) 
 Cyclin E1 HuR Upregulated (Guo and Hartley 2006) 
 N-myc HuD Upregulated (Lazarova et al. 1999) 




Upregulated (Levine et al. 1993) 
(King 2000) 
(King 2000) 
(Milne et al. 2006) 
 NP53 HuR Upregulated (Yan et al. 2012) 
Invasion and 
Metastasis 
B-Actin HuR Upregulated (Dong, R. et al. 2007, 
Dormoy-Raclet et al. 2007)  
 uPA HuR Upregulated (López de Silanes et al. 
2004) 
 Snai1 HuR Upregulated (Dong, R. et al. 2007) 
 MMP-9 HuR Upregulated (Dong, R. et al. 2014) 
Angiogenesis VEGF HuC 
HuD  
HuR 
Upregulated (King 2000) 
(King 2000) 
(Nabors et al. 2003) 
 Hif-1 α HuR Upregulated (Dong, R. et al. 2014) 
 COX-2 HuR Upregulated (Nabors et al. 2001) 
Immunomodulation TNF-ß HuR Upregulated (Nabors et al. 2001) 
 TNF-α HuR Upregulated (Nabors et al. 2003) 
 IL-8 HuR Upregulated (Nabors et al. 2001) 
 IL-6 HuR Upregulated (Nabors et al. 2001) 
Table 1.1: mRNA targets of Hu proteins. Table 1.1 shows the variation of effects Hu proteins can have 
influencing the expression of other protein factors involved in tumour growth, tumorigenesis, invasion 
and metastasis, angiogenesis and tumour inflammation.  
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In cancer, cellular polarity and senescence are disrupted, these cellular processes are 
influenced by Hu proteins. HuR regulates Tumour protein 63 (∆Np63) transcript that 
maintains cell proliferation and polarity in normal mammary epithelial cells. RNA 
electrophoretic mobility shift assays performed on immortalized mammary epithelial cells, 
MCF10A, identified HuR binding regions in p63 transcript. HuR binds directly to one of two U-
rich elements in the 3’-UTR of the ∆Np63 mRNA inhibiting ΔNp63 protein expression through 
translation. Thus, HuR maintains cell proliferation and polarity of MCF10A cells at least in part 
via regulating ΔNp63 expression (Yan et al. 2012). 
During cell senescence cells reach their replicative life span in vitro and ultimately experience 
irreversible growth arrest. In humans, the Ink4a-Rb pathway plays a crucial role in senescence. 
HuR destabilises Ink4a mRNA in human diploid fibroblasts as well as controlling the regulation 
of other genes that function in senescence notably p53, p21 and cyclin D1. HuR is also known 
to repress the alternative reading frame (ARF) tumour suppressor of the p14ARF pathway 
which allows the replicative potential of the cells to increase (Kawagishi et al. 2013). Cellular 
senescence potentially acts as an anti-cancer mechanism whereas microglial senescence is 
thought to contribute towards Neurodegeneration. During cellular replicative senescence, 
HuR expression is suppressed and this is linked to a decreased capability of the protein to 
stabilise mRNA of pro-survival factors (Campos-Melo et al. 2014). 
Hu proteins regulate alternative splicing and polyadenylation. The complex nature of 
alternative splicing, polyadenylation and their deregulation is thought to initiate or contribute 
to many human diseases (Faustino et al. 2003). HuR regulates pre-mRNA splicing of FAS, an 
apoptotic-promoting receptor. When FAS endures alternative splicing, exclusion of exon 6 
results in an isoform that prevents programmed cell death. HuR promotes the exon 6 skipping 
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by binding to an exonic spicing silencer. This confirms HuR’s role in alternative splicing and in 
influencing cell fate (Izquierdo 2008). This is particularly significant in hepatocellular 
carcinoma where HuR restricts translation of FAS mRNA obstructing Fas-mediated apoptosis. 
Ultimately this results in an increase in cell survival and proliferate increasing the growth of 
the tumour (Zhu et al. 2015).  
Zaharieva et al. (2015) shows that specificity of RBPs binding patterns on mRNA transcripts 
are relative to its concentration, activity and localization. An interrelationship between Hu 
ectopic or over-expression and larger malignant tumours, advanced stage disease, positive 
lymph nodes, chemo resistance to standard cancer treatments and consequently poor 
survival rates (Denkert et al. 2004). Table 1.2 details Hu proteins aberrant or overexpression 
in cancers.  
Calaluce et al. (2010) described how HuR controls genes in different stages of cancer and 
hypothesized HuR is a tumour-maintenance gene, allowing for cancer progression once it is 
established. Its overexpression and cytoplasmic presence in many cancers suggests it could 
be used as a prognostic marker and a target in therapeutic treatments. Since these proteins 
share similar structure and function, it can be assumed that the other Hu proteins also can in 
this manner. Additionally, in mammals, Hu genes are alternatively spliced to produced 
different protein isoforms. Most variation occurs due to alternative splicing coding for the 
hinge region (Keene 1999). HuR isoforms often have different functions and are expressed 
based on their need and this may influence aberrant Hu protein expression in cancers, 






Cancer Expression Subcellular 
Location 
Reference 
HuB Small cell lung 
cancer 
Aberrant expression  (King 1997) 
 Medulloblastoma Aberrant expression Cytoplasmic (Gao and Keene 1996) 
HuC Large cell 
neuroendocrine 
carcinoma 
Aberrant expression  (Matsumoto et al. 2012) 
 Small cell lung 
cancer 
Aberrant expression  (Matsumoto et al. 2012) 
HuD Small cell lung 
cancer 
Aberrant expression  (King 1997) 
 Neuroblastoma Aberrant expression  (Dalmau, J et al. 1995)  
HuR Oral cancer Over-expression Cytoplasmic (Kakuguchi et al. 2010) 
 Oesophageal cancer Over-expression Cytoplasmic (Zhang et al. 2014) 
 Cervical cancer Over-expression  (Cho et al. 2006) 
 Colon cancer 
 
Over-expression Both (López de Silanes et al. 
2003) 
 Small cell lung 
cancer 
Over-expression  (Wurth 2012) 
 Non-small cell lung 
cancer 
Over-expression Cytoplasmic (Wang et al. 2011) 
 Breast cancer Over-expression Cytoplasmic (Hostetter et al. 2008) 
 Renal cancer Over-expression Cytoplasmic (Datta et al. 2005) 
 Merkel cell 
carcinoma (Skin) 
Over-expression Cytoplasmic (Koljonen et al. 2008) 
 Mesothelioma Over-expression Cytoplasmic (Stoppoloni et al. 2008) 
 Ovarian cancer Over-expression Cytoplasmic (Prislei et al. 2013) 
 Urinary    tract 
urothelial carcinoma 
 Cytoplasmic (Liang et al. 2012) 
 Bladder cancer Over-expression Cytoplasmic (Miyata et al. 2013) 
 Glioblastoma Over-expression Cytoplasmic (Nabors et al. 2003) 
 Gastric cancer Over-expression Nuclear (Milne et al. 2006) 
 Pancreatic cancer Over-expression Cytoplasmic (Jimbo et al. 2015) 
 Prostate cancer Over-expression Cytoplasmic (Niesporek et al. 2008) 
 Thyroid cancer Over-expression  (Danilin et al. 2009) 
 Medulloblastoma Over-expression  (Nabors et al. 2001) 
Table 1.2: Association of Hu protein expression in Cancer. Summary of Hu proteins and their 
implication in cancer. This data particularly highlights a correlation between cytoplasmic over-
expression of HuR in cancer. 
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The localisation of RBPs within cells importantly influences its role in gene regulation events 
and its target mRNA transcripts. Although HuR protein is predominantly localised to the 
nucleus of normal cells, in response to environmental stimuli HuR can in an adaptive response 
translocate to the cytoplasm whereby it can participate in cytoplasmic gene regulation events 
(Atasoy et al. 1998, Nabors et al. 2001). In the cytoplasm, Hu proteins influence aberrant 
regulation of many mRNA transcripts. They can decrease the stability of tumour suppressor 
genes but more commonly increase the stability and translation of proto-oncogenes, cyclins, 
kinases, inflammatory factors, apoptosis-related factors that each have a direct influence of 
tumour formation and development(Wang et al. 2013). It is also important to consider the 
level of expression of Hu proteins in human cells since overexpression of the Hu homologue 
ELAV protein in Drosophila Melanogaster has shown to be lethal or produce cellular defects. 
This concentration-based functionality has also been observed in other RBPs (Zaharieva et al. 
2015b).  
Both the HuB protein isoforms are discussed in more detail in Section 1.6, are expressed in 
human Medulloblastoma cells and display different expression patterns in human brain and 
tumour cells (Gao et al. 1994). In Medulloblastoma cells extracted from a brain tumour, HuB 
proteins were found predominantly expressed in the cytoplasm. HuB proteins reside in 
granular structures that contain multiple protein molecules bound to each mRNA forming a 
multimeric RNP that then associates with polysomes. This highlights their involvement in 
translation or mRNA stability. Additionally, both HuB isoforms are also expressed in Small-cell 
lung carcinoma (Gao and Keene 1996). 
As discussed in Section 1.7.4, HuR proteins auto-regulation occurs through a negative 
feedback loop. This feature allows a stable nucleocytoplasmic distribution in normal cells (Dai 
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et al. 2012). In cancer, cytoplasmic HuR expression is related to the ability to bind and 
upregulate the stability of cancer-related mRNA transcripts, this helps accelerate the cancers 
progression. This is thought to occur in oesophageal cancers where upregulated cytoplasmic 
HuR expression is observed and associated with positive lymph node metastasis, deep tumour 
invasion, high-grade malignancy and poor survival rates during diagnosis (Zhang et al. 2014). 
Similarly, HuR cytoplasmic overexpression is seen in in breast cancer with characteristic large 
tumours, p53 positivity and oestrogen and progesterone receptor negativity (Heinonen et al. 
2007, Calaluce et al.2010). Knockdown of HuR in HeLa, a cervical carcinoma cell line, revealed 
HuR is a suppressor of apoptosis. Cellular stress caused by UV-radiation in HeLa cells showed 
upregulation of HuR and therefore extreme survival under stress (Lal et al. 2005). The role of 
HuR in transcript stabilisation is seen with Vascular endothelial growth factor-A (VEGF-A) and 
cyclooxygenase-2 (COX-2) mRNA. HuR bind specifically to AU-rich sequences in the 3’ UTR of 
VEGF and COX-2 transcripts. In tumour microenvironments, cytoplasmic HuR protein 
responds to hypoxia by stabilising of the mRNA transcripts of VEGF-A and COX-2 (Levy et al. 
1998, Kurosu et al. 2011). Under normal conditions, VEGF protein participates in a variety of 
physiological and pathological processes including stimulating the formation of blood vessels 
particularly during embryo development and wound healing. Overexpression of VEGF and its 
receptors, VEGFR-1, VEGFR-2, neuropilin-1, are associated with poor prognosis in Breast 
cancer (Ghosh et al. 2008).  
Recent research suggests RBPs influence miRNAs activity and stability and vice versa 
indicating a combined contribution towards regulating gene expression. HuR functions 
alongside miRNAs to aid the stabilisation process (Wurth 2012). For example, in breast cancer, 
HuR upregulates cyclin E1 expression by interacting directly within its transcript. Additionally, 
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miR-16 represses cyclin E1 through similar binding. This concludes that miR-16 can override 
HuR upregulation of cyclin E1 without affecting HuR expression and direct association with 
the cyclin E1 mRNA (Guo and Hartley 2006).  
1.11 Lung cancers 
Lung cancers are one of the leading causes of cancer-related deaths worldwide (Matsumoto 
et al. 2012). Lung cancer accounts for 12.7% of all cancer registrations in England and is the 
second most common malignant cancer for both females and males, after breast cancer in 
females and prostate cancer in males (King and Broggio 2018).  
Lung cancers are divided into two categories, Small cell lung cancer (SCLC) and Non-small cell 
lung cancer (NSCLC) which includes Squamous cell carcinoma, Large cell carcinoma and 
Adenocarcinoma (Van Meerbeeck et al. 2011). Whilst treatments for NSCLC have improved 
vastly in recent years, SCLC treatment is limited. This highlights the need for a deeper 
understanding of the disease, identification of novel targets and discovery of treatments 
(Lovly and Carbone 2011). 
1.11.1 Small cell lung cancer 
Small cell lung cancer (SCLC) is highly malignant and one of the most aggressive pulmonary 
neoplasms, with a rapid onset of symptoms (Ehrlich et al. 2014). Patients diagnosed with 
limited disease survive for 15-20 months with treatment. Patients with extensive disease at 
diagnosis survive between 7-11 months with treatment and without the median survival time 
is 2-4 months (Lampaki et al. 2016). Metastases are commonly found upon diagnosis in the 
liver, adrenals, bone, bone marrow and brain (Ehrlich et al. 2014, Glisson and Byers 2015). 
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SCLC originates from neuroendocrine cells (Glisson and Byers 2015). It was first referred to as 
‘Oat cell carcinoma’ when it was identified in 1936 in a asbestosis patient (Roodhouse Gloyne 
1936). 
SCLC shows a considerable degree of morphological histopathological variability. SCLC cells 
are small round, oval or spindle shaped cells with scanty cytoplasm (Brambilla et al. 2001). Of 
all lung cancers diagnosis, tumours with less than 10% of large cells is classified as pure SCLC 
by the World Health Organisation (WHO). Within the tumour, the size of the cells can vary 
however finely granulated chromatic, no prominent nucleoli and the lack of cell boarders are 
typical for SCLC morphology (Travis et al. 2015, Rekhtman 2010).  SCLC is distinguished from 
NSCLC physiologically due to aggressive nature, fast growth and easily developed metastases 
(Glisson and Byers 2015).  
Since 1970, there has been over 40 clinical trials conducted on SCLC patients with no 
significant change therefore the combination of chemotherapeutic drugs remain the same 
(Lampaki et al. 2016). Current research supports the idea that identifying a set of new novel 
antibody markers, more specific to the biology and behaviour of the SCLC will allow the 
development of a national screening program, improved targeted diagnosis and monitoring 
and specific treatments to overall improve the survival rate.  
SCLCs initiation and progression is a complex multi-step procedure. Progressive genetic 
alterations involving proto-oncogenes include the myc family, c-myb, c-kit, c-jun and c-src. 
Additionally two tumour suppressor genes that are affected are p53 and Retinoblastoma-
associated (Rb) (Cook et al. 1993). The use of paraffin-embedded tissue, highly polymorphic 
markers and PCR-based analysis revealed allelic loss on chromosomes 3p, 5q, 13q, and 17p 
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was found in 75-100% of SCLCs tumours obtained at autopsy. The 13q is typically significant 
of alteration to the Rb tumour suppressor gene (Merlo et al. 1994).  
Drug resistance often develops in SCLC. Early studies of the NCI-H69 SCLC cell line revealed 
amplification and expression of the P-glycoprotein encoded by MDR-1 and highlighted this as 
a cause of multidrug resistance in some SCLC tumours (Reeve et al. 1989). 
1.11.2 Non-small cell lung cancer 
Non-small cell lung cancer describes a series of Lung cancers including Adenocarcinoma 
(38%), Squamous cell carcinoma (20%), Large-cell carcinoma (5%), and other poorly 
differentiated variants (Goldstraw et al. 2011). In comparison to SCLC, it is seen to have better 
survival rates and clinically more manageable disease. 
Non-small cell tumours are defined by cells that are large, have a low nuclear to cytoplasmic 
ratio, have vesicular, coarse or fine chromatin and frequent nucleoli. Not all non-small cell 
lung tumour meet this criteria but are still considered NSCLC due to their large size and 
abundant cytoplasm (Travis et al. 1999). 
NSCLC is typically characterised by several genetic changes downregulating tumour 
suppressor genes and upregulating oncogenes. Research has sought to identify susceptibility 
genes that predispose Lung cancer. Of interest is 15q24–25, this region contains several genes 
of interest, including three genes that encode nicotinic acetylcholine receptor subunits 
(Thorgeirsson et al. 2008). Genes of interest in NSCLC include the tumour suppressors, tumour 
protein-53 (TP53), retinoblastoma-associated 1 (RB1), that govern two complementary 
regulatory pathways of proliferation control. Additional genes of interest are those including 
76 
 
epidermal growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4-
anaplastic lymphoma kinase (EML4-ALK) and cyclin-dependant kinase (p16INK4a). Genetic 
alterations including allelic loss of heterozygosity at chromosomes 3p and 17p are frequent 
in Lung cancers and has been shown to correlate with clinical parameters and poor prognosis 
(Chmara et al. 2004). 
Treatments targeting genetic alterations or the pathways they influence are in development. 
In NSCLC treatment, targeted gene therapies have focussed on mutations in EGFR and 
rearrangements in ALK. EGFR mutations are seen more commonly in Asian patients 
accounting for 30-50% of NSCLC cases in this population. Clinical trials using tyrosine-kinase 
inhibitors targeting EGFR proteins in patients positive for the EGFR mutation have shown 
promising results (Rosell et al. 2012). Alterations to the oncogenic fusion genes EML4-ALK is 
often seen in non-smokers and younger patients representing 2-7% of tumours (Reck et al. 
2013). ALK protein inhibition of EML4-ALK rearrangement-positive tumours saw a reduction 
in tumour size and a more stable disease in most patients (Kwak et al. 2010). 
1.12 Hu proteins in Small cell lung cancer 
The Hu protein family are considered tumour antigens in Small cell lung cancer (SCLC) 
(D’Alessandro et al. 2008). The neuronal Hu family members, HuB, HuC and HuD are 
ectopically expressed in SCLC tumours, but not in Non-small cell lung cancers. An over-
expression of HuR is common in both cancers (Manley et al. 1995). Paraneoplastic 
encephalomyelitis/sensory neuropathy (PEM/PSN) which accounts for 3-5% of all SCLC 
patients, although lower titres of Hu antibodies can be seen in about 15-20% of SCLC patients 
without autoimmune symptoms (Dalmau, Josep and Rosenfeld 2008, Kanaji et al. 2014).  
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As discussed in Section 1.12, the presence of Hu proteins in SCLC specifically is often symbolic 
of a more favourable cancer prognosis. Hu antigens initiate a humeral immune response 
producing an autoimmune attack on the nervous system where autoantibodies destroy Hu 
tumour antigens and normal immune antigens in the nervous system resulting in non-
reversible neurological paraneoplastic syndromes (Harmsma et al. 2013). Although a higher 
survival rate is predicted, the patients quality of life is reduced due to the symptoms of the 
paraneoplastic syndrome (Graus et al. 1997).  
Kazarian et al. (2009) showed in mice, anti-Hu levels rise before the cancer is chemically 
detectable. D’Alessandro et al. (2008) showed that in newly diagnosed SCLC patients, low 
anti-Hu-Ab are detected. Hu proteins could be used as biomarkers for this tumour type 
especially. Harmsma et al. (2013) summarised that the presence of Hu and anti-Hu 
autoantibodies is a good indicator of SCLC particularly since the immune response to Hu 
proteins may occur whilst the cancer is still small, asymptomatic and undetectable by routine 
methods. The cancer diagnosis could then be confirmed using imaging methods. Hu mRNA 
was detectable in the peripheral blood of SCLC patients, using RT-qPCR technologies 
suggesting a method to prompt further tests and secondly as monitoring tool (D’Alessandro 
et al. 2008). The immunoreactive regions of HuD protein have been mapped to the N-terminal 
region and in the first and second RRMs (Manley et al. 1995, Kazarian et al. 2009). 
A study looked at the role of MHC proteins in SCLC and the role they play in regulating the 
anti-Hu immune response. MHC Class I molecules are required for the presentation of viral or 
tumour antigens to cytotoxic T lymphocytes. MHC Class I proteins are found to be lowly 
expressed in SCLC, which is associated with a poor prognosis and increased metastatic 
potential. It was concluded that co-expression of Class I MHC and Hu antigen by tumours may 
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play a role in the development of anti-Hu associated paraneoplastic disorders (Dalmau et al. 
1995). 
Analysis of 20 primary human neuroendocrine lung tumour tissues revealed HuD ectopic 
expression. Sequencing revealed two inactivating somatic mutations in the coding sequence 
of HuD mRNA in 7 of the tumours. A stop codon mutation, (c.655C>T), resulting in a truncated 
protein and a frameshift caused by c.424delA. Loss of heterozygosity is common in cancer 
and results in the loss of gene function. This was seen in seven of the tumours studied 
(D’Alessandro et al. 2010). In the same study, genetic analysis of five SCLC cell lines revealed 
one mutation that was previously documented by Sekido et al. (1994). HuD mRNA 
experiences alternative splicing of its 5'-coding region resulting in an additional 87 base pairs 
of sequence and a termination codon. This codes for a small truncated protein of 11 amino 
acids but its function was undetermined. 
SCLC is associated with overexpression of c-myc protein and this contributes towards the 
cancers malignant and aggressive nature (Little et al. 1983). As previously described in Section 
1.10, HuD has additionally been shown to bind to AU-rich stability sequences of c-Myc mRNA, 
upregulating its expression (Cook et al. 1993, Liu et al. 1995). 
RT-qPCR and Western blot studies revealed HuC mRNA and HuC protein in 5 of 6 SCLC cell 
lines and 2 of 2 Large cell neuroendocrine carcinoma (LCNEC) cell lines which is a rare 
pulmonary tumour. Of SCLC patients with and without PEM/SN, 12.9% displayed anti-HuC 




Neuroblastoma (NB) is an embryonal tumour of the peripheral sympathetic nervous system 
characterized by a substantial phenotypic diversity. NB is the most common extra-cranial solid 
tumour diagnosed in children and represents 15% of all childhood cancer deaths (Maris et al. 
2007). NB has an average 5-year survival rate of less than 50% (Ehrlich et al. 2014). The 
severity of this disease highlights the need to yield actionable therapeutic targets for the 
highly fatal cancer (Louis and Shohet 2015). 
Neuroblastoma is a heterogenous disease in its pathology and in its molecular profile. This 
heterogeneity is responsible for the exceptional phenotypic diversity resulting in contrasting 
clinical presentations and varied treatment responses (Louis and Shohet 2015). At one end of 
the spectrum, it is possible that the cells reach maturity and even spontaneous regression. 
On the contrary, significant disease progression irrespective of treatment can be fatal due to 
the transient state of neuronal crest cells.  
Screening of thousands of NB cases have not found a single homogenous genetic or epigenetic 
mutation further supporting the molecular heterogeneity. Familial NB accounts for 1-2% of 
cases with the primary cause identified as a germline mutation in the anaplastic lymphoma 
kinase (ALK) gene (Mossé et al. 2008). Patients with an increased expression of N-myc proto-
oncogene (MYCN) have showed to have a poorer prognosis. N-Myc protein is a transcriptional 
regulator expressed in the peripheral neural crest. In normal cells it controls proliferation, 
migration and stem cell homeostasis (Westermark et al. 2011). The molecular profile of this 
cancer might provide an insight into development of the disease and give rise to new novel 
targets for new therapies. 
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Neuroblastoma provides an ideal disease model to study functional cellular hierarchy in solid 
tumours in relation to the cancer stem cell (CSC) theory, due to its embryonal origin and 
heterogeneity (Hansford et al. 2007). Additionally, its wide range of clinical behaviours that 
can show spontaneous regression or a very aggressive metastatic disease, with limited 
response to treatment also supports the CSC model (Monclair et al. 2009). The CSC model 
describes a functional cellular hierarchy for malignancy or clonal evolution within the tumour 
which is entirely supported by tumour initiating cell (TICs) (Kreso and Dick 2017, Coulon et al. 
2011). Hansford et al. (2007) investigated characteristics including self-renewal through 
sequential sphere-forming cells, tumorigenicity, drug resistance and the ability to 
differentiate towards distinct lineages to identify tumour initiating cells. They concluded NB 
cells contain cancer stem cell properties adequate in tumour-initiating ability. Coulon et al. 
(2011) later confirmed and showed that the CSC model correlated with NB tumour-initiating 
cells which was suggestive of functional stem cell-like characteristics and contributors of 
tumour progression. 
1.14 Hu proteins in Neuroblastoma 
Hu proteins and their corresponding antibodies have been found in Neuroblastoma. In 1992, 
Dalmau and Furneaux, showed HuD protein is aberrantly expressed in over 50% of 
Neuroblastoma cells. Later in 1997, Ball and King described HuD and HuB proteins as excellent 
neuronal markers of Neuroblastoma. Their study on 36 primary tissue samples and 11 
cultured cell lines, showed HuB or HuD were expressed in 98% of their test samples.  
Cytoplasmic protein aggregates causes cell death and neurotoxicity in Neurodegenerative 
diseases, however in cancer, increased protein expression has no effect showing their ability 
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to tolerate these aggregates and continue proliferation (Zaharieva et al. 2012). Also, seen in 
neurodegeneration is ectopic expression of proteins which leads to protein inspecificity and 
function and therefore cell death (Zaharieva et al. 2015b). 
In a third of all Neuroblastoma cases, over expression of the proto-oncogene, MYCN, is 
observed. The level of MYCN expression can be used to determine the clinical behaviour of 
the Neuroblastoma since its expression correlates with rapid disease progression. HuD is 
known to modulate the expression of n-Myc protein through post-transcriptional events 
(Lazarova et al. 1999). HuB is predominantly expressed in Neuroblastoma tumours with 
unamplified n-Myc status. HuD specifically was associated with a clinically favourable 
prognosis since it’s expression is associated with single copy n-Myc status and limited disease 
progression (Ball and King 1997). 
A study identifying the presence of Hu antigens in Neuroblastoma patients found them 
present in 78% cases with less than 4% having clinically detectable titres anti-Hu antibodies 
in their blood serum. This suggests the measure of Hu antigens is a good indicator of tumour 
presence. Neuroblastoma tumours expressing little or no Class I MHC proteins were more 
aggressive and had more metastasis. Correlation between expression of MHC Class I proteins 
and the anti-Hu immune response in Neuroblastoma was suggestive of an additional T-cell 
mediated cytotoxic response but this would need further clarification (Dalmau et al. 1995).  
1.15 Glioblastoma multiforme 
Glioblastoma Multiforme also known as Glioblastoma, are very aggressive tumours of the 
central nervous system (Nabors et al. 2003). Brain tumours are classified according to their 
origin including astrocytic tumours, oligodendrogliomas, ependymomas, and mixed gliomas. 
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Glioblastoma are a type of astrocytoma and have an extremely poor prognosis 
(Schwartzbaum et al. 2006).  
Todays grading system is based on the initial findings of Bailey and Cushing (1926) and  
Glioblastomas are always graded IV due to their high malignancy, invasiveness and growth 
rate and the tumours contain undifferentiated cells (Ferguson and Lesniak 2005). 
Glioblastomas are easily distinguished from low-grade astrocytic tumours, due to their 
distinct histopathological features including cellular atypia, mitotic figures, necrotic foci with 
peripheral cellular pseudopalisading and microvascular hyperplasia.   
Glioblastomas are the most common primary malignant brain tumour accounting for 16% of 
primary brain and central nervous system neoplasms. Generally it is considered a rare tumour 
with an incidence of less than 10 in 100,000 people globally (Thakkar et al. 2014).  
Glioblastoma develop by two different mechanisms, and although the tumours are not 
morphologically different, they contain different patterns of promoter methylation and 
expression profiles at both RNA and protein levels (Ohgaki and Kleihues 2007). 90% of 
Glioblastoma cases develop de novo where normal glial cells endure multistep tumorigenesis 
and are termed primary Glioblastoma. Genetically 70% are characterised by loss of 
heterozygosity 10q, 36% have epidermal growth factor receptor (EGFR) amplification, 31% 
have a p16INK4a deletion and 25% have phosphate and tensin homologue (PTEN) mutations. 
Tumours display rapid growth developing in 3 months on average and manifests in older 
people (Ohgaki and Kleihues 2007). Secondary Glioblastomas develop through progression 
from low-grade tumours including low-grade glial tumours or anaplastic glial tumours. 
Genetic mutations in the TP53 gene, amplification of platelet-derived growth factor receptors 
and loss of heterozygosity at 17p, 19q, and 10q are often found. Secondary Glioblastomas 
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develop over time but generally present in younger patients (Kleihues and Ohgaki 1999). 
Previously, it was thought Glioblastoma only developed from glial cells. However, it was 
recently shown that it can develop from multiple cell types if they have neural stem-cell like 
properties. The cells in these tumours vary in stages of differentiation with their phenotypic 
variations induced by alterations to the Akt and Notch signalling pathways (Phillips et al. 
2006).  
The cause of Glioblastoma is under consideration. One factor known to increase the risk of 
glioma is ionising radiation exposure. This typically appears years later following treatment 
for a different tumour or condition where the risk of developing Glioblastoma following 
radiotherapy is estimated at 2.5% (Johnson et al. 2015, Salvati et al. 2003). Other 
environmental factors are thought to include exposure to pesticides, smoking, 
electromagnetic fields, formaldehyde, and nonionizing radiation from mobile phones 
although evidence is limited for these factors (Alifieris and Trafalis 2015).  
Development of Gliomas is correlated with some genetic diseases including 
Neurofibromatosis 1 and 2, Tuberous sclerosis, Li-Fraumeni syndrome, Retinoblastoma, and 
Turcot syndrome. However, these genetic diseases account for less than 1% of all 
Glioblastoma patients (Ellor et al. 2014). 
Genome studies of the U87-MG Glioblastoma cell line highlighted 512 genes with 
homozygous mutations. The mutations included an array of different types including single 
nucleotide polymorphisms, small insertions and deletions, microdeletions and 
interchromosomal translocations (Clark et al. 2010). A further study of more than 200 tumour 
samples and 600 genes produced a genetic profile where three key signalling pathways that 
were commonly activated. These were the p53 pathway, the receptor tyrosine 
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kinase/Ras/phosphoinositide 3-kinase signalling pathway, and the retinoblastoma pathway. 
Activation of these pathways results in uncontrolled cell proliferation and enhanced cell 
survival, essentially driving the process of gliomagenesis (Chen et al. 2012). 
Glioblastoma is associated with a significantly poor prognosis which is preliminary determined 
by the patients age and the histological type of their tumour as described above 
(Schwartzbaum et al. 2006, Thakkar et al. 2014). The two-year survival rate for adults between 
46-64 years of age is 7.7% and for people over 65, it is 2.1% which emphasises the  aggressive 
nature of the disease (Bolognani et al. 2012). More recently, gene expression studies have 
given rise to genetic profiling allowing a prediction of patient outcome and response to 
treatment through the relationships of implicated genes in tumour biology (Sulman et al. 
2009).  
Glioblastoma are particularly challenging to treat because they embed in deep, specialised 
areas of the brain that control aspects of speech, motor function and the senses. The tumours 
proliferate and invade other tissues very quickly and there are no effective treatments 
available (Ware et al. 2003). Initially, seizures can be treated with antiepileptic drugs. Whilst 
corticosteroids help control vasogenic oedema and its symptoms. The ability of surgical 
resection has improved over the years, however the survival rate is still low (Thakkar et al. 
2014). Chemotherapy is an additional option and often follows surgical resection. Despite 
maximal initial resection and multimodality therapy, recurrence of GBM is common affecting 
around 70% of patients (Stupp et al. 2009).  
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1.16 Hu proteins in Glioblastoma multiforme 
In the brain, RBPs ensure RNA regulation by performing roles both within the nucleus and at 
distant sites (Darnell and DeAngelis 1993). RBPs also regulate protein translation at synapses 
possibly providing an insight into learning and long-term memory (McKee et al. 2005).  
In normal glial cells, HuR is in the nucleus whilst in Gliomas HuR experiences nucleoplasmic 
shuttling to the cytoplasm where it upregulates growth factors and promotes neoplastic 
progression. Another common feature in malignant Gliomas is that HuR is expressed in 
excessive amounts (López de Silanes et al. 2005, Wang et al. 2013, Nabors et al. 2003).  
HuR’s target-mRNA transcripts decay rates were analysed in Gliomas and it was determined 
to be slower than in astrocytes (Bolognani et al. 2012). Disruption to the cell cycle is a common 
feature in most Gliomas including apoptosis, proliferation and migration (Schwartzbaum et 
al. 2006, Ware et al. 2003). Glioblastoma has been identified to have TP53 mutation and EGFR 
amplification. HuR is known to stabilise and regulate the transcription of mRNA transcripts 
TNF-α, VEGF and IL-8 in Glioblastoma as they contain a 3’ untranslated region (UTR) with an 
AU- or U- rich cis-regulatory sequence optimal for the binding of Hu proteins. Stabilisation of 
these oncogenes promotes a higher grade tumour and poorer prognosis (Nabors et al. 2003). 
Filippova et al. (2011) determined that in Glioma cells, HuR increased cell proliferation, 
anchorage-independent growth and chemoresistance to regular glioma treatments. They also 
identified that the known oncogenic BCL-2 family are target sequences for HuR increasing Bcl-
2 protein expression levels.  
As previously mentioned, Musashi1 (MSI1) gene encodes an oncogenic protein that is found 
aberrantly expressed in high quantities in Glioblastoma but also Lung and Colon cancer. Msi1 
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protein regulates gene expression involved in cancer-related processes including cell 
proliferation, apoptosis, cell cycle and differentiation. MSI1’s 3’UTR contains AU- or U- rich 
cis-regulatory sequences to which Hu proteins can bind. HuD has previously been implicated 
as a post-transcriptional regulator of MSI1 in normal stem cells influencing differentiation 
(Bolognani et al. 2012). Whilst Vo et al’s (2012) study provided evidence that high expression 
of MSI1 was partially influenced by HuR through direct binding to and increasing stability 
leading to an increased protein expression of Msi1 proteins. This highlights the importance of 
HuR in Gliomagenesis (Vo et al. 2012).   
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1.17 Aims of this study 
The fact that Hu proteins are ectopically or overexpressed in Small cell lung cancer, 
Neuroblastoma and Glioblastoma raises the question about their role in these cancers. 
Therefore, the main aim of this study is to identify which of the four Hu proteins are expressed 
in the three different cancers and if a knockdown of Hu expression can identify specific targets 
that may contribute to the cancerous phenotype. 
To address this overall aim the following objectives were established: 
• RT-qPCR will determine the expression levels of HuB, HuC, HuD and HuR genes in the 
human cancer cell lines; SK-N-AS and SH-SY5Y for Neuroblastoma and U87-MG for 
Glioblastomas and NCI-H69, NCI-H345 and CorL88 for Small cell lung cancer. 
• After the initial expression level of the four Hu proteins in the cancer cell lines is 
analysed, a siRNA knockdown will be established. The efficiency of the knockdown will 
be confirmed at RNA expression level as well as at protein level through RT-qPCR, 
western blotting and immunofluorescence techniques. 
• MTS assay, migration assays and microscopy will be used to analyse cell viability, 
migration and morphology following siRNA knockdown 
• To characterise the role of Hu genes on a molecular level, expression levels of target 
genes described to play a role in the cancer development of Neuroblastoma and 
Glioblastoma will be analysed before and after the knockdown.  
• MTS assay, migration assays and microscopy will allow analysis of viability, migration 
and morphology following siRNA knockdown 
• To characterise the role of Hu genes on a molecular level, RT-qPCR of genes involved 
in each cancer’s development will be analysed to determine Hu proteins mRNA targets 




Methods & Materials 
2.1 Cell culture 
All cell culture was performed in a Category 2 laminar flow cabinet (Nuaire) to prevent 
airborne contamination. Cell lines were maintained in T25 and T75 tissue culture flasks (Fisher 
Scientific) and passaged regularly to maintain growth of cells by avoiding contact inhibition. 
Cells were incubated under standard conditions in a humidified incubator (Nuaire) at 37°C 
and 5% CO2.  
2.1.1 Cancer cell lines 
The human Glioblastoma, astrocytoma cell line, Uppsala 87 Malignant Glioma (U87-MG) were 
cultured as a monolayer in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza, Switzerland) 
supplemented with Penicillin 100U/ml, Streptomycin 100µg/ml, 10% heat-inactivated Foetal 
Bovine Serum (FBS) (Fisher), Glucose, 2mM L-Glutamine and non-essential amino acids. U87-
MG is one of the most commonly studied Glioblastoma vitro cell line models. It was derived 
from a male of unknown age (ATCC 2016h). 
The human Neuroblastoma cell lines, SK-N-AS and SH-SY5Y were cultured in DMEM (Lonza, 
Switzerland) supplemented with Penicillin 100U/ml, Streptomycin 100µg/ml, 10% heat 
inactivated FBS, Glucose, 2mM L-Glutamine and non-essential amino acids. Both cell lines 
derived from the metastatic site of the bone marrow. SK-N-AS is fully adherent and was 
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obtained from a six-year-old Caucasian female (ATCC 2016f), whilst SH-SY5Y is semi-adherent 
and was obtained from a four-year-old Caucasian female (ATCC 2016e). 
Human Small-Cell Lung Carcinoma (SCLC) cell lines, NCI-H69, NCI-H345 and CorL88 are 
suspension cell lines maintained in Roswell Park Memorial Institute medium (X GI 1640) also 
complete with Penicillin 100U/ml, Streptomycin 100µg/ml, 10% heat inactivated FBS, 
Glucose, 2mM L-Glutamine and non-essential amino acids. NCI-H345 was derived from the 
metastatic site of the bone marrow from a 64-year-old Caucasian male (ATCC 2016b). NCI-
H69 was taken directly from the lung as floating aggregates from a 55-year-old Caucasian 
male (ATCC 2016d). NCI-H345and NCI-H69 grow as clumps in suspension. COR-L88 was 
derived from the pleural effusion of a 55-year-old Caucasian male and grows semi-adherent 
(Sigma-Aldrich 2017a). 
Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines, NCI-H322 and NCI-H358 were 
maintained in X GI 1640 complete with Penicillin 100U/ml, Streptomycin 100µg/ml, 10% heat 
inactivated FBS, 2mM Glucose, L-Glutamine and non-essential amino acids. NCI-H322 
derived from a primary bronchioalveolar carcinoma of the lung from a 52-year-old male taken 
prior to treatment (Sigma-Aldrich 2017b). NCI-H358 was isolated from a primary 
bronchioalveolar carcinoma of the lung from a Caucasian male taken prior to treatment (ATCC 
2016c). Both cell lines grow as an adherent monolayer.  
2.1.2 Normal cell lines 
The human normal lung cell line BEAS-2B was maintained in Bronchial Epithelial Cell Growth 
Medium Bullet Kit (BEGM™) (Lonza, Switzerland) not including the gentamycin-amphotericin 
B mix (GA1000) provided with the BEGM kit. This media was supplemented with Penicillin 
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100U/ml, Streptomycin 100µg/ml. BEAS-2B cells were derived from normal bronchial 
epithelium obtained from autopsy of non-cancerous individuals (ATCC 2016a). These cells 
grow as an adherent monolayer. 
The normal human brain cell line SVG p12 was cultured in Eagle's Minimum Essential Medium 
(EMEM) (Lonza, Switzerland) supplemented with 10% FBS and Penicillin 100U/ml, 
Streptomycin 100µg/ml. This cell line grows as an adherent monolayer. These cells were 
extracted from the brain of healthy patients (ATCC 2016g). 
2.1.3 Cell harvesting 
Harvesting of cells from tissue culture flasks of 80% confluency was completed for general 
passaging, preparation for experiments or cryopreservation of cells.  
To subculture the adherent cell lines, the nutrient-depleted growth media was discarded, the 
cells were washed once with 10ml Dulbecco’s Phosphate Buffered Saline (DPBS) 
(2.7mM potassium chloride, 137mM sodium chloride, and 1.76mM potassium phosphate per 
litre in H2O, pH7.4) to remove any traces of serum, Calcium and Magnesium that inhibit the 
trypsin process. 1ml of Trypsin (0.5%) enzyme was added and incubated for 5 minutes at 37°C 
to detach the cells from the flask. Tapping of the flask allowed any final attached cells to be 
released. Fresh growth medium, warmed to 37°C in a heated water bath (Clifton) was added 
to re-suspend detached cells which could then be split into additional flasks for continued 
growth or transferred to a 20ml universal tube, pelleted at 1500x g in an Eppendorf centrifuge 
5702 (Eppendorf), counted and used in further experiments. 
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Suspension cells line were split by transferring nutrient-depleted media containing cells to a 
new flask and adding sufficient fresh media to allow further growth. Alternatively, for 
experiments, the cells in media were transferred to a 20ml universal tube and centrifuged at 
1500x g for 5 minutes in an Eppendorf centrifuge 5702. The pelleted cells were then re-
suspended in fresh media. The method of cell counting follows in Section 2.4.1. 
2.1.4 Cell counting 
Harvested cells were transferred to a 20ml universal tube and centrifuged for 5 minutes at 
1500x g to obtain a cell pellet. After the supernatant was discarded, the pellet was suspended 
in 10ml fresh medium and mixed by pipetting. A 200µl aliquot of the new cell suspension was 
mixed 1:1 dilution with 0.4% Trypan Blue stain (Gibco) once again ensuring sufficient mixing.  
Live unstained cells were counted by loading 15 µl to the bottom of a coverslip loaded on a 
haemocytometer, which is evenly distributed along the counting chamber by capillary action. 
Using a microscope set on the 10X objective, the corner sixteen squares of the 
haemocytometer were counted using a hand tally counter. 
2.1.4.1 Calculating viable cell number 
An average of the corner 16 squares was calculated, multiplied by 2, the dilution factor to 
allow for the trypan blue stain (Gibco), and further multiplied (104), the standard conversion 
factor for the haemocytometer. The calculated number is the number of viable cells/ml of the 
original suspension.  
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2.1.5 Cryopreservation of cells 
In preparation for long-term storage, cells were harvested from 80% confluent cell culture 
flasks and pelleted by centrifugation for 5 minutes at 1500x g then the supernatant was 
discarded. Cell pellets were then re-suspended in 1.5ml of cold freezing-media (complete 
media containing an extra 20% FBS and 10% Dimethyl sulfoxide). Dimethyl sulfoxide (DMSO) 
lowers the freezing temperature of the medium allowing it to cool more slowly, reducing the 
chance of ice crystals forming therefore preventing cell death. The cell suspension was 
transferred to polypropylene cryovials (Sarstedt, Germany). To preserve cells for long term 
storage, cell lines were stored in the gas stage above liquid nitrogen, whilst for short term 
storage, cell lines were kept at -80°C in a freezer (Sanyo, Japan).  
2.1.5.1 Thawing of cryopreserved cells 
Frozen cell aliquots were thawed quickly by agitating the cryovials in a 37°C water bath 
(Clifton) to avoid DMSO-related cell death. The cells were then transferred to a T25 flask 
containing warmed complete cell culture medium. Following a 24-hour incubation at 37°C 
and 5% CO2, cells were either sub-cultured or the medium replaced.  
2.1.6 Microscopy  
Cells were assessed for confluency using the Eclipse II inverted fluorescent microscope. Cell 
images were obtained by a Microtec camera for single images. More information  
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2.2 Gene studies 
Polymerase Chain Reaction (PCR) was used to determine the expression level of each Hu gene 
in each cancer cell line and non-cancerous control cell lines and additionally, confirm the 
annealing temperature of each primer set. Real-time quantitative PCR (RT-qPCR) was then 
performed as a more accurate method of gene expression. In preparation for all PCR 
reactions, the following steps occur: RNA isolation, RNA quantification, RNA purity analysis by 
gel electrophoresis and reverse transcription for the conversion of RNA to synthesis 
complementary DNA (cDNA). 
2.2.1 Total RNA isolation 
Total RNA from all the cell lines was extracted using the TRIsure reagent following the 
manufacturer’s guidelines with addition steps detailed below (Sigma-Aldrich). Cells were 
harvested from flasks using 1ml TRIsure or from a well-plate using 0.5ml TRIsure and a cell 
scraper. The contents were then transferred to an Eppendorf tube and mixed by pipetting to 
lyse the cells. This suspension was then transferred to an Eppendorf tube and incubated at 
room temperature for 5 minutes before 0.2ml of chloroform was added. Following vigorous 
mixing for 15 seconds, a further incubation for 3 minutes at room temperature followed by 
centrifugation for 15 minutes at 12,000g. The contents separated into three layers, a lower 
organic phase, an interphase that contain proteins and deoxyribonucleic acid (DNA) and an 
upper aqueous phase containing the RNA. The aqueous layer was carefully transferred to a 
new Eppendorf tube. To further eliminate traces of the TRIsure reagent, the chloroform step 
was repeated. An equal volume of ice-cold isopropanol allows the RNA to precipitate out of 
the aqueous phase. Samples were incubated at room temperature for 10 minutes and 
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centrifuged for 10 minutes at 12,000g. Additionally, for smaller samples with a lower RNA 
yield, 1µl glycogen was added at this stage. Glycogen acts as a carrier and improves the 
visibility of the RNA pellet. The pellet was washed with 70% ethanol by vortex mixing and 
undergoes a final centrifuge of 7500g for 5 minutes. The RNA pellet was air-dried and eluted 
in 12-20µl of Diethylpyrocarbonate (DEPC)-treated water dependent of the size of the starting 
sample. RNA was either stored in the -80°C or kept on ice ready for cDNA preparation. 
2.2.1.2 Removal of genomic DNA contamination 
All RNA samples were treated to remove any traces of DNA. This process was done using the 
Invitrogen TURBO DNA-free™ kit. 0.1 volume of 10X buffer and 1µl of TURBO DNase was 
added to the RNA. Following mixing by pipetting, the samples were incubated for 30 minutes 
at 37°C. 0.1 volume of DNase Inactivation reagent was added, and the samples mixed well. 
The samples were incubated at room temperature for 5 mins to allow the inactivation to work 
and finally the samples were centrifuged for 90 seconds at 10,000g to pellet the inactivation 
reagent and contained contaminants and the RNA transferred to a new tube.  
To further purify the RNA sample, 200µl of phenol and 180µl of DEPC-treated water were 
added to the samples. The samples were mixed via vortex and spun for 10 minutes at 13,000g. 
The samples separated to three phases of which the upper phase was transferred to a new 
tube. To the new tube, 200µl of 24:1 chloroform-isoamylalcohol was added and a further 
centrifuge for spin 5 minutes at 13,000g. The aqueous phase was transfer to a new tube. To 
this tube 20µl of 10% sodium acetate, 1µl of glycerol and 500µl of Ethanol were added. The 
samples were mixed thoroughly then incubated at -20°C for 20 minutes. A spin of 30 minutes 
at 10,000g was performed. The supernatant was removed then 200µl 75% ethanol was added 
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and a final spin of 10 minutes at 10,000g. The supernatant was discarded, and the RNA pellet 
was resuspended in 20µl of DEPC-treated water. 
2.2.2 RNA quantification  
The quality and quantity of the extracted RNA samples was analysed using a Nanodrop One™ 
spectrophotometer (Thermo Fisher Scientific) set at 260nm. 2µl of the RNA sample was 
loaded onto the pedestal of the spectrophotometer. RNA Purity was measured by a ratio of 
absorbance at 260 nm and 280 nm. 
2.2.3 Gel electrophoresis for RNA Integrity 
Agarose gel electrophoresis was used to analyse the integrity of the RNA, absence of other 
nucleic acid contamination and visualise ribosomal RNA subunits. Tris/acetic acid/EDTA (TAE) 
buffer (40mM Tris, 20mM acetic acid, 1mM Ethylenediamine tetraacetic acid (EDTA) buffer 
and 1.5% gel was used. RNA samples were mixed with 1x loading dye (2.5% Ficoll®-400, 11mM 
EDTA, 3.3mM Tris-HCl, 0.017% SDS, 0.015% bromophenol blue) and FastRuler™ Middle Range 
DNA Ladder (10mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 60% glycerol and 60mM 
EDTA) with the band sizes 100, 400, 850, 2000 and 5000bp. To visualise separated nucleic 
acids under ultraviolet (UV) light, 2µl GelRed™, a nucleic acid intercalating dye was added to 
melted agarose. 40V was applied to the gel (Bio-Rad) and then analysed using a UV Analyser 
(Bio-Rad) at 302nm and Bio-Rad Image Lab 4.1 software. 
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2.2.4 cDNA synthesis 
RNA was reverse-transcribed using the Tetro cDNA synthesis kit (Bioline) following the 
manufacturer’s protocol. 1500ng of RNA was used for all cDNA reactions. Mastermix 
consisting of oligo (dT)18 primers, 10mM dNTP mix, 5x RT buffer, 1 u/µl Ribosafe RNase 
Inhibitor, 200u/µl Tetro Reverse Transcriptase and DEPC-treated water was made to total 
20µl. Samples are incubated for 45°C for 30 minutes followed by a termination incubation of 
85°C for 5 minutes. The temperature changes were controlled by the Eppendorf Mastercycler 
Gradient (Eppendorf). The cDNA samples were chilled on ice and used immediately or stored 
at -20°C. 
2.2.5 Polymerase chain reaction 
PCR analysis was undertaken to test for primer specify and to confirm the product size 
determined primer blast software (NCBI 2017). 
For each reaction, 0.6µl dNTP, 3.0µl buffer, 0.2µl Taq, 1.5µl of each primer set for each Hu 
gene and β-Actin housekeeping gene and 300ng cDNA together with water to total 25µl. 
Samples were run in triplicate with a negative control for each primer set. For PCR, the 








PCR Stage Temperature Time 
Initial Denaturation 97ºC 5 minutes 
Denaturation 94ºC 1 minute 
Annealing 56ºC 1 minute 
Extension 72ºC 1 minute 
Repeat for 39 Cycles   
Final Extension 72ºC 10 minutes 
Hold 4 ºC  
Table 2.1: Benchtop PCR protocol. The cycling temperature and time period used at each PCR stage. 
 
The optimal annealing temperatures were determined by a gradient temperature PCR with 
temperatures ranging from 55°C to 61°C increasing 1°C every cycle. Initially two primer sets 
for each Hu protein were used alongside one ß-Actin primer as a positive control. Following 
optimisation one primer set for each Hu protein was selected and used in further PCR 
applications. The primers for HuB, HuC, HuD, HuR, GAPDH and β-Actin were purchased from 
Invitrogen and the sequences are detailed in Table 2.3. 
2.2.5.1 Gel electrophoresis for PCR band analysis 
The PCR products were analysed using 1.5% agarose Tris/Borate/EDTA (TBE) gel 
electrophoresis described in Section 2.2.3 and a PCR marker (New England Biolabs) displaying 
bands of 50, 150, 300, 500 and 766bp. TBE buffer consists of 89mM tris base, 89mM boric 
acid, 2mM EDTA.NA22H20 per 1 litre, pH8.  
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2.2.6 Real time-quantitative polymerase chain reaction 
Real time quantitative PCR (RT-qPCR) was performed using Hard-Shell® 96-Well, low profile, 
semi-skirted, green PCR Plates (Bio-Rad) sealed by a Microseal® Adhesive film (Bio-Rad) and 
the Bio-Rad CFX96 PCR Detection System (Bio-Rad). For each reaction, 0.4µM of each primer, 
300ng of cDNA and milli-Q water was added to 5µl of iTaq™ universal SYBR® Green supermix 
(x2) (Bio-Rad) creating a 10µl reaction. Primer sequences are listed below in Table 2.3. 
The amplification protocol is detailed in Table 2.2. β-actin served as a positive control and to 
normalise expression levels in analysis. Negative controls containing extra Milli-Q water in 
replace of cDNA were used. Each sample had three replicates. 
 
PCR Stage Temperature Time 
Initial Denaturation 95°C 3 minutes 
Denaturation 95°C 20 seconds 
Annealing 60°C 30 seconds 
Extension 72°C 30 seconds 
Repeat for 39 Cycles   
Melt Curve 55°C – 95°C 5 seconds 
Table 2.2: RT-qPCR cycling. The cycling conditions showing temperature and time period used at each 
RT-qPCR stage. 
2.2.6.1 Real time-quantitative polymerase chain reaction analysis 
Quantitative PCR data was initially interpreted by the Bio-Rad CFX manager software. The 
mean threshold cycle values (Ct) were determined for each Hu gene and β-actin. For general 
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gene expression, the relative quantification (RQ) method, the expression change in fold-
difference was calculated using the formula:  
ΔCT = Ct target – Ct β-Actin 
This determines the quantification of the target gene against the housekeeping gene to 
investigate physiological changes in gene expressions levels.  
When comparing fold gene expression before and after small interfering RNA (siRNA) 
knockdown experiments, I used the normalised expression analysis for which the formula is: 
RQ= 2- ΔΔCT 
Where, ΔΔCT = ΔCT treated – ΔCT control 
The normalised quantification analysis shows any changes to expression levels of target genes 
following treatment.  
Melting curve analysis was conducted to measures the dissociation of double-stranded DNA 
during the heating process described in Table 2.2, by recording the absorbance intensity of 
fluorescent probes.  
2.2.7 Primer design for qualitative polymerase chain reaction 
All primers were designed using Primer-BLAST: a tool to design target-specific primers for 




Gene Size Primer Sequence 
HuB(1) 75bp Forward  5′- TGGGAGAACTGCACCGTTAC -3′ 
  Reverse  5′- TGGCAGCAATTACCTGCTTT -3’ 
HuB(2) 396bp Forward  5’- AAACCTTAAGGGAGAAAGCAGG -3’ 
  Reverse  5’- AGAAGCTGAACTTGGGCGAG -3’ 
HuC(1) 526bp Forward  5′- ACAAGATCACAGGGCAGAGC -3′ 
  Reverse  5′- CCGTAGGCCATGTTGAGCA -3’ 
HuC(2) 318bp Forward  5’- GACCAGGTCACAGGTGTCTC -3’ 
  Reverse  5’- GATGGCGATCGGCGAGAA -3’ 
HuD(1) 585bp Forward  5′- GGTTTCAGCTCACTGCTCCT -3′ 
  Reverse  5′- GGACGGGCATATGAGACCTTT -3’ 
HuD(2) 592bp Forward  5’- ATCGGGGGTTTCAGCTCACT -3’ 
  Reverse  5’- CGGACGGGCATATGAGACCTTT -3’ 
HuD(3) 359bp Forward  5′- GTCTCTTCGGGAGCATTGGT -3′ 
  Reverse  5′- CCTCTTATCAAAGCGGAT -3’ 
HuD(4) 112bp Forward  5’- CCAGGCCCTGCTGTCCC -3’ 
  Reverse  5’- AGGCTTCTCATTCCATC -3’ 
HuD(5) 245bp Forward  5′- AGCCAATTTCAGCAAGGCTC -3′ 
  Reverse  5′- GCAGAGCTTCGACTCTTCTG -3’ 
HuD(6) 73bp Forward  5’- ACACATACACGAAAGAGAGAGAAACAA -3’ 
  Reverse  5’- AACACTGGCTTATAAAGTCCATGGT -3’ 
HuR(1) 302bp Forward  5′- CGGGATAAAGTAGCAGGACACA -3′ 
  Reverse  5′- CGGATAAACGCAACCCCTCT -3’ 
HuR(2)  277bp Forward  5’- GAAGACCACATGGCCGAAGA -3’ 
  Reverse  5’- GGCGAGCATACGACACCTTA -3’ 
ß-Actin 168bp Forward 5’- CTGGAACGGTGAAGGTGACA -3’ 
  Reverse 5’- AAGGGACTTCCTGTAACAATGCA -3’ 
Table 2.3: Hu primer sequences. Sequences and target amplicon size for each primer. 
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2.2.8 PrimePCR™ assays  
To study individual genes affected by the Hu proteins, PrimePCR™ pathway plates with 
primers for specific genes already loaded in were purchased from Bio-Rad. For Glioma, we 
used the plate, Human Glioma Tier 1 and for Neuroblastoma we used Human Neuroepithelial 
Neoplasms Tier 1. The PCR plates also include general PCR controls. The Plates were loaded 
the same as normal PCR plates but without primers. 
2.7.9 Statistical analysis of transfections 
All results represent the mean ± standard deviation from three independent experiments. An 
unpaired two-tailed T-test was used to evaluate the differences between the control cells and 
Hu knockdown cells in GraphPad prism software. Significant significance is displayed as *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. 
2.3 Western blotting 
Western blotting allows the detection of specific proteins with in a cell line. Firstly, protein is 
extracted from a cell line, it is then quantified and prepared for western blotting. 
2.3.1. Cell lysis 
Whole cell lysates were prepared from all cell lines by adding 1ml of ice-cold RIPA (Radio 
Immuno-Precipitation Assay) buffer containing 150mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50mM Tris with pH 8.0, directly to a 75cm2 confluent flask which has 
been washed with PBS. For 6-well plates a smaller volume of 0.5ml RIPA buffer was used. Cell 
scrapers aided detaching of the cells from the flask and collection into an Eppendorf tube. The 
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suspension was left rocking for 30 minutes at 4°C. The samples were then centrifuged at 
13,000g for 20 minutes to pellet cell debris and the supernatant was transferred to a new 
tube. Samples were stored on ice prior to protein spectrophotometry, Western blotting or 
storage at -20°C for longer periods of time.  
2.3.2 Protein quantification 
2.3.2.1 Spectrophotometry 
The protein concentrations were initially determined using a spectrophotometer at 280nm using 
RIPA buffer as a blank. Aliquots were stored at -20°C. 
2.3.2.2 Bradford assay 
To optimise the protein quantification, the Bradford assay was used. A series of standard 
Bovine Serum Albumin (BSA) concentrations were prepared from 100 to 1000µg/ml with a 
blank sample at 0µg/ml. The BSA was diluted in deionised water. At the same time, five 
dilutions of the unknown protein isolations were diluted also in deionised water to create a 
range between 0 and 1:15. All dilutions were performed in cuvettes to which 1ml of Bradford 
reagent was added, mixed and incubated at room temperature for five minutes. The 
absorbance of the standards and unknown samples were read at 595nm.  
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2.3.3 Protein preparation 
The proteins were mixed 1:1 ratio with SDS loading buffer (1M TrisHCl pH 6.8, 10% SDS, 0.2% 
Bromophenol blue, 1M DTT and Glycerol in MilliQ water). The samples were boiled at 95ºC for 
5 minutes in a heating block to ensure denaturation. 
2.3.4 Sodium dodecyl sulphate-polyacrylamide gels  
A 12% SDS-PAGE gel composed of a 4% stacking gel (30% Acrylamide, 1m Tris HCl pH6.8, 10% 
SDS and water) and a 12% separating gel (4x Lower gel buffer (1.5M Tris Base, 0.5% SDS and 
H2O), 30% acrylamide, 10% ammonium persulphate, TEMED and water) was used to separate 
proteins of different samples.  
To improve the efficiency and manage time restraints, 12-well Mini-Protean® TGX Stain-free™ 
Any kD™ Precast Gels (Bio-Rad) were also used.  
2.3.5 Separation of proteins 
The Mini-PROTEAN® electrophoresis tank (Bio-Rad) was filled with 1L protein running buffer 
(3.5mM SDS, 25mM Tris, 192mM Glycine and water) ensuring both inside and outside of the 
chambers were filled. Once the gel combs were removed, the wells were loaded with 20µl of 
sample and at least one well contained 5 µl Precision Plus Protein™ Dual Colour Standard (Bio-
Rad) which has stained bands ranging between 10-250kD.  
Current was applied to the SDS-PAGE gel at 20mA for 10 minutes, followed by 25mA (until the 
gel had run to the end) for a single gel to allow the separation of proteins. The current was 
increased on the addition of more gels into the tank.  
104 
 
2.3.6 Transfer to nitrocellulose membrane 
On completion of the electrophoresis, the gels were released from the plates and proteins were 
transferred from the gel to a nitrocellulose membrane, either by a wet blot system or later a 
semi dry blotting. For the wet blot method, a sandwich of Grade 3MM Chromatography blotting 
paper (Fisher), gel and Amersham Protran 0.45 nitrocellulose membrane (Fisher Scientific) was 
held tightly in a holder and 70V was applied to the tank containing Transfer buffer (25mM Tris, 
192mM glycine, 20% (v/v) methanol, 0.1% SDS in water) for approximately 1 hour at room 
temperature. For the semi-dry blot method, a Trans-Blot® Turbo™ Midi PVDF Transfer Pack 
(Bio-Rad) and Trans-Blot®Turbo™ Blotting System (Bio-Rad) were used. The gel was placed 
onto a nitrocellulose membrane directed towards the anode. The Bio-Rad pre-defined 
method for a mixed molecular weight turbo mode which runs for 7 minutes at 55V, 1.3A was 
used for all membranes. 
2.3.7 Membrane blocking 
The membrane was blocked in 5% semi-skimmed milk powder diluted in Tris-buffered saline 
with/Tween solution (50mM Tris-HCl, pH 7.6; 150mM NaCl, H20 and 0.05% Tween20) (TBST) 
for 30 minutes on a Gyro-rocker (Stuart Scientific Bibby). The remaining binding surface of the 
membrane is blocked to prevent nonspecific binding of the antibodies. The milk was removed 
ready for the addition of antibodies.  
2.3.8 Immunolabelling 
The primary Hu Antibodies were sourced from Santa Cruz Biotechnology. Anti-HuB (N-15): sc-
5982 goat polyclonal IgG, anti-HuC (G-15): sc-5981 goat polyclonal IgG, anti-HuD (E-1): sc-28299 
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mouse monoclonal IgG, anti-HuR (G-8): sc-365816 mouse monoclonal IgG. Anti-GAPDH (14C10) 
rabbit monoclonal IgG was purchased from Cell Signalling. Primary antibodies were added to 
membranes at a 1:1000 dilution in TBST containing 10% semi-skimmed milk powder. The 
membranes were left in the antibody solution on the gyro-rocker (Stuart Scientific Bibby) 
overnight at 4°C.  
The non-bound primary antibody was removed by washing the membrane in TBST for three 
times for 10 minutes on the gyro rocker (Stuart Scientific Bibby). Horse-radish peroxidase (HRP)-
conjugated secondary antibodies, goat anti-mouse IgG (H+L) Poly-HRP conjugated antibody 
(Life technologies) at a concentration of 1:10000 or goat anti-rabbit fluorescent HRP-conjugated 
antibody (Cell signalling), Rabbit anti-goat IgG (H+L) Secondary Antibody HRP conjugate (Life 
Technologies) 1:2000 in TBST 0.5% semi-skimmed milk powder was added to the membrane and 
left to incubate at room temperature for 1 hour with constant rocking. Three final washes of 10 
minutes in TBST occurred to remove unbound secondary antibody.  
2.3.9 Immunodetection  
To develop the membrane, Supersignal® West Femto Maximum Sensitivity Substrate 
Chemiluminescent kit (Thermo Fisher Scientific) was used following the manufacturer’s 
instructions, of which 1ml of luminol enhancer solution and 1ml of stable peroxide buffer was 
added and left to develop for two minutes. Immunodetection of Hu proteins and controls were 




2.4 Immunofluorescence protein labelling 
Cells were double-immunostained to confirm the presence and localisation of Hu proteins and 
the cell nucleus.  
2.4.1 Adherent cell lines  
The cell lines were seeded into sterile 6-well plates containing 19mm glass cover slips at 
0.5x105/ml. Cells were incubated overnight at 37ºC and 5% CO2. The adhered cells were washed 
with PBS three times for 10 minutes and fixed with cold 4% paraformaldehyde for 20 minutes. 
Cells were washed to remove the fix, three times for 10 minutes with PBST (1x PBS, 10% FBS, 
0.1% Triton X100). Primary antibody anti-HuB goat polyclonal IgG, anti-HuC goat polyclonal IgG, 
anti-HuD mouse monoclonal IgG, anti-HuR mouse monoclonal IgG (Santa Cruz Biotechnology) 
was added to the well diluted in Phosphate buffered saline with Tween 20 (PBST). The plates 
were left overnight at 4°C in the dark. The wells were then washed with three times with PBST 
again. The secondary mouse anti-goat Alexa Green 488 Fluorescein isothiocyanate (FITC) IgG 
(Invitrogen) or goat anti-mouse Alexa 488 FITC IgG (Fisher) was applied to the wells 1:250 
dilution 4',6-diamidino-2-phenylindole (DAPI) nucleus stain 1:1000 in PBST and incubated for 1 
hour. Cells were washed a final three times for 10 minutes in PBST. Analysis is described below 
in section 2.4.3. 
2.4.2 Suspension cell lines 
Cells were seeded into 6-well plates at a concentration of 1x105/ml. Following 24 hours’ 
incubation, the cells were transferred to an Eppendorf tube, to pellet the cells, the tube was 
spun at 800rcf for 3 minutes and the media discarded. The pellet was re-suspended in 160µl of 
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PBS and 20µl of 3.7% paraformaldehyde was added to the suspension. Following incubation at 
room temperature for 15 minutes, the suspension was centrifuged for 3 minutes at 800rcf and 
the supernatant was discarded. 1ml of PBS was added and the tube was spun at 800rcf for 3 
minutes and the supernatant discarded, and the wash step repeated. To permeabilise the cells, 
the pellet was re-suspended in 500µl of 0.3% Triton X100 in PBS. The tube was centrifuged at 
800rcf for 3 minutes and the supernatant removed. 1µl primary antibody for anti-HuB, anti-HuC, 
anti-HuD or anti-HuR suspended in PBST was then added and incubated at room temperature 
overnight. The cells were centrifuged for 3 minutes at 800rcf followed by a wash with 500µl PBST 
and a spin for 3mins at 800rcf twice. The secondary antibodies were added along with 1µl DAPI 
nucleus stain. This suspension was left for 1 hour at room temperature. The tube was spun at 
800rcf for 3 minutes and the supernatant removed. Two final washes in PBT spun at 800rcf for 
3 minutes occurred. Following the discard of the final supernatant the cells were transferred to 
a coverslip. 
2.4.3 Analysis of immunofluorescence 
Before fluorescence microscope analysis, all the coverslips were mounted on a microscope slide 
using Vectashield (Vectorlabs) to protect the fluorescent labelled samples from photobleaching 
the presence and cellular localisation of the different proteins were visualised and 
photographed using the Nikon Eclipse II fluorescent microscope, Microtec camera with the DAPI 
- 358nm and Fluorescein isothiocyanate (FITC) - 495nm filters and imaged using the SOFTWARE. 
Images were then overlaid using the software Image-J (National Institute of Health, US). 
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2.5 Cell migration assays 
Cell movement was recorded on a CytoSMART™ microscope camera (Lonza, Switzerland) set 
to image every 15 minutes until the migration is complete or a given time. Due to malfunction 
of this equipment mid-project, cell movement was recorded using the Nikon Eclipse II 
fluorescent microscope and Microtec camera. 
2.5.1 Agarose-gel migration 
Prior to cells seeding, a 10µl droplet of 0.5% solution of electrophoresis grade agarose gel was 
created in 24-well opening. After 15 minutes’ cells were seeded into 24-well plate at a 
concentration of 5x104 in 500µl of fresh media. Cells were incubated for 24-hours to allow 
the cells to adhere to the wells before imaging began. Images were captured every 15 mins. 
The images analysed were every 6 hours over a 42-hour period. Images were acquired by a 
CytoSMART™ camera. 
2.5.2 Scratch-wound assays 
Cells were seeded into 6-well plates SK-N-AS 0.7x105/ml, SH-SY5Y 1x105/ml and U87-MG 
0.65x105/ml, 72-hours post transfection once protein knockdown was confirmed, multiple 
wounds were made per well using a sterile metal syringe edge to disturb the monolayer. 
Detached cells were removed by replacing the media. The wound was imaged every 24 hours 
for 96 hours. Between imaging cells were incubated under normal conditions.  
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2.5.3 Data analysis of migration assay 
All imagery analysis of migration assays was achieved using the software Image-J (National 
Institute of Health, US). Percentage area of cell migrated into agarose gel and percentage area 
of cells invading an man-made gap was calculated. 
2.6 Cell metabolism assay 
To determine any changes in cell growth before and after transfection, CellTiter 96® AQueous 
One Solution Cell Proliferation Assay (MTS) (Promega, US) was used. All studies were under 
normal cell culture conditions. 
This cell proliferation assay focuses on the reduction of the tetrazolium compound [3-(4,5-
dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt also 
known as MTS. Like the MTT assay described above, NADPH and NADH produced by 
dehydrogenase enzymes in metabolically active cells aid the reduction process. Phenazine 
ethosulfate (PES) combines with MTS to form a stable solution. 48-hour post-transfection, 
20µl of the CellTiter 96® AQueous One Solution Reagent was added to each well of the 96-well 
plate containing cells in 100µl of medium. The plate was then incubated under normal 
conditions for 2 hours. The absorbance of the plate was then read at 490nm using the 
fluorescent plate reader.  
From the absorbance readings, we could calculate the percentage of cell growth and cell 
growth inhibition using the following equations. 
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2.6.1 Data analysis of proliferation assays 
Changes were calculated as percentage of control cell growth using the formula: 
Change in proliferation = 
(%) 
Mean absorbance of Hu siRNA 
transfection 
X100 
Mean absorbance of Hu siRNA 
control transfection 
 
Significance was calculated by a two-tailed t-test.  This analysis allows the linear relationship 
between cell number and signal produced to be documented.  
2.7 Transfection 
Each cell line was tested to derive the most suitable cell seeding, incubation periods, 
transfection reagent and concentrations of those transfection regents and siRNAs.  
2.7.1 Small-interfering RNAs  
All siRNA was purchased in a stock of 10nmol which was suspended in 500ul of 1X siRNA 
buffer (Thermo Fisher Scientific) to produce a 20uM stock. Further dilutions of this stock were 








































2.7.2 JETprime transfection 
JETprime (Polyplus transfection) regent was determined the most suitable for SK-N-AS 
transfection. SK-N-AS cells were seeded at 1.4x105 for RNA or 1.3x105 for protein analysis in 
6-well plates and left under normal cell culture conditions for 24 hours. siRNAs were diluted 
to give a final concentration of 50nM and 4ul of JETprime was added. After a quick vortex and 
spin, it was left to incubate at room temperature for 15 minutes for the JETprime/siRNA 
complexes to form. To mix was then added dropwise to the wells containing 2ml Antibiotic-
free media and incubated for 48 hours at 37ºC and 5% CO2. After transfection, cells were 
harvested for RT-PCR at 48 hours’ post-transfection or protein analyses at 72-hour post-
transfection. 
2.7.3 DharmaFECT I transfection 
DharmaFECT I (Dharmacon) reagent was used for both U87-MG and SH-SY5Y cell lines. For a 
6-well plate, cells were seeded at SH-SY5Y 1x105/ml and U87-MG 0.65x105/ml for RNA 
analysis and SH-SY5Y 0.95x105/ml and U87-MG 0.6x105/ml for protein analysis into media 
containing no serum and incubated for 24 hours under normal conditions. For each Hu protein 
and controls, two separate solutions were prepared in sterile Eppendorf tubes. The first 
containing siRNA to a to a final concentration of 25nM and the second containing 6ul of 
DharmaFECT I in 200ul of serum-free media. The two tubes were mixed on a vortex and spun 
for several seconds followed by an incubation for 15 minutes at room temperature to allow 
the DharmaFECT I/siRNA complexes to form. The tubes were combined and mixed by vortex 
and centrifugation and incubated for a further 20 minutes. After this time, 1600ul of antibiotic 
free-media was added to the mix and the whole solution applied to the well of the cells. Cells 
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were incubated in the transfection mix for 48 hours at 37ºC and 5% CO2 before harvesting 
RNA and or for 72 hours for harvesting protein for analysis. 
2.7.4 Lipofectamine RNAi MAX 
Lipofectamine RNAi MAX (Invitrogen) was used during initial testing of siRNA knockdown 
experiments. Different concentrations of Lipofectamine RNAi MAX and all Hu genes siRNA 
were trialled following the manufacturers guidelines. In one Eppendorf tube, Lipofectamine 
RNAi MAX was diluted in 150µl of Gibco™ Opti-MEM™ - Reduced Serum Media (ThermoFisher 
Scientific). In a second Eppendorf tube, the siRNA was diluted also in 150µl Gibco™ Opti-
MEM™. The two tubes were mixed together and incubated at room temperature for 20 
minutes to allow the Lipofectamine/siRNA complex to form. 250µl of the solution was added 
to each well followed by 2250µl of antibiotic-free media. Incubation at 37ºC and 5% CO2 for 
48 hours before harvesting protein and RNA.  
2.7.5 Statistical analysis of transfections 
All results represent the mean ± standard deviation from three independent experiments. 
The T-test was used to evaluate the differences between the control cells and Hu knockdown 
cells in Graphpad Prism software. Significant significance is displayed as *P ≤ 0.05, **P ≤ 0.01, 







Part I: Expression of Hu proteins in Small cell lung 
cancer, Non-small cell Lung Cancer and normal 
bronchial epithelial cells 
Hu protein expression was first identified in patients with Small cell lung cancer (SCLC) and 
paraneoplastic encephalomyelitis and/or a sub-acute sensory neuropathy (PEM/SN) (Szabo,  
a et al. 1991). All SCLC tumours aberrantly express neuronal HuD protein and the tumour-
initiated immune response can be detected in up to 20% of those patients, however PEM/SN 
is thought to occur in only 1% of all SCLC patients (Dalmau and Furneaux 1992, DeLuca et al. 
2009).  
The aim of this study was to investigate the presence of Hu RNA-binding proteins in lung 
cancer cells and normal bronchial epithelial cells as a control. A detailed analysis of Hu 
expression could potentially be used to detect SCLC at an early stage of disease and improve 
treatment options that are currently very limited. Detection could be done through blood 
screening for Hu antibodies or following tissue extraction (D’Alessandro et al. 2008). The 
development of molecular markers for targets of drug therapies could improve the low 
survival rates associated with SCLC.  
To investigate the expression of HuB, HuC, HuD and HuR in Small cell lung cancer the NCI-
H345, NCI-H69 and CorL88 cell lines were used. Additionally, the normal bronchial epithelial 
cell line BEAS2B was used as a control, whilst Non-small cell lung cancer cell lines NCI-H322 
and NCI-H358 allowed the comparison of these characteristically different lung cancers.  
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In addition to Hu gene and protein expression and localisation, a comparison of the 
morphology of the normal lung and cancerous lung cell lines and the motility of the NSCLC 
cells compared to the normal bronchial epithelial cells. These particular cell lines have not 
previously been examined for this property.  
3.1 Hu gene and protein expression and localisation in Small cell lung 
cancer, Non-small cell lung cancer and normal bronchial epithelial 
cells 
The aberrant expression of Hu genes is often recognised within cancers. To build an 
expression profile, each Hu gene and protein was analysed separately in all cell lines for gene 
expression, protein expression and protein localisation. 
Investigations into HuB gene expression levels in the normal bronchial epithelial cells, NSCLC 
and SCLC cell lines were performed by real time-quantitative polymerase chain reaction (RT-
qPCR) (described in Section 2.26) measuring mRNA levels. Primers sequences are listed in 
Table 2.3 in Section 2.27. 
Gene expression studies at RNA level do not necessarily reflect on the abundance of the gene 
product. Therefore, Western blot was used to determine the protein expression level. There 
is much evidence to suggest the localisation of Hu proteins within a cell determine its function 
therefore immunofluorescent staining confirmed protein localisation within the cells 
(Kasashima, K et al. 1999). 
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3.1.1 HuB expression 
RT-qPCR analysis of HuB gene expression in the normal bronchial epithelial cells, NSCLC and 
SCLC cell lines used the primers HuB (1) and β-Actin that are described in Table 2.3. The mRNA 
expression of HuB in SCLC, NSCLC and normal bronchial epithelial cells is displayed in Fig. 3.1. 

































Figure 3.1: HuB gene expression in SCLC, NSCLC and normal bronchial epithelial cell lines. HuB gene 
expression was analysed by RT-qPCR in Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-
H69, Non-small cell lung cancer cell lines, NCI-H322 and NCI-H358 and normal bronchial epithelial cells 
BEAS2B. The ΔCt results shown are an average of three replicates normalised to β-Actin gene 
expression, relative to zero. Error bars display ± standard error of the mean (SEM). Statistical 
significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. (n=3).  
 
The examined gene, HuB, is a member of the Hu RNA-binding protein family and normally 
exclusive to the neurons and gonads. The expression of HuB gene was absent in the normal 
bronchial epithelial cells, NSCLC cells and CorL88 SCLC cells. Significant HuB expression was 
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observed in two of the SCLC cell lines, NCI-H345 and NCI-H69 when compared to the control 
normal bronchial epithelial cells. A 2.6-fold-increase of HuB gene expression was seen in NCI-
H345 cells when compared to the control BEAS2B cells. Whilst a 3.1-fold-increase of HuB gene 
expression was observed in NCI-H69 cells. These results indicate aberrant expression of HuB 
gene in the NCI-H345 and NCI-H69 SCLC cell lines. 
To further analyse if the gene expression of the HuB RNA-binding protein could be detected 
at protein level, western blotting was performed (Figure 3.2). Each cell line derived from 
normal bronchial epithelial cells, Small cell lung cancer and Non-small cell lung cancer was 
blotted and stained for HuB protein. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was used as a loading control. 
 
Figure 3.2: Representative example of HuB protein expression detected by western blot. HuB 
protein expression in normal bronchial epithelial cell line BEAS2B, Non-small cell lung cancer cell lines, 
NCI-H322 and NCI-H358 and Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-H69. GAPDH 
protein expression was used as a loading control (n=3). 
 
The strongest HuB expression was observed in the SCLC cell lines CorL88, NCI-H345 and NCI-
H69 represented by darker bands that are less than the loading control. Weaker expression 
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was observed in the NSCLC cell lines NCI-H322 and NCI-H358 displayed by fainter bands 
showing less expression than the loading control. Only GAPDH protein could be detected in 
the lane containing protein extracted from the normal bronchial epithelial cells BEAS2B, 
confirming an absence of HuB protein expression. 
Whilst there was an absence of HuB gene expression in both NSCLC cell lines and SCLC cell 
line CorL88 (Fig. 3.2), a low level of HuB gene expression must be present to produce these 
proteins that is detected when the gene expression data is normalised. 
To determine the subcellular localisation of HuB proteins, immunofluorescent staining was 
performed with primary anti-HuB IgG and secondary Alexa green 488 FITC IgG (Fig 3.3). Cells 





Figure 3.3: Representative example of HuB protein localisation in SCLC, NSCLC and normal bronchial 
epithelial cells. Cellular localisation of HuB in the normal bronchial epithelial cells BEAS2B, Non-small 
cell lung cancer cell lines, NCI-H322 and NCI-H358 and Small cell lung cancer cell lines, CorL88, NCI-
H345 and NCI-H69. The left column showed staining of nuclei with DAPI (blue), the is middle column 
with anti-Hu (green) and the right column displays merged pictures. Magnification 20x. (n=3). 
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A low signal was detected for HuB protein in BEAS2B however, there was no HuB gene 
expression detected (Fig. 3.1) and it was absent from the western blot protein analysis (Fig. 
3.2). An explanation for this is that it is background noise arising from fluorescence or 
nonspecific staining. Lack of fluorescent anti-Hu staining confirmed HuB was absent in the 
NSCLC cell lines NCI-H322 and NCI-H358. Whilst, two of the SCLC cell lines, NCI-H345 and NCI-
H69 showed HuB protein expression consistent with the gene expression data (Fig. 3.1) and 
western blot protein determination shown in Fig. 3.2. CorL88 displayed some HuB protein 
expression in some of the cells that localised in the cytoplasm. 
In NCI-H69 cells, anti-HuB staining co-localised with the DAPI nucleus stain therefore 
confirming HuB protein is localised in the nucleus of these cells. NCI-H345 showed stronger 
HuB expression than NCI-H69 however, in this cell line HuB protein was clearly localised in 
the cytoplasm. 
3.1.2 HuC expression 
Next, analysis of HuC gene expression in cell lines representative of the normal bronchial 
epithelial cells, NSCLC and SCLC was performed using RT-qPCR. The mRNA expression of HuC 
in SCLC, NSCLC and normal bronchial epithelial cells is shown in Fig. 3.4. 
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Figure 3.4: Gene expression of HuC in SCLC, NSCLC and normal bronchial epithelial cells. HuC gene 
expression was analysed by RT-qPCR in Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-
H69, Non-small cell lung cancer cell lines, NCI-H322 and NCI-H358 and normal bronchial epithelial cells 
BEAS2B. The ΔCt results shown are an average of three replicates normalised to β-Actin gene 
expression relative to zero. Error bars display ± standard error of the mean (SEM). Statistical 
significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. (n=3). 
 
The expression of HuC was absent in the NSCLC and normal bronchial epithelial cells. HuC 
gene expression was observed in CorL88, NCI-H345 and NCI-H69 confirming significant 
aberrant expression of HuC in SCLC when compared to the normal bronchial epithelial cells. 
A 1.55-fold-increase of HuB gene expression was observed in CorL88 compared to the normal 
bronchial epithelial cells, BEAS2B. A 2.7-fold-increase of HuC expression was observed in NCI-
H345 and a 1.0-fold-increase of HuC was shown in NCI-H69.  
122 
 
To detect if the gene expression was present at a protein level, western blotting (Section 2.3) 
of HuC protein using anti-HuC IgG was performed in each cell line derived from normal 
bronchial epithelial cells, Small cell lung cancer and Non-small cell lung cancer. GAPDH was 
used as a control protein with anti-GAPDH IgG to compare protein expression. Horse-radish 
peroxidase (HRP)-conjugated secondary antibodies were used to allow a detectable signal. The 
protein expression of HuC, RNA-binding protein in SCLC, NSCLC and normal bronchial epithelial 
cells is shown in Fig. 3.5. 
 
 
Figure 3.5: Representative example of HuC protein detected by western blot. HuC protein expression 
in normal bronchial epithelial cells BEAS2B, Non-small cell lung cancer cell lines, NCI-H322 and NCI-
H358 and Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-H69. GAPDH protein expression 
was used as a loading control (n=3). 
 
The results confirm an absence of HuC protein expression in the cell extracts of the normal 
bronchial epithelial cell line BEAS2B and NSCLC cell lines, NCI-H322 and NCI-H358. HuC 
protein was detected in the SCLC cell lines NCI-H345 and NCI-H69, correlating with the gene 
expression profile (Fig. 3.4). The bands detected for HuC protein in NCI-H345 and NCI-H69 are 
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less than the loading control. Interestingly, HuC gene was expressed in CorL88, but could not 
be detected at protein level. 
Immunofluorescence staining was performed to confirm the HuC protein presence in the 
normal and cancer cell lines and to identify its subcellular localisation using anti-HuC and 




Figure 3.6: Example of HuC protein localisation in SCLC, NSCLC and normal bronchial epithelial cells. 
Cellular localisation of HuC in the normal bronchial epithelial cells BEAS2B, Non-small cell lung cancer 
cell lines, NCI-H322 and NCI-H358 and Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-H69. 
The left column showed staining of nuclei with DAPI (blue), the is middle column with anti-Hu (green) 




A very low fluorescence of HuC protein in BEAS2B cells was observed. However, since there 
was no HuC gene expressed (Fig. 3.4) and it was absent in the western blot protein analysis 
(Fig. 3.5), this must therefore be background fluorescence. This background fluorescence was 
also detected in staining of HuB protein in the BEAS2B cells strongly suggesting these cells 
autofluorescence.  
HuC was absent from both NSCLC cell lines, NCI-H358 and NCI-H322 as expected. Two of the 
three SCLC cell lines, NCI-H345 and NCI-H69 showed HuC protein expression which differs 
from the gene expression results where all three SCLC cell lines including CorL88 showed HuC 
gene expression (Fig. 3.4).  
NCI-H69 displays HuC protein that co-localises with the DAPI nucleus stain, therefore 
confirming HuC protein was localised to the nucleus of these cells. NCI-H345 showed stronger 
HuC protein expression than NCI-H69 and the staining was inconsistent with the DAPI nucleus 
stain. This concludes HuC protein was localised to the cytoplasm in these cells. These findings 
highlight variation of Hu protein localisation in SCLC cell lines.  
Additionally, correlation was seen between the varied localisation of aberrantly expressed 
HuB and HuC proteins in the NCI-H345 and NCI-H69 cell lines individually. Like HuB protein in 
Fig 3.3, Fig3.6 showed HuC protein was present in the cytoplasm of NCI-H345 whereas HuB 
and HuC proteins were present in the nucleus of NCI-H69. 
3.1.3 HuD expression 
HuD gene expression analysis in cell lines representative of the normal bronchial epithelial 
cells, NSCLC and SCLC was performed by RT-qPCR described in Section 2.2.6. The mRNA 
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expression of HuD RNA-binding protein in SCLC, NSCLC and normal bronchial epithelial cells 
is shown in Fig. 3.7. 
 



































Figure 3.7: Gene expression of HuD in SCLC, NSCLC and normal bronchial epithelial cells. HuD gene 
expression was analysed by RT-qPCR in Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-
H69, Non-small cell lung cancer cell lines, NCI-H322 and NCI-H358 and normal bronchial epithelial cells 
BEAS2B. The ΔCt results shown are an average of three replicates normalised to β-Actin gene 
expression relative to zero. Error bars display ± standard error of the mean (SEM). Statistical 
significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. (n=3). 
 
The expression of HuD gene was absent in the normal bronchial epithelial cells, BEAS2B and 
NSCLC cells, NCI-H322 and NCI-H358. HuD gene was expressed in all SCLC cell lines CorL88, 
NCI-H345 and NCI-H69, highlighting significant aberrant expression of HuD in this cancer 
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compared to the normal bronchial epithelial cells. A 1.2-fold-increase of HuD gene expression 
was observed in CorL88 compared to the normal bronchial epithelial cells, BEAS2B. A 2.6-fold-
increase of HuD gene expression was observed in NCI-H345 and a 2.0-fold-increase of HuD 
gene expression was observed in NCI-H69.  
To confirm if the HuD gene expression is effectively translated to a protein, western blot 
analysis (Section 2.3) was performed. Anti-HuD IgG was used for the detection of HuD protein 
in each cell lines derived from normal bronchial epithelial cells, Small cell lung cancer and 
Non-small cell lung cancer. GAPDH expression was also detected using anti-GAPDH IgG and 
used as a loading control. The protein expression of HuD, RNA-binding protein in normal 
bronchial epithelial cells, NSCLC and SCLC cell lines is displayed in Fig. 3.8.  
 
 
Figure 3.8: Representative western blot of HuD protein with anti-HuD antibody. HuD protein 
expression in normal bronchial epithelial cells BEAS2B, Non-small cell lung cancer cell lines, NCI-H322 
and NCI-H358 and Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-H69. GAPDH protein 




An absence of HuD protein expression was observed in the normal bronchial epithelial cell 
line BEAS2B and NSCLC cell lines, NCI-H322 and NCI-H358 correlating with gene expression 
results where HuD mRNA was not expressed (Fig. 3.7). HuD protein was detected in two of 
the three SCLC cell lines. NCI-H345 and NCI-H69 cells show faint bands indicating HuD protein 
expression whilst no band is present in the CorL88 cells. This differs from HuD gene expression 
shown in Fig. 3.7 where CorL88 also expressed HuD mRNA. 
To clarify the data above and identify HuD’s subcellular localisation in SCLC cell NCI-H345 and 
NCI-H69, immunofluorescence staining was performed. Anti-HuD IgG was used with the 





Figure 3.9: Representative localisation of HuD protein in SCLC, NSCLC and normal bronchial 
epithelial cells. Cellular localisation of HuD in the normal bronchial epithelial cells BEAS2B, Non-small 
cell lung cancer cell lines, NCI-H322 and NCI-H358 and Small cell lung cancer cell lines, CorL88, NCI-
H345 and NCI-H69. The left column showed staining of nuclei with DAPI (blue), the is middle column 
with anti-Hu (green) and the right column displays merged pictures. Magnification 20x. (n=3). 
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The Immunofluorescence staining shown in Fig. 3.9 collaborates gene expression (Fig. 3.7) 
and western blot data (Fig. 3.8), where an absence of HuD gene and protein is shown in the 
normal bronchial epithelial cell line BEAS2B and the NSCLC cell lines NCI-H322 and NCI-H358. 
HuD gene expression (Fig. 3.7) in CorL88 is confirmed at a protein level by 
immunofluorescence confirms a protein expression with a low signal observed in CorL88 SCLC 
cells. HuD protein expression in CorL88 was not detected during western blot (Fig. 3.8) and 
low protein expression level was most likely the cause of this. Additionally, low fluorescence 
of HuD protein was detected in the SCLC NCI-H345 cells, contrasting the strong fluorescence 
observed in SCLC NCI-H69 cells. 
The HuD staining in CorL88 and NCI-H345 cells was inconsistent with the DAPI nucleus stain 
ultimately showing HuD was localised in the cytoplasm in these cells. NCI-H69 has HuB 
staining that co-localises with the DAPI nucleus stain and confirming its expression there. 
3.1.4 HuR expression 
Analysis of HuR gene expression in cell lines representative of the normal bronchial epithelial 
cells, NSCLC and SCLC was performed by RT-qPCR (Section 2.2.6). The fold-change of gene 
expression was calculated comparing expression to the normal bronchial epithelial cells 
BEAS2B. The data was normalised to the housekeeping gene β-Actin. HuR (2) and β-Actin 
primers are listed in Table 2.3. Statistical significance was calculated by a two-tailed t-test. 
The mRNA expression of HuR RNA-binding protein in normal bronchial epithelial cells, BEAS2B 
cell line, NSCLC cell lines NCI-H322 and NCI-H358 and SCLC cell lines CorL88, NCI-H345 and 
NCI-H69 is shown in Fig. 3.10.  
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Figure 3.10: Gene expression of HuR in SCLC, NSCLC and normal bronchial epithelial cells. HuR gene 
expression was analysed by RT-qPCR in Small cell lung cancer cell lines, CorL88, NCI-H345 and NCI-
H69, Non-small cell lung cancer cell lines, NCI-H322 and NCI-H358 and normal bronchial epithelial cells 
BEAS2B. The ΔCt results shown are an average of three replicates normalised to β-Actin gene 
expression relative to zero. Error bars display ± standard error of the mean (SEM). Statistical 
significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. (n=3). 
 
HuR gene is ubiquitously expressed in human cells and this was confirmed by RT-qPCR where 
HuR gene expression was confirmed in all cell lines (Wang et al. 2013). Overall, a higher 2-ΔΔCt 
HuR mRNA expression was observed in the cancer cell lines in comparison to the normal 
bronchial epithelial cells control with a significant increase observed in the NSCLC cell line 
NCI-H322 and SCLC cell line CorL88 and NCI-H345. Of the two NSCLC cell lines, a 1.51 fold-
increase was observed for NCI-H322 whilst a 0.44 fold-increase was observed in NCI-H358, 
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the latter was not significant. The three SCLC cell lines revealed a 1.44 fold-increase in HuR 
expression for CorL88, a 1.61 fold-increase in NCI-H345 and a 0.51 fold-increase in NCI-H69, 
again the latter was not significant.  
To confirm if the HuR gene was present at a protein level, western blot analysis using anti-
HuR IgG was carried out in each cell line derived from normal bronchial epithelial cells, Small 
cell lung cancer and Non-small cell lung cancer was compared. Anti-GAPDH IgG was also used 
for the detection of GAPDH as a loading control. Horseradish peroxidase (HRP)-conjugated 
secondary antibodies were used to allow a detectable signal. 
The protein expression of HuR, RNA-binding protein in normal bronchial epithelial cells, NSCLC 





Figure 3.11:  Example western blot analysis of HuR protein with anti-HuR antibody. A) HuR protein 
expression in normal bronchial epithelial cell line and different NCLC and SCLC cell lines. B) HuR protein 
expression in the normal bronchial epithelial cells and NSCLC cell lines only. GAPDH protein expression 
was used as a loading control in both blots. (n=3). 
 
HuR protein was detected in the cell extracts from NSCLC cell lines NCI-H322 and NCI-H358, 
and SCLC cell lines CorL88, NCI-H69 and NCI-H345 cell lines represented by two distinct bands 
around 36kDa, the expected size of HuR. A possible explanation for the two bands is that HuR 
has experienced posttranslational modifications such as phosphorylation resulting in two 
slightly different sized proteins. GAPDH protein was detected at the expected size of 37kDa. 
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Strongest staining was observed in the NSCLC NCI-H358 cell line and SCLC cell lines CorL88 
and NCI-H345. The SCLC protein expression matches the gene expression data (Fig. 3.10) 
where CorL88 and NCI-H345 cells showed the highest HuR mRNA expression. However, for 
the NSCLC cells, the protein expression varies from the gene expression data (Fig. 3.10) that 
showed more HuR mRNA expressed in the NSCLC NCI-H322 than the NCI-H358 cell line. This 
could be explained by post-transcriptional modifications resulting in more HuR gene 
translated in some cell lines than others although there is no evidence to support this.   
Whilst the normal bronchial epithelial cell line, BEAS2B, displayed no HuR protein expression, 
HuR gene expression was previously shown to be expressed in the lungs in Fig. 3.10. To 
confirm if HuR protein lied under the detection level due to the high level of detection of the 
other bands shown in Fig. 3.11A, a second western blot with only NSCLC and normal bronchial 
epithelial cells was performed. This confirmed an absence of HuR protein expression in the 
BEAS2B cell lines. 
To confirm the HuR protein presence and identify the location of the proteins in all the 
analysed cell lines, immunofluorescence staining was performed using anti-HuR mouse IgG 
and secondary Alexa 488 FITC IgG. Cells were counterstained with DAPI nucleus stain for 
nuclear localisation. 
HuR protein fluorescence shown in Fig. 3.12 was observed in all cell lines BEAS2B, NCI-H322, 




Figure 3.12: Representative localisation of HuR protein in normal bronchial epithelial cells and 
NSCLC and SCLC cell lines. Cellular localisation of HuR in the normal bronchial epithelial cells BEAS2B, 
Non-small cell lung cancer cell lines, NCI-H322 and NCI-H358 and Small cell lung cancer cell lines, 
CorL88, NCI-H345 and NCI-H69. The left column showed staining of nuclei with DAPI (blue), the is 




In NCI-H322 cells, only a weak signal could be detected for HuR protein in the nucleus. This 
was consistent with western blot results where only a weak band could be detected in NCI-
H322 cell extract. 
The fluorescence of HuR protein in the normal bronchial epithelial cell line BEAS2B was co-
localised with the DAPI nucleus stain therefore HuR protein was localised to the nucleus. 
Strong fluorescence in the nucleus was also observed in both NSCLC cell lines NCI-H322 and 
NCI-H358. Two of the SCLC cell lines also display HuR nuclear localisation CorL88 and NCI-H69. 
The remaining SCLC cell line NCI-H345 displayed strong cytoplasmic localisation of HuR. 
3.2 Morphology of lung cell lines 
Lung cancers are easily distinguishable into Non-small cell lung cancers and Small cell lung 
cancer due to their size. A tumour with less than 10% of large cells is classified as SCLC by 
WHO (Travis et al. 2015). Often cellular changes to the morphology or lung cells is how lung 
cancers are observed through biopsies during diagnosis. 
SCLC showed a considerable degree of morphological histopathological variability during in-
vitro studies. SCLC cells are small, round, oval or spindle shaped cells with scanty cytoplasm 
(Brambilla et al. 2001). Their nucleus contain granular nuclear chromatin and very faint or 
absent nucleoli and lack of cell boarders (Travis et al. 1999). Krohn et al. (2014) reports of two 
cells types. Some cells float in clusters, are smaller, round and have small nuclei. Attached 
cells are larger (although still smaller than three lymphocytes defining cells ‘small’) and grow 
in little clumps with less cell-cell contacts and a large cytoplasm-to-nucleus ratio. 
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Non-small cell lung cancer tumours contain large cells, that have a small nuclear to 
cytoplasmic ratio, also contain vesicular, coarse or fine chromatin and common nucleoli. Not 
all NSCLC tumours meet this criteria but are still considered NSCLC due to their bigger size 
and large cytoplasm (Travis et al. 1999). 
To observe difference in the morphology of cell lines derived from the lung cell images were 
obtained using an Eclipse II fluorescent inverted microscope and Microtec camera as described 
in Section 2.1.6. These are shown in Fig. 3.13. 
 
Figure 3.13: Microscopy images of each lung cell line. Inverted microscopy at x20 Objective. A) 
Normal lung cell line, BEAS2B. B) NSCLC cell line, NCI-H322. C) NSCLC cell line, NCI-H358. D) SCLC cell 
line, CorL88. E) SCLC cell line, NCI-H345. F) SCLC cell line, NCI-H69. 
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The normal bronchial epithelial cells (Fig. 3.13A) grew with similar properties to that of the 
two NSCLC cell lines NCI-H322 (Fig. 3.13B) and NCI-H358 (Fig. 3.13C). These are adherent cells 
that grow as a single monolayer. They have an epithelial-like shape.  
In contrast, the three SCLC cells lines studied, collectively feature both semi-adherent and 
suspension cells described by Krohn et al. (2014). The CorL88 (Fig. 3.13D) is a semi-adherent 
cell line whilst the NCI-H345 (Fig. 3.13E) and NCI-H69 (Fig. 3.13F) cell lines are grow in 
suspension. All SCLC cell lines grow in multi-cellular aggregates and have a visually similar 
morphology. NCI-H345 and NCI-H69 are solely suspension cell lines that grow in large clumps 
and are very similar. CorL88 also feature these large clumps in suspension however, as a semi-
adherent cell line, the adherent cells form small clumps that anchor to the cell culture flask 
rather than float in suspension. These anchored cells often show a fibroblast-like appearance, 
while suspended cells attached to this clump are round. The SCLC cells are distinctly smaller 
than NSCLC cells. 
3.3 Motility of lung cells 
An assessment of cell motility was made to compare the normal bronchial epithelial cells and 
NSCLC cells. This aimed to determine the invasiveness of NSCLC cells in culture, since a key 
characteristic of cancer cells is the ability to invade into distant tissues. Unfortunately, a 
measure of SCLC invasiveness could not be determined by this method as two of the SCLC cell 
lines grow in suspension in culture and the other is semi-adherent. 
The cell motility was analysed in normal bronchial epithelial cells BEAS2B and NSCLC, NCI-
H322 and NCI-H358 cell lines. It was measured by the ability of the cells to invade into a 0.5% 
agarose gel matrix captured through several microscopy imaging equipment. The images 
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below show time-lapse photography by a CytoSMART™ camera, described in Sections 2.5 and 
2.5.1.  
 
Figure 3.14: The non-migration of BEAS2B, normal bronchial epithelial cells into an agarose gel 
matrix. During the observed 42-hour period, no migration into the gel matrix was detected. Time-





The normal bronchial epithelial cells, BEAS2B, did not move into the agarose gel during the 
observed 42-hours as expected for a non-cancer cell line. Instead they grew densely in a line 
surrounding the agarose. 
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When the NSCLC, NCI-H322 cells, were observed for their motility over 42 hours, they too, 




Figure 3.15: The non-migration of NCI-H322, Non-small cell lung cancer cells into an agarose gel 
matrix. Over the observed 42-hour period, no migration into the gel matrix was detected. Time-lapse 





Next, the second NCSLC NCI-H358 cell line was analysed for their migrative ability. In contrast 




Figure 3.16: The migration of NCI-H358, Non-small cell lung cancer into an agarose gel matrix. Over 
the observed 42-hour period, cells migrated into the gel matrix. Time-lapse photography of the cell 





As seen in Fig. 3.16, the NCI-H358 cells can be seen collecting around the agarose gel at 0 
hours. From 6 hours the cells began to migrate into the gel matrix. 
Imagery analysis displayed above is representative of one attempt although consistently 
observed was the ability of the NCI-H358 cells to migrate into the gel whilst NCI-H322 and 
BEAS2B cells were not able to. 
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Figure 3.17: The migration of NCI-H358 NSCLC cells compared to the non-migration of normal 
bronchial epithelial cells BEAS2B and NSCLC NCI-H322. Percentage area of the gel matrix invaded by 
NCI-H358 cells. 
 
As seen in Fig. 3.17, NCI-H358 cells were able to invade into the gel matrix potentially 
replicating their invasiveness in the body. Over a 42-hour period cells invaded 31.11% of the 
observed section of gel matrix (Fig. 3.17).  
3.4 Summary  
For the first time, an expression profile comparing Hu expression in different lung cancer cell 
lines has been established. Concluded in Table 3.1 is the Hu protein expression detected in 




 Hu Protein 
Cell type Cell line HuB HuC HuD HuR 








NCI-H322            N 
NCI-H358            N 
Small Cell 
Lung Cancer 
CorL88         C   N 
NCI-H345   C   C   C   C 
NCI-H69   N   N   N   N 
Table 3.1: Overall expression of HuB, HuC, HuD and HuR proteins in cell lines of normal bronchial 
epithelial cells, Non-Small Cell Lung Cancer and Small Cell Lung Cancer cells. Each method of analysis 
including RT-qPCR (PCR), western blotting (WB) and immunofluorescent staining (IF) is shown. Green 
represents a positive result. Also shown is the localisation of the proteins determined through immune 
fluorescence cytoplasm is shown by C  and the nucleus is represented by N. 
 
There are several conclusions that can be drawn from the investigation into the presence of 
Hu RNA-binding proteins in lung cancers. Gene expression analysis showed a difference 
between the expression of the neuronal Hu protein family members HuB, HuC and HuD in the 
normal bronchial epithelial cells and different lung cancer groups. All neuronal Hu genes were 
expressed in the Small cell lung cancer cell lines apart from HuB in CorL88. This is significant 
since HuB, HuC and HuD are not naturally expressed within lung tissue. Additionally, there 
was an absence of the neuronal Hu genes in the normal bronchial epithelial cells and NSCLC 
cell lines. This data confirms these genes are only present in SCLC providing an insight into a 
functional role required for the development of the cancer.  
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HuR gene was detected in all the lung cell lines which was expected since it is ubiquitously 
expressed in all tissues in the human body. In each cancer, at least one cell line showed 
significant upregulated HuR gene expression in comparison to the normal bronchial epithelial 
cell line BEAS2B supporting the idea that HuR is functionally upregulated in cancers. 
Whilst gene expression is important in cancer studies, the active status of a gene and its ability 
to translate into a functional protein is of equal significance. Western blot studies 
interestingly showed, HuC and HuD proteins were only present in two of the SCLC cell lines 
NCI-H345 and NCI-H69 despite CorL88 also expressing these genes at an RNA level. 
Conversely, HuB gene was detected at a high level though RT-qPCR in NCI-H345 and NCI-H69 
cell lines yet at a protein level, it was detected at high levels in all three SCLC, NCI-H345, NCI-
H69 and CorL88 cell lines. Interestingly, CorL88 differs from NCI-H69 and NCI-H345 in its 
morphology in culture. CorL88 is semi-adherent whilst NCI-H345 and NCI-H69 grows in 
suspension, suggestive of alternative characteristics within SCLC tumours.  
Despite the aberrant and over expression of these Hu proteins that has been described in this 
study at both gene and protein levels, the location of the Hu proteins within the cell has been 
shown to influence the pathogenicity of some cancers. 
Anti-Hu fluorescent staining revealed all the Hu proteins present in the nucleus of the NCI-
H69 cells, whilst all Hu proteins were detected in the cytoplasm in the NCI-H345 cells. CorL88 
cells revealed HuD protein localises in the cytoplasm and HuR protein in the nucleus. HuD 
protein was previously undetected by western blot and whilst the fluorescent staining is 
weak, it does confirm HuD protein is actively translated in this cell line. However, during the 
western blot, the strong bands of the HuD in the other two SCLC cell lines NCI-H345 and NCI-
H69, CorL88 HuD fluorescence remained undetected. Interestingly, western blot of HuR 
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detected two bands significant of a phosphorylation event of HuR resulting in two differently 
sized HuR protein monomers. This has previously been described by (Kim and Gorospe, 2008).  
During western blot studies in comparison to the loading control GAPDH, the NSCLC cell line 
NCI-H358, showed a strong expression of HuR. Whilst NCI-H322 did display weak staining 
despite HuR gene expression being significantly higher in NCI-H322. HuR immunofluorescence 
studies showed its expression was localised to the nucleus in both NSCLC cells lines.  
HuR protein expression could not be detected in normal bronchial epithelial cells using 
western blotting however, antibody staining methods did and confirmed its localisation in the 
nucleus. During the western blot, HuR protein expression was most likely missed due its 
expression remaining under the detection level.  
In summary, all Hu proteins are found expressed in two of the SCLC cell line NCI-H69 and NCI-
H345. CorL88, also a SCLC cell line showed HuD and HuR expression at both RNA and protein 
levels. HuC was expressed at RNA level but not at a protein level. In the normal bronchial 
epithelial cells and NSCLC cell lines NCI-H322 and NCI-H358, only HuR was present at both 
gene and protein level. 
Cell culture observations show a similarity in the morphology of the different lung cancer 
groups in comparison to the normal bronchial epithelial cells suggestive of similar 
characteristics within the named cancers and potentially their pathogenicity. The differences 
in size, growth as a monolayer or as multicellular aggregates, nuclear to cytoplasm ratio, 
nucleoli presence and chromatin structure aids diagnosis and the ability to distinguish 
between SCLC and NSCLC. 
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When determining the invasive potential of the NSCLC cell lines, interestingly only one of the 
cell lines NCI-H322 cells managed to penetrate the gel matrix. This is clinically significant of 
the ability for cells to migrate into other organs and form tumour growth and highlights a 
difference in migrative potential within the NSCLC cell types. 
Overall, there are several conclusions that can be drawn from the results in this Chapter. 
Firstly, the ectopic presence of the neuronal genes in SCLC is established and an 
overexpression of HuR expression in both NSCLC and SCLC is shown. Within this expression 
there was still distinct differences within protein expression and localisation within the cells 
despite cell morphology similarities. In summary, this highlights differences within tumour 





Chapter 4  
Results  
Part II: Expression of Hu proteins, their role and mRNA 
targets in Neuroblastoma  
Hu proteins were first described in Neuroblastoma by Dalmau, Josep and Furneaux (1992), 
whereby analysis of neuroendocrine tumours such as Small cell lung cancer, Neuroblastoma, 
Sarcoma, and Prostate carcinoma revealed about 50% of Neuroblastoma tumours express Hu 
proteins. Later is was described that specifically HuB and HuD were identified in some 
Neuroblastoma patients (Ball, N. S. and King, Peter H. 1997). In these patients and similar to 
the effect in SCLC, the triggered immune response initiates neuronal apoptosis resulting in 
enteric nervous system impairment underlying paraneoplastic gut dysmotility (De Giorgio et 
al. 2003). However, the extent of all Hu proteins expression and their biological function of 
Hu proteins in Neuroblastoma has not been established. 
The general expression of each Hu gene and protein in Neuroblastoma was determined 
through studies on two Neuroblastoma cell lines SK-N-AS and SH-SY5Y compared to a normal 
astrocyte cell line SVG p12. Next, knockdown studies of Hu genes were established to 
ultimately define how Hu expression may influence a cancerous phenotype through tumour 
initiation and development characteristics. Finally, these studies analysed mRNA transcripts 
targeted by the Hu RNA-binding protein family and sought to determine the Hu protein 
family’s overall influence on molecular pathways and the downstream effects of these 
pathways in cancer development.  
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4.1 Hu gene expression in Neuroblastoma and normal astrocytes 
The gene expression of all Hu proteins in two Neuroblastoma cell lines SH-SY5Y and SK-N-AS 
and in normal astrocytes SVG p12 was determined using quantitative RT-PCR. The fold-change 
of expression was analysed by comparing expression levels to the normal astrocyte cell line 
SVG p12. β-Actin was the housekeeping gene to which the data was normalised. Statistical 
significance was calculated by a two-tailed t-test. The relative transcript expression levels of 
all Hu genes in the two Neuroblastoma cell lines in comparison to the normal astrocyte cell 
line is displayed in Fig. 4.1.  





































Figure 4.1: Gene expression of all the Hu protein family members in normal astrocytes and 
Neuroblastoma cells. HuB, HuC, HuD and HuR gene expression was analysed by RT-qPCR in normal 
astrocytes, SVG p12 and Neuroblastoma cell lines, SH-SY5Y and SK-N-AS. The ΔCt results shown are 
an average of three replicates normalised to β-Actin, relative to zero. Error bars display ± SEM. 
Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. (n=3). 
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The normal astrocyte cell line SVG p12 expressed HuB, HuC or HuD mRNA in very low levels 
that upon normalisation of the data, is not displayed on the graph. SVG p12 cells do express 
HuR gene. All Hu genes was expressed in the Neuroblastoma cell lines SH-SY5Y and SK-N-AS. 
All upregulated gene expression values were statistically significant except HuR expression in 
SK-N-AS Neuroblastoma cells.  
A 1.05 fold-increase of HuB gene expression was observed for SK-N-AS in comparison to the 
normal astrocyte line SVG p12, whilst a 1.05 fold-increase of HuB gene expression was 
observed for SH-SY5Y. HuC and HuD gene expression was seen upregulated the most in SH-
SY5Y cells with a 1.71 fold-increase in HuC expression and a 1.71 fold-increase also in HuD 
expression. In SK-N-AS cells, HuC was increased by 0.16 fold-change whilst HuD was increased 
0.17 fold-change. The gene expression of HuR only showed a small increase of 0.15 in SK-N-
AS cells. A 1.42 fold-increase in HuR expression was observed in the SH-SY5Y cells.  
4.2 Hu protein expression and localisation in Neuroblastoma and 
normal astrocytes  
Gene expression does not always reflect the amount of protein expressed due to post-
transcription gene regulation. Therefore, the presence of Hu proteins in the normal astrocytes 
SVG p12 and Neuroblastoma cells SK-N-AS and SH-SY5Y was determined using Western 
Blotting (Section 2.3).  Whilst subcellular localisation of Hu proteins was determined by 
immunofluorescent staining methods (Section 2.41). 
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4.2.1 HuB protein expression and localisation 
HuB protein expression in SK-N-AS and SH-SY5Y Neuroblastoma cells and SVG p12 normal 
astrocytes was determined by western blot analysis (Fig. 4.2). Blots were probed for the 
presence of HuB protein with anti-HuB IgG. Anti-GAPDH IgG, was used to detect GAPDH as a 
loading control. 
 
Figure 4.2: Representative western blot of HuB protein with anti-HuB antibody. HuB and GAPDH 
protein expression in normal astrocytes SVG p12, and Neuroblastoma cells SK-N-AS and SH-SY5Y.  
GAPDH protein expression was used as a loading control (n=3). 
 
HuB protein was detected in the normal astrocytes, SVG p12 at the expected size of 38kDa. A 
higher migrating band was detected in all cell lines, SVG p12, SK-N-AS and SH-SY5Y at around 
75kDa. Since this is about double the expected size of the HuB protein and the Hu family is 
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known to form dimers (Kasashima et al. 2002), this leads to the conclusion it is a result of 
dimerisation. GAPDH was detected at the expected size of 37kDa. 
Western blot analysis showed that HuB gene is expressed in very high amounts in normal 
astrocytes in comparison to the Neuroblastoma cell lines. At a protein level, HuB is expressed  
more than GADPH protein expression. The western blot and RT-qPCR results suggest that HuB 
is translated very efficiently in the normal astrocytes cells, SVG p12 since there was very little 
HuB gene expression (Fig 4.1).  
Of the two Neuroblastoma cell lines, HuB gene expression was highest in the SK-N-AS cells 
(Fig. 4.1) and this was also observed at the protein expression level (Fig. 4.2). HuB protein 
expression was comparable to GAPDH protein expression whilst in SH-SY5Y cells, HuB protein 
was less than the GAPDH expression. 
Subcellular Hu protein localisation was determined for all Neuroblastoma and normal 
astrocytes cell lines using immunofluorescent staining (Section 2.4.1). To detect HuB protein, 
anti-HuB IgG was used with the secondary Alexa green 488 FITC IgG and counterstained with 
DAPI nucleus stain.  
As seen in Fig. 4.3, HuB fluorescence is observed in all cell lines, SVG p12, SK-N-AS and SH-




Figure 4.3: Example of cellular localisation of HuB protein in normal astrocytes SVG p12 and 
Neuroblastoma cells SK-N-AS and SH-SY5Y. The left column displays staining of nuclei with DAPI 
(blue), the middle column is stained with anti-HuB (green) and the right column displays a merged 
picture of DAPI and anti-HuB staining. Magnification x20. (n=3).  
 
HuB protein expression was observed in both the nucleus and the cytoplasm of all cell lines. 
The strongest HuB protein fluorescence was observed in regions co-localised to the DAPI 
nuclei counterstain confirming HuB is predominantly nuclear.  
4.2.2 HuC protein expression and localisation 
HuC protein expression and localisation was determined through western blot analysis 
(Section 2.3) and anti-HuC immunofluorescence (Section 2.4.1). 
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Detection of HuC protein was carried out in each cell line derived from normal astrocytes and 
Neuroblastoma by western blot (Fig. 4.4). GAPDH was used as a control protein to compare 
protein expression to. Anti-HuC IgG detected HuC protein whilst anti-GAPDH IgG detected 
GAPDH, used as a loading control. 
 
Figure 4.4: Representative western blot of HuC protein with anti-HuC antibody. HuC and GAPDH 
protein expression in normal astrocytes SVG p12, and Neuroblastoma cells SK-N-AS and SH-SY5Y. 
GAPDH protein expression was used as a loading control. (n=3). 
 
Like HuB protein, HuC protein was detected in the normal astrocytes at its expected size of 
39kDa and an additional migrating band was observed in all cell lines for normal astrocytes 
and Neuroblastoma at around 150kDa. As this is four times the expected band size, it is most 
likely due to HuC multimerisation. With this observation, Fig. 4.4 displays the astrocytes and 
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both Neuroblastoma cell line express HuC protein. GAPDH, used as a loading control was 
detected at 37kDa as expected for its molecular weight. 
HuC expression at RNA level (Fig. 4.1) showed HuC gene is expressed in very low amounts in 
normal astrocytes in comparison to the Neuroblastoma cell lines, yet western blot analysis 
reveals HuC protein is expressed more than GADPH protein. The western blot results suggest 
that like HuB, HuC is very efficiently translated in normal astrocytes. 
Immunofluorescent HuC protein labelling (Section 2.4.1) was performed to identify its 
subcellular localisation. Anti-HuC IgG was used with the secondary Alexa green 488 FITC IgG. 





Figure 4.5: Example of cellular localisation of HuC protein in normal astrocytes SVG p12 and 
Neuroblastoma cells SK-N-AS and SH-SY5Y. The left column showed staining of nuclei with DAPI 
(blue), the middle column is stained with anti-HuC (green) and the right column displays a merged 
picture of DAPI and anti-HuC staining. Magnification x20. (n=3). 
 
As seen in Fig. 4.5, HuC protein expression was observed in SVG p12, SK-N-AS and SH-SY5Y 
cell lines, confirming western blot data shown in Fig. 4.4. The strongest HuC protein 
fluorescence was observed in SVG p12 cell line which is co-localising with the DAPI nucleus 
stain indicating its localisation in the nucleus. A weaker staining was also observed in the 
cytoplasm. In the SH-SY5Y and SK-N-AS Neuroblastoma cell lines, HuC protein labelling was 




4.2.3 HuD protein expression and localisation 
To confirm if the HuD gene expression is effectively translated to a protein, western blot 
(Section 2.3) was performed using anti-HuD to detect HuD protein in each cell line derived 
from normal astrocytes SVG p12 and Neuroblastoma cells SK-N-AS and SH-SY5Y. 
As shown in Fig. 4.6, HuD protein was detected at its expected molecular weight of 42kDa in 
both Neuroblastoma cell lines SK-N-AS and SH-SY5Y. A distinct absence of HuD protein was 
observed in the normal astrocyte cell line SVG p12. 
 
Figure 4.6: Representative western blot of HuD protein with anti-HuD antibody. HuD and GAPDH 
protein expression in normal astrocytes SVG p12, and Neuroblastoma cells SK-N-AS and SH-SY5Y. 
GAPDH protein expression was used as a loading control. (n=3). 
 
HuD expression at RNA level displayed in in Fig. 4.1 showed more HuD gene expression in the 
SH-SY5Y cells followed by SK-N-AS cells with little or no expression of HuD in the normal 
astrocyte cell line SVG p12 strongly correlating the protein expression shown in Fig. 4.6. 
157 
 
GAPDH protein detection was used as a loading control and was detected at the expected size 
of 37kDa. HuD protein expression level in SH-SY5Y cells was comparable to that of the GAPDH 
protein expression. The HuD protein expression in the SK-N-AS Neuroblastoma cell line was 
less than the GAPDH protein expression.  
The prominent expression of HuD protein was comparable to HuD gene expression and an 
indication of a relative translation rate of the upregulated HuD gene in Neuroblastoma. 
To identify the subcellular localisation of HuD proteins in normal astrocytes and 
Neuroblastoma, immunofluorescence staining was performed as described in Section 2.4.1.  
Anti-HuD IgG was used with secondary Alexa 488 FITC IgG and counterstaining with DAPI was 






Figure 4.7: Example of cellular localisation of HuD protein in normal astrocytes SVG p12 and 
Neuroblastoma cells SK-N-AS and SH-SY5Y. The left column showed staining of nuclei with DAPI 
(blue), the middle column is stained with anti-HuD (green) and the right column displays a merged 
picture of DAPI and anti-HuD staining. Magnification x20. (n=3). 
 
No HuD protein expression could be detected by immunostaining in SVG p12 normal 
astrocytes. Strong fluorescence was observed in both Neuroblastoma cell lines SK-N-AS and 
SH-SY5Y. These findings agree with western blot data of HuD protein expression (Fig. 4.6) and 
HuD gene expression profile (Fig. 4.1) in these cell lines. 
HuD expression in both Neuroblastoma cell lines SK-N-AS and SH-SY5Y did not show a co-
localisation with nuclear DAPI staining therefore argues a cytoplasmic localisation of HuD 
protein in these cells.  
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4.2.4 HuR protein expression and localisation 
Finally, the protein expression level and cellular localisation of ubiquitously expressed HuR 
was analysed. Western blot was performed as described in section 2.3. Anti-HuR IgG and 
loading control anti-GAPDH IgG were used for detection of HuR and GAPDH proteins 
respectively. As seen in Fig. 4.8, HuR protein was detected at its expected size of 36kDa and 
the loading control, GAPDH was observed at 37kDa.  
 
 
Figure 4.8: Representative western blot of HuR protein with anti-HuR antibody. HuR and GAPDH 
protein expression in normal astrocytes SVG p12, and Neuroblastoma cells SK-N-AS and SH-SY5Y. 
GAPDH protein expression was used as a loading control. (n=3). 
 
HuR protein expression was faintly observed in the normal astrocyte cell line SVG p12. The 
gene expression profile in Fig. 4.1 displayed a large expression of HuR mRNA in the SVG p12 
cell line. This shows that the HuR gene to protein translation is low and could be explained by 
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post-transcriptional modifications and post-translational regulatory events. HuR expression 
at RNA-level (Fig. 4.1) revealed HuR was upregulated in Neuroblastoma cells in comparison 
to the normal astrocyte. The highest expression was observed in the SH-SY5Y cells.  
HuR protein was detected by western blot in both Neuroblastoma cell lines and was 
expressed slightly higher than the GAPDH control. SH-SY5Y cell line showed HuR expression  
higher than the control whilst SK-N-AS cells showed a higher expression.  
To identify the location of the Hu RNA-binding proteins in all the analysed cell lines, 
immunofluorescent staining (Section 2.4.1) was performed (Fig. 4.9). Anti-HuR IgG was used 






Figure 4.9: Example of cellular localisation of HuR protein in normal astrocytes SVG p12 and 
Neuroblastoma cells SK-N-AS and SH-SY5Y. The left column showed staining of nuclei with DAPI 
(blue), the middle column with anti-HuR (green) and the right column displays a merged picture of 
DAPI and anti-HuR. Magnification x20. (n=3). 
 
Displayed in Fig. 4.9, HuR protein expression is observed in normal astrocytes SVG p12 and 
Neuroblastoma cells SK-N-AS and SH-SY5Y. In SVG p12 cells, strong nucleus staining of HuR 
protein was observed with a weaker staining in the cytoplasm. In SK-N-AS cells, HuR protein 
was only localised to the nucleus whilst in the second Neuroblastoma cell line SH-SY5Y, HuR 
expression was predominantly observed in the cytoplasm. 
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4.3 Establishing Hu gene knockdowns using siRNA interference in 
Neuroblastoma cells 
To gain an insight into the molecular role of Hu protein expression and its contribution to a 
cancerous phenotype, siRNA interference was established to downregulate Hu gene 
expression in the Neuroblastoma cell lines, SK-N-AS and SH-SY5Y. Each cell line was tested for 
the most efficient transfection by trialling different transfection reagents, concentration of 
siRNAs and different time periods. Following RT-qPCR, all samples were analysed using the 2-
Δ ΔCT method.  
4.3.1 Hu gene knockdown in SH-SY5Y Neuroblastoma cells 
For each individual Hu gene in the SH-SY5Y Neuroblastoma cell line, a knockdown was 
established through transfection with ON-TARGETplus SMARTpool small-interfering RNA 
(siRNA). These commercially available siRNAs were purchased to interfere with the genes 
HuB, HuC, HuD, HuR, GAPDH and a non-targeting siRNA. Each siRNA contained a pool of four 
interfering sequences listed in Table 2.4. 
The optimum transfection in SH-SY5Y Neuroblastoma cells was achieved using DharmaFECT I 
transfection reagent over 48 hours for which the protocol is provided in Section 2.7.3.  
RT-qPCR was performed to confirm Hu gene knockdowns. The cycling and reactions of RT-
qPCR are described in Section 2.26. HuB (1), HuC (1), HuD (6), HuR (2) and β-Actin primer 
sequences are listed in Table 2.3 of Section 2.27. The fold-change of expression was analysed 
by comparing expression levels to the control non-targeting siRNA. β-Actin was the 
housekeeping gene to which the data was normalised. Statistical significance was calculated 
by a two-tailed t-test. 
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Figure 4.10 displays the mRNA-transcript levels that were determined by RT-qPCR 48-hours 





































































































































Figure 4.10: Knockdown efficiency of Hu genes after individual Hu siRNA interference in the 
Neuroblastoma cell line SH-SY5Y. HuB (A), HuC (B), HuD (C) and HuR (D) gene expression following Hu 
gene knockdowns was analysed by RT-qPCR in the Neuroblastoma cell line, SH-SY5Y. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin gene expression and compared with 
the control set at 1.00. Error bars display ± SEM. Statistical significance was calculated by a two-tailed 
t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
In the Neuroblastoma cell line, SH-SY5Y, the knockdown decreased 4.7-fold for HuB, 2.0-fold 
for HuC, 2.2-fold for HuD and 5.5-fold for HuR.  
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To observe the effects of a combined Hu gene family knockdown in Neuroblastoma, SH-
SY5Y cells were transfected with all Hu gene siRNAs in a single attempt using the same 




















































































Figure 4.11: Combined siRNA interference of all Hu genes in the Neuroblastoma cell line SH-SY5Y. 
HuB, HuC, HuD and HuR gene expression following a full knockdown of each Hu gene in a single 
attempt in the SH-SY5Y Neuroblastoma cells. Samples were analysed by RT-qPCR. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin gene expression and compared with 
the control set at 1.00. Error bars display ± SEM. Statistical significance was calculated by a two-tailed 
t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
A combined knockdown of all four HuB, HuC, HuD and HuR genes was successful. The gene 
expression profile showed the mRNA expression of each Hu gene in the control non-targeting 
siRNA sample and its reduced expression in the combined siRNA transfection attempt.  
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When comparing the knockdown of each Hu gene individually and in combination, the 
combined knockdown increased the knockdown efficiency of HuC and HuD gene when 
compared to single siRNA knockdown attempts.  
Single HuB gene knockdown and combined Hu gene family knockdown achieved a 4.76- fold 
decrease and 4.54-fold decrease in HuB gene expression respectively showing little 
difference.  
Interestingly, HuC knockdown efficiency increased by 0.5-fold from a 2.0-fold decrease 
following single HuC knockdown to a 2.5-fold HuC gene decrease in combined Hu gene family 
knockdown. HuD efficiency increased by 0.3-fold from a 2.2-fold HuD gene reduction in single 
HuD gene knockdown to 2.5-fold following combined Hu gene family knockdown. 
Surprisingly, HuR gene expression revealed a decrease in knockdown efficiency of 1.9-fold 
from a 5.3-fold decrease by single HuR knockdown to a 3.4-fold decrease following combined 
Hu family knockdown attempts. 
Since the knockdown amounts differ between single knockdowns and combined knockdown, 
this suggests an external factor may influence Hu gene expression when other Hu members 
expression is compromised. 
4.3.2 Hu gene knockdown in SK-N-AS Neuroblastoma cells  
Hu gene knockdown was achieved in the SK-N-AS Neuroblastoma cell line using jetPRIME 
transfection reagent over 48 hours described in Section 2.7.2. ON-TARGETplus SMARTpool 
siRNAs targeted the HuB, HuC, HuD, HuR, GAPDH genes and a non-targeting siRNA was used 
as a control.  
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RT-qPCR was performed to confirm Hu gene knockdown with the primers HuB (1), HuC (1), 
HuD (6), HuR (2) and β-Actin (Sequences listed in Table 2.3 of Section 2.27). The fold-change 
of expression was analysed by comparing expression levels to the control non-targeting siRNA 
transfection. β-Actin was the housekeeping gene to which the data was normalised. Statistical 
significance was calculated by a two-tailed t-test. 
Displayed in Fig. 4.12, gene expression was analysed by RT-qPCR 48-hours post-transfection 
and showed the knockdown efficiency was 2.0-fold for HuB, 2.6-fold for HuC, 2.2-fold for HuD 








































































































































Figure 4.12: Hu gene expression levels in the Neuroblastoma cell line SK-N-AS following individual 
Hu RNA interference. HuB (A), HuC (B), HuD (C) and HuR (D) gene expression was analysed by RT-qPCR 
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in SK-N-AS Neuroblastoma cells. The 2-ΔΔCt results shown are an average of three replicates normalised 
to β-Actin gene expression and compared with the non-targeting control set at 1.00. Error bars display 
± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Overall, the knockdown efficiency in SK-N-AS cells compared to SH-SY5Y cells was lower, 
however HuB, HuD and HuR gene reductions were still statistically significant. 
A combined knockdown of each Hu gene family member was established using siRNAs for 


















































































Figure 4.13: Combined siRNA interference of all Hu genes in the Neuroblastoma cell line SK-N-AS. 
HuB, HuC, HuD and HuR gene expression following a single knockdown in the SK-N-AS Neuroblastoma 
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cells. Samples were analysed by RT-qPCR. The 2-ΔΔCt results shown are an average of three replicates 
normalised to β-Actin gene expression and compared with the non-targeting control set at 1.00. Error 
bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P 
≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The combined knockdown off all Hu genes in SK-N-AS resulted in a 1.4-fold reduction of a HuB 
expression, a 1.7-fold reduction in HuC expression, a 2.5-fold reduction in HuD expression and 
a 1.5-fold reduction in HuR expression however only the reduction in HuD was statistically 
significant. 
When all Hu genes were knocked down, the mRNA expression of HuB, HuC and HuR showed 
a smaller reduction compared to individual knockdowns. 
HuB transfection decreased by 0.6-fold from a 2.0-fold decrease achieved during single 
knockdown to a 1.4-fold decrease during combined Hu knockdown. HuC expression 
decreased from 2.6-fold during single HuC knockdown to a 1.7-fold decrease following 
transfection with all Hu siRNAs, a difference of 0.9-fold. HuR transfection decreased by 17.1-
fold from an 18.6-fold decrease with single HuR knockdown to a 1.5-fold decrease with 
combined Hu family knockdown. HuD transfection increased slightly by 0.3-fold from a 2.2-
fold decrease during single knockdown to a 2.5-fold decrease when all Hu genes were 
knocked down.  
4.3.3 Hu gene knockdowns confirmed at a protein level 
To confirm the Hu genes knockdowns and the impact at protein-level, protein expression 
levels were analysed by western blot analysis (Section 2.3). Cellular target protein levels may 
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remain in the cell following gene expression knockdown, dependent upon protein half-life. 
Protein expression was therefore analysed 96-hours post-transfection.  
Each Hu gene knockdown both individually and in combination in each Neuroblastoma cell 
line SK-N-AS and SH-SY5Y was blotted and stained for Hu proteins. The primary antibodies 
anti-HuB IgG, anti-HuC IgG, anti-HuD IgG, anti-HuR IgG and anti-GAPDH IgG were used along 
with Horse-radish peroxidase (HRP)-conjugated secondary antibodies. GAPDH was used as a 
control protein to normalise expression.  
SH-SY5Y Neuroblastoma cells with siRNAs targeting HuB, HuC and HuR individually and in 
combination were probed for the target proteins. The results are displayed in Figure 4.14. Hu 




Figure 4.14: Hu protein expression during single and combined Hu knockdowns in SH-SY5Y 
Neuroblastoma cells. A) HuB protein expression following single HuB and combined Hu family 
knockdown. B) HuC protein reduction following single HuC and combined Hu knockdown. C) HuD 
protein partial reduction following single HuD and combined Hu knockdown. D) HuR protein 
knockdown following single HuR and combined Hu family knockdown. GAPDH protein expression was 
used as a loading control. 
 
As previously described in Section 4.2.1, HuB protein was detected as a dimer (Fig. 4.2) and 
that is also observed here. The HuB protein both in monomer and dimer complex show a 50% 
depletion following individual HuB knockdown and a 90% knockdown following combined Hu 
family knockdown (Fig. 4.14A). The same effect is seen for HuD protein expression that was 
detected at 42kDa (Fig. 4.14C). 
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The previously described HuC multimer at 156kDa (Fig. 4.4) shows little change following the 
single HuC gene knockdown and a 50% reduction following the combined Hu knockdown. HuR 
individual knockdown was effective in knocking down HuR protein which was detected at 
36kDa in the non-targeting control sample. These protein results correlate with Hu gene 
expression data following gene knockdowns displayed in Fig. 4.10 and Fig. 4.11. 
Figure 4.15 displays Hu protein knockdown confirmation following siRNA interference.  
 
Figure 4.15: Hu protein expression during single and combined Hu knockdowns in SK-N-AS 
Neuroblastoma cells. A) HuB protein expression following single HuB and combined Hu family 
knockdown. B) HuC protein reduction following single HuC and combined Hu knockdown. C) HuD 
protein partial reduction following single HuD and combined Hu knockdown. D) HuR protein 
knockdown following single HuR and combined Hu family knockdown. GAPDH protein expression was 
used as a loading control. 
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As previously described in Section 4.2.1, HuB protein was detected as a dimer (Fig. 4.2) and 
that is also observed here. The HuB dimer at 75kDa is present in the control non-targeting 
siRNA interference sample yet absent in the single and combined siRNA transfections. 
Additionally, the HuC multimer at 156kDa (Fig. 4.4) first observed in Section 4.2.2 is present 
in the control but absent in the single and combined Hu knockdown. HuR individual 
knockdown was enough to knockdown HuR protein which was detected at 36kDa in the non-
targeting control sample. All these results of full protein knockdowns are despite a lower 
knockdown efficiency observed in the combined gene knockdowns displayed in Fig. 4.13. 
A 50% reduction of HuD protein (42kDa) was observed through single HuD siRNA interference. 
In the combined Hu siRNA interference, HuD protein expression decreased by 90% when 
compared to HuD control and comparable GAPDH expression in all samples.  
At protein level, in HuD single and combined knockdown attempts there was a difference in 
Hu proteins expression when individual Hu knockdown efficiency was compared to the 
combined knockdown. This may be due to complex interplay between the Hu family members 
in that they are able to influence expression or translational efficiency by targeting their own 
or family members sequences and up-regulating their expression although further studies 
look to confirm this hypothesis below in Section 4.4. 
4.4 Differential gene expression of Hu proteins following individual 
and combined Hu gene knockdowns 
Due to the described differences in gene and protein expression following single and 
combined knockdowns and the known ability of HuR to -regulate its own expression, a gene 
expression profile was established to explore the possibility of a regulatory mechanism within 
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the Hu family of RNA-binding proteins. The level of all Hu genes individual expression 
following individual Hu gene knockdowns was analysed. 
4.4.1 Hu gene expression profiling in SH-SY5Y Neuroblastoma cells 
RT-qPCR (Section 2.26) was performed to confirm Hu gene knockdowns and to determine any 
changes to the expression levels of other Hu genes.  The primers HuB (1), HuC (1), HuD (6), 
HuR (2) and β-Actin were used. β-Actin was the housekeeping gene to which the data was 
normalised and compared to the non-target control. Statistical significance was calculated by 
a two-tailed t-test. 
Figure 4.16 displays the effect on other Hu genes expression level following individual Hu 










































































































































Figure 4.16: Influence of individual Hu gene knockdowns on other Hu family members gene 
expression in SH-SY5Y Neuroblastoma cells. A) HuB Knockdown B) HuC Knockdown C) HuD 
Knockdown D) HuR Knockdown. The 2-2-ΔΔCt results shown are an average of three replicates 
normalised to β-Actin gene expression and compared with the non-target control. Error bars display 
± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. (n=3). 
 
In Fig. 4.16A, a 4.6-fold knockdown of HuB gene expression resulted in a significant increase 
of HuC and HuD by 1.1-fold and 0.5-fold respectively. No significant change was observed for 
HuR gene expression.  
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A 2-fold interference of HuC expression also showed a significant 0.6-fold increase in 
HuR expression. No significant change was observed for HuB and HuD gene expression 
following HuC knockdown. 
Interestingly, a 2.2-fold decrease of HuD gene expression showed an opposite effect to HuB 
and HuC siRNA knockdown and a significant decrease in gene expression of HuB and HuC was 
observed. HuB gene expression decreased by 2.18-fold, whilst HuC gene expression 
decreased by 2.3-fold. No significant change was observed for HuR gene expression. 
HuR knockdown significantly decreased the expression of the other three family members. A 
5.3-fold reduction of HuR gene expression resulted in HuB gene expression decrease of 2.6-
fold, HuC gene expression decrease of 2.4-fold and HuD gene expression decrease of 2.1-fold.  
To provide a clearer visual representation, highlight key characteristics and gain a better 
understanding of the effect of each Hu gene knockdown, a full expression profile was 
established. This data shown is Figure 4.17 is a combination of that shown in Fig. 4.10, Fig. 
4.11 and Fig. 4.16. The data is normalised to the same non-target controls of the siRNA 
interference transfection.  
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Figure 4.17: The complete profile of Hu gene expression in Neuroblastoma cell line SH-SY5Y, after 
knockdown of each individual Hu protein individually and combined. HuB, HuC, HuD and HuR 
expression following knockdown of each Hu gene both individually and in combination was analysed 
by RT-qPCR in SH-SY5Y cells. The 2-ΔΔCt results shown are an average of three replicates normalised to 
β-Actin gene expression and compared with the non-targeting control. Error bars display ± SEM. 
Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. (n=3). 
 
The effect of the individual and combined knockdowns on Hu gene expression is shown in 
displayed in Fig. 4.17. Here it is clear that generally, HuB knockdown results in an increase of 
the other Hu family members. HuC knockdown decreases the expression of HuB and increases 
the expression of HuR. Similarities are highlighted between HuD, HuR and combined Hu 
knockdown in that all other Hu family members are also decreased upon their reduced 
expression. This suggests HuD and HuR may be major players in the reduction of Hu genes 
and therefore also responsible for the results observed in the combined Hu knockdown. 
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The overall knockdown profile is summarised as percentages in a heatmap is displayed in Fig. 
4.18. 
 
Figure 4.18: Heatmap summarising Hu gene expression change after single and combined 
knockdown experiments in SH-SY5Y Neuroblastoma cells. Colour intensity proportional to the 
amount. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. (n=3). 
 
In summary, a similar Hu gene expression profile is observed when all Hu genes are knocked 
down in combination, with that of HuD and HuR knockdowns. Upregulation of Hu gene family 
members only occurs during HuB and HuC knockdowns. 
The changes in expression levels of the different Hu family members following knockdown of 
single Hu genes could be explained in three ways. A compensatory effect through which other 
Hu genes become more expressed to compensate for the reduced expression of a different 
Hu family member. A second interpretation is a regulatory effect whereby Hu family members 
actively target each other’s transcripts affecting its stability and ultimately controlling its 
expression. A third idea is that there may be off-target effects of the Hu gene downregulation. 
This is explained by different mRNA targets that Hu genes normally regulate form part of a 
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pathway that upon Hu gene knockdown, a series of downstream effects result in other Hu 
gene family members subsequent upregulation or downregulation. 
The model in Fig. 4.19 displays how different Hu family members can regulate each other’s 
expression in the Neuroblastoma cell-line SH-SY5Y.  
 
Figure 4.19: A model representing the regulation of the Hu protein family in the Neuroblastoma cell-
line SH-SY5Y. Colour intensity proportional to the change in regulation.  
 
The model in Fig. 4.19 is based only on significant changes in gene expression determined by 
a two-tailed T-test. This data indicates that HuB knockdown increased the gene expression of 
HuC and HuD. HuC knockdown increased the gene expression of HuR. Whilst individual HuD 
knockdown decreased HuB and HuC gene expression and HuR knockdown significantly 
decreased the gene expression of all the other Hu family members.  
Based on the three theories described above of compensatory expression, regulatory 
influences within the Hu family or off-target effects, there are several conclusions that can be 
drawn in the SH-SY5Y Neuroblastoma cell model. 
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4.4.2 Hu gene expression profiling in SK-N-AS Neuroblastoma cells 
For the second Neuroblastoma cell line SK-N-AS, a RT-qPCR expression profile (Section 2.2.6) 
was established to identify the general expression of Hu genes and any regulatory influences 
between the family members. RT-qPCR was performed to confirm Hu gene knockdowns and 
changes in the gene expression of other Hu family members (Fig. 4.20) using the primers HuB 
(1), HuC (1), HuD (6), HuR (2) and β-Actin. β-Actin was the housekeeping gene to which the 




































































































































Figure 4.20: Influence of individual Hu gene knockdowns on other Hu gene family members 
expression levels in SK-N-AS, Neuroblastoma cells A) HuB Knockdown B) HuC Knockdown. C) HuD 
Knockdown. D) HuR Knockdown. The 2-2-ΔΔCt results shown are an average of three replicates 
normalised to β-Actin gene expression and compared with the control. Error bars display ± SEM. 
Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. (n=3). 
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The amount of gene expression change was calculated and normalised to the non-target 
siRNA control. A HuB knockdown of 2.0-fold resulted in a 1.0-fold increase in HuR gene 
expression (Fig. 4.20A). No significant change was observed in HuC and HuD gene expression. 
HuC siRNA decreased HuC gene expression by 2.57-fold. As seen in Fig. 4.20B, this reduction 
in HuC gene expression resulted in a 1.1-fold increase of HuB gene expression. No significant 
change was observed for HuD and HuR gene expression levels. 
A HuD knockdown of 2.2-fold resulted in a 1.0-fold increase in HuB gene expression. No 
statistical change was observed for HuC and HuR gene expression. 
siRNA transfection of HuR resulted in a decrease of HuR gene expression by 18.6 fold. As seen 
in Fig. 4.20D, this gene knockdown did not result in any significant change to the other Hu 
family members expression.  
To provide a clearer visual representation, highlight key characteristics and gain a better 
understanding of the effect of each Hu gene knockdown, a full expression profile was 
established. Fig. 4.24 is a summary of the results presented in Fig. 4.12, Fig. 4.13 and Fig. 4.20. 
The data is normalised to the same non-target siRNA controls of the transfection.  
A complete Hu gene expression profile in SK-N-AS Neuroblastoma cells following individual 





















































Figure 4.21: The complete profile of Hu gene expression in Neuroblastoma cell line SK-N-AS, after 
knockdown of each individual Hu protein individually and combined. HuB, HuC, HuD and HuR 
expression knockdown of each Hu gene individually and following combined knockdown was analysed 
by RT-qPCR in SK-N-AS cells. The 2-ΔΔCt results shown are an average of three replicates normalised to 
β-Actin gene expression and compared with the non-targeting control. Error bars display ± SEM. 
Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. (n=3). 
 
Generally, HuB knockdown results in an increase of HuR expression. HuC knockdown 
increased HuC and HuR expression but decreased HuD expression. HuD siRNA interference 
results in an increased in HuB and HuC expression whilst a decrease of HuR expression is 
observed. HuR siRNA interference results in an increase of HuB gene expression and a 
decreased in HuC and HuD gene expression. Combined Hu siRNA clearly reduces all Hu genes 
expression. 





Figure 4.22: Heatmap displaying Hu gene expression change after Knockdown experiments in SK-N-
AS Neuroblastoma cells. Colour intensity proportional to the amount. Statistical significance was 
calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The heatmap displayed in Fig. 4.22 includes less statistically significant regulatory features. A 
model was developed to portray the significant regulation observed in a visual 
representation. Fig. 4.23 shows a model regulatory influences within the Hu family that exist 
in the SK-N-AS Neuroblastoma cell line. 
 
 
Figure 4.23: A model representing the statistically significant regulation of the Hu protein family in 
the Neuroblastoma cell like SK-N-AS. Colour intensity proportional to the change of gene expression 
compared to the control. 
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Based on levels of significance conducted by statistical two tailed t-test, decreases in HuC and 
HuD gene expression see an increase HuB expression. Additionally, a decreased expression of 
HuR significantly upregulated HuC expression.  
Upon comparing both Neuroblastoma cell models of regulatory interactions, the only 
significant similarity between the two models is the decrease of HuC gene expression when 
HuR gene is knocked down. Since these two cell lines portray two initial different expression 
profiles of the Hu proteins, it is unfeasible to combine the two data sets but show that the 
observed regulatory effects of Hu proteins are possible. 
4.5 Cellular morphology and invasion of normal astrocytes and 
Neuroblastoma cells 
Human cancer is often diagnosed and classified through microscopy techniques through 
identification of cell origin and various cell attributes. Morphological characteristics of cells 
are often related to their functional abilities particularly those that are malignant (Idikio 
2011).  
4.5.1 Cellular morphological analysis 
Often, cancer cells are defined by a large nucleus with prominent nucleoli, have little 
cytoplasm and are overall an irregular shape and size (Baba and Câtoi 2007). Microscopic 
analysis of Neuroblastoma and normal astrocytes is shown in Fig. 4.24. Cell images were 
obtained using an Eclipse II fluorescent inverted microscope and Microtec camera as described 




Figure 4.24: Microscopy images of each brain and Neuroblastoma cell line. Light microscopy at x20 
objective. A) Normal astrocytes cell line, SVG p12. B) Neuroblastoma cell line, SK-N-AS. C) 
Neuroblastoma cell line, SH-SY5Y.  
 
The Neuroblastoma cell lines grow as adherent monolayers and have an epithelial-like shape. 
There is a considerable degree of similarity in morphology of each Neuroblastoma cell line.  
The normal astrocytes cell line SVG p12 typically grow in star-shaped cells called fibroblasts. 
4.5.2 Cellular migrative potential 
One hallmark of cancer cells is their ability to migrate and invade into distant tissues forming 
tumour metastases. To measure the invasiveness of the Neuroblastoma cells in culture, cell 
migration was calculated by the ability of the cells to invade into a 0.5% agarose gel matrix. It 
was captured through several microscopy imaging equipment. The images below were 
achieve using time-lapse photography captured by the CytoSMART™ camera as described in 
Sections 2.5 and 2.5.1.  
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First, the ability of the normal astrocytes to migrate into the gel was assessed and is shown in 
Fig. 4.25. The normal astrocyte cells SVG p12 did not migrate into the agarose gel matrix 
during the observed 42 hours as expected for a non-cancer cell line. The cells proliferate and 
grew in a line surrounding the agarose. 
 
 
Figure 4.25: The migration of SVG p12, normal astrocyte cells into an agarose gel matrix. During the 
observed 42-hour period, no migration into the gel matrix was detected. Time-lapse photography of 







The Neuroblastoma cells were then assessed for their ability to penetrate the gel matrix. In 
contrast to the normal astrocytes, both Neuroblastoma cell lines migrated into the agarose 
gel matrix as displayed in Fig. 4.26 and 4.27. A difference in migration rate over the observed 
42-hour was seen.  
 
Figure 4.26: The migration of SK-N-AS Neuroblastoma cells into an agarose gel matrix. Over the 
observed 42-hour period, cells migrated into the gel matrix. Time-lapse photography of the cell 




The migration of SK-N-AS cells into the agarose gel matrix is shown in Fig. 4.26. SK-N-AS cells 
immediately started to migrate into the matrix (0 Hours). Over the 42-hour period, the cells 




Figure 4.27: The migration of SH-SY5Y Neuroblastoma cells into an agarose gel matrix. Over the 
observed 42-hour period, cells migrated into the gel matrix. Time-lapse photography of the cell 





The migration of SH-SY5Y cells into the agarose gel matrix is shown in Fig. 4.27. The cells were 
seeded 24-hour post-transfection and once adhered to the flask, immediately began 
migrating into the gel matrix. Over the 42-hour period, the SH-SY5Y cells migrated into 18.92% 
of the displayed gel matrix. 
The invasiveness of the Neuroblastoma cell lines SK-N-AS and SH-SY5Y and the normal 
astrocyte cells SVG p12 was compared and is shown in Fig. 4.28.  
188 
 






















Figure 4.28: The migration of SK-N-AS and SH-SY5Y Neuroblastoma cells compared to the non-
migration of SVG p12 astrocyte cells. Migration into the gel matrix was calculated by the percentage 
surface area invaded by the cells. 
 
Migration of the normal astrocyte and Neuroblastoma cell lines over 42 hours is displayed in 
Fig. 4.28. SK-N-AS was the most migrative with a 12.45% increase in the migrative potential 
than the SH-SY5Y cells whilst normal astrocyte SVG p12 were shown to not penetrate the gel. 
In summary, the Neuroblastoma cell lines have a greater migrative potential than the normal 
astrocytes. 
4.6 Cellular morphology, viability and migration following Hu 
knockdown in Neuroblastoma cells 
Often cancer cells experience genomic alterations causing mutations that influence 
proliferation, cell motility and changes to cell morphology (Baba and Câtoi 2007). Cell 
189 
 
morphology can help determine the physiological state of the cells and can therefore be used 
to qualitatively assess to cell health.  
4.6.1 Effect of Hu knockdowns in SH-SY5Y cells  
To assess the effect of Hu gene expression on these features in Neuroblastoma, cells 
morphology was analysed following individual and combined  Hu gene knockdowns. Cells were 
imaged to assess any changes to cell morphology through size and shape following Hu gene 
knockdowns. RT-qPCR of knockdown experiments confirmed a Hu gene knockdown at 48 
hours, subsequently cell morphology was observed at this time point. Cell images were 
obtained using an Eclipse II fluorescent inverted microscope and Microtec camera as described 
in Section 2.1.6. 
It is also important to mention, the images displayed in Figure 4.29 do not confer the 
confluency of the cell lines following Hu knockdowns. Other methods evaluate the 
proliferation rates described later in this section. Some cells had died, these were removed 





Figure 4.29: SH-SY5Y cell morphology 48-hours post-transfection with Hu siRNAs. SH-SY5Y cells with 
Hu genes knocked down in combination and individually. Light microscopy at 20x objective. 
 
The morphology of SH-SY5Y has not been influenced by the individual or combined Hu gene 
knockdowns compared to the control non-target siRNA transfected cells. 
The cell viability after Hu knockdowns both individually and in combination were assessed 
over 120 hours in SH-SY5Y cells using CellTiter 96® AQueous One Solution assay (Section 2.6). 
Readings were taken at 24 hour intervals, 48 hours after transfection. 
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Figure 4.30: Cell viability of SH-SY5Y cells after knockdown experiments. Mean cell viability 
normalised to the control non-target siRNA treated cells. A) Effect of HuB knockdown. B) Effect of HuC 
knockdown. C) Effect of HuD knockdown. D) Effect of HuR knockdown. E) Effect of combined Hu 
knockdown. MTS absorbance was recorded at 490nm over a 120-hour period. Data are expressed as 
mean values ± SD. n=3. Statistical significance was calculated by a two-tailed t-test and is displayed by 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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The SH-SY5Y cell viability profiles displayed in Fig. 4.30 showed that the highest variability of 
Hu knockdowns was at the 120-hour time point. At this time point, cell viability increased 
43.72% following HuB knockdown, 9.92% following HuC knockdown and 41.23% in the 
combined Hu knockdown cells which were all significant. HuC showed a significant increase 
in viability when compared to the 48 hour sample whilst the combined Hu knockdown also 
showed a significant increase when compared to the 48 and 72 hours time points. HuD and 
HuR knockdown samples showed no significant change on viability between time points or 
when compared to the control. 
Cell motility was measured before and after individual and combination Hu gene knockdowns 
with a scratch wound assay (Section 2.5.2). This assay measures the ability and speed of the 
cells to migrate into an artificially created cell-free gap until new cell-cell contacts are 
established. Cells were imaged every 24 hours.  
The visual representation of SH-SY5Y cells migrating into a gap is shown in Fig. 4.31, Fig. 4.32 
and Fig. 4.33. Whilst this method can show variable results, quantitative measurements for 
the 48-hour timepoint were recorded. Later timepoints although captured visually, show 
great variability due to changes in cell viability. 
The control cells with a non-targeting siRNA (Fig. 4.31) showed an increase in motility 






Figure 4.31: Scratch wound assays in control SH-SY5Y Neuroblastoma cells with non-targeting 
siRNA. Migration was assessed 48 hours post-transfection when cells were confluent. Images were 
taken for 72 hours. Wounds were generated after cell confluence following siRNA interference. 
Timepoints state the number of hours post-wound making. Yellow lines highlight the gap. 
Magnification x10. 
 
Next, the effect of individual Hu gene knockdowns were observed (Fig. 4.32). Again a similar 
effect was observed in that an increase in motility following 24 hours resulted in the cells 
becoming too confluent and consequently start to detach at the wound edge. HuC knockdown 
resulted in detaching of cells following 48-hours so no images were obtained following that 





Figure 4.32: Scratch wound assays in SH-SY5Y Neuroblastoma cells following knockdown of Hu genes individually. Migration was assessed 48 hours post-
transfection when cells were confluent. Images were taken for 72 hours. A) HuB knockdown B) HuC knockdown C) HuD knockdown D) HuR knockdown. 
Timepoints state the number of hours post-wound making. Yellow lines highlight the gap. Magnification x10. 
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The effect of a combined knockdown is shown in Figure 4.33. 
 
 
Figure 4.33: Scratch wound assays in SH-SY5Y Neuroblastoma cells following knockdown of Hu 
genes combined. Migration was assessed 48 hours post-transfection when cells were confluent. 
Images were taken for 72 hours. Wounds were generated after cell confluence following siRNA 
interference. Timepoints state the number of hours post-wound making. Yellow lines highlight the 
gap. Magnification x10. 
 
Percentage migration into the cell-free gap was calculated for the 48 hour timepoint using 
ImageJ pixel analysis. Two-tailed t-test determined the statistical significance. This data is 
show in Fig. 4.33 
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Figure 4.34: Cell migration of Neuroblastoma cells SH-SY5Y represented as the percentage of 
migration into the cell-free gap over 48 hours. The measure of cell motility was calculated in ImageJ 
through the measurement of pixels and conversion into a percentage to determine the rate of cell 
migration. Data showed the mean migration of cells into the cell-free gap over 48 hours. Error bars 
display ± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Whilst defining the role of the Hu-family of RNA binding proteins in cell migration, it was 
observed that the most variation between individual and combined Hu gene knockdowns 
compared to the non-target control at the 48 hours timepoint. This is displayed in Fig. 4.33. 
All cells with either individual or combined Hu gene knockdowns had a greater directional 
migratory response in comparison to the controls.  
Changes to the cellular properties observed following Hu gene knockdowns in the SH-SY5Y 




Figure 4.35: Changes in cellular properties following Individual and combined Hu gene family 
knockdown in the Neuroblastoma cell line SH-SY5Y.  
 
Knockdown of individual Hu or combined Hu genes did not result in any morphological 
changes. However, an increase in viability could be seen following HuB, HuC and the 
combined knockdown of all four Hu genes. Additionally, a reduction of HuB, HuC and HuR 
individually and all Hu genes in combination revealed an increased migrative potential.  
4.6.2 Effect of Hu knockdowns in SK-N-AS cells 
Cells were imaged to assess any changes to cell morphology through size and shape following 
Hu gene knockdowns (Fig. 4.36). Images were obtained using an Eclipse II fluorescent inverted 




Figure 4.36: SK-N-AS cell morphology 48-hours post-treatment with siRNA. SK-N-AS cells with Hu 
genes knocked down in combination and individually. Light microscopy at 20x objective. 
No morphological changes could be observed in SK-N-AS cells following knockdown of all Hu 
proteins individually and in combination in comparison to the control untreated cells.  
The cell viability after Hu knockdowns both individually and in combination were assessed 
over 120 hours in SK-N-AS cells using CellTiter 96® AQueous One Solution assay (Section 2.6). 
Readings were taken in 24 hour intervals, 48 hours after transfection.  
The cell viability profile for SK-N-AS cells is displayed in Fig. 4.37. 
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Figure 4.37: Cell viability of SK-N-AS cells after knockdown experiments. Cell viability normalised to 
the non-target control. A) Effect of HuB siRNA transfection. B) Effect of HuC siRNA transfection. C) 
Effect of HuD siRNA transfection. D) Effect of HuR siRNA transfection. E) Effect of combined Hu siRNA 
transfection. MTS absorbance was recorded at 570nm over a 120-hour period. Data are expressed as 
mean values ± SD of at least three separate determinations. No statistical significance was detected 
by a two-tailed t-test. 
 
The cell viability of the control is set at 100%. At 96 hours where most variability is seen, 
viability increased 27.23% following HuB knockdown and 21.75% following HuR knockdown 
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although these values are not statistically significant. Cell viability reduced 7.08% following 
HuC knockdown,19.54% following HuD knockdown and 8.25% when all Hu genes were 
knocked down. Unfortunately, none of these values held significance. 
To address if any of the Hu knockdowns influence cell motility, a scratch wound assay (Section 
2.5.2) was performed and captured at 24 hour intervals starting 48 hours post-transfection. 
Images were captured using an Eclipse II fluorescent inverted microscope and Microtec camera 
as described in Section 2.1.6. The visual representation of SK-N-AS cells migrating are shown 
in Fig. 4.38, Fig. 4.39 and Fig. 4.40. 
Whilst this method can show variable results, quantitative data for the 24-hour timepoint was 
recorded. Later timepoints although captured visually, show great variability due to changes 
in cell viability. 
Damage induced by the wound to the cell layer showed a different pattern of disruption when 
comparing this cell line to the other Neuroblastoma cell line. This can be explained as a 
different effect to the extracellular matrix formed by all adherent cells in culture. Whilst 
wounds were induced using the same methods, SH-SY5Y cells formed a more uniform gap 
compared to the  irregular disruption inflicted on the SK-N-AS cell monolayer. These cells still 
managed to migrate towards each other, filling in smaller areas but generally at a slower rate 






Figure 4.38: Scratch wound assays in control SK-N-AS Neuroblastoma cells with non-targeting siRNA. 
Migration was assessed 48 hours post-transfection when cells were confluent for 72 hours. Wounds 
were generated after cell confluence following siRNA interference. Timepoints state the number of 
hours post-wound making. Yellow lines highlight the gap. Magnification x10. 
 




Figure 4.39: Scratch wound assays in SK-N-AS Neuroblastoma cells before and after knockdown of Hu genes individually. Migration was assessed 48 hours 
post-transfection when cells were confluent for 72 hours. A) HuB knockdown B) HuC knockdown C) HuD knockdown D) HuR knockdown. Timepoints state the 
number of hours post-wound making. Yellow lines highlight the gap. Magnification x10. 
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HuD knockdown resulted in detaching of cells following 24-hours so no images were obtained 
following that timepoint for that sample. The same occurred with HuC knockdown and 
combined Hu knockdowns after 72 hours. Interestingly, this correlates with viability data 
shown for this Neuroblastoma cell line SK-N-AS detailed in Fig. 4.37. Although not statistically 
significant, a decrease in viability is observed for these knockdowns at the 96-hours timepoint 




Figure 4.40: Scratch wound assays in SK-N-AS Neuroblastoma cells before and after knockdown of 
all Hu genes combined. Migration was assessed 48 hours post-transfection when cells were confluent 
for 72 hours. Wounds were generated after cell confluence following siRNA interference. Timepoints 




Percentage migration into the cell-free gap was calculated for the 24 hour timepoint using 
ImageJ pixel analysis. Two-tailed t-test determined the statistical significance. This data is 
show in Fig. 4.41. 






























Figure 4.41: Cell migration of Neuroblastoma cells SK-N-AS represented as the percentage of 
migration into the cell-free gap over 24 hours. The measure of cell motility was calculated in ImageJ 
through the measurement of pixels and conversion into a percentage to determine the rate of cell 
migration. Data showed the mean migration of cells into the cell-free gap over 24 hours. Error bars 
display SEM. (n=3). Statistical significance was calculated by a two-tailed t-test and is displayed by *P 
≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.  
 
The cell migration profile displayed in Fig. 4.41 details a different migratory rate than the 
other Neuroblastoma cell line examined (Fig. 4.33). Whilst defining the role of the Hu-family 
of RNA binding proteins in cell migration in the SK-N-AS cell line, the most reliable data was 
at the 24-hour timepoint as cell growth was not affected during this time. At 24-hours, a 
significant 24.06% increase in the migratory rate of SK-N-AS cells was seen following HuB 
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knockdown. 10.62% increase following HuC knockdown and a 21.96% increase following 
combined Hu knockdown that were insignificant. HuD and HuR knockdowns showed a 
reduced migratory potential of 10.04% and 7.62% respectively both of which were also 
insignificant. 
A summary of the overall effect of Hu interference in SK-N-AS cells is displayed in Figure 4.42. 
Knockdown of individual Hu or combined Hu genes in SK-N-AS cells did not result in any 
morphological changes. HuB knockdown increased the migrative potential of SK-N-AS cells. 
 
 
Figure 4.42: Changes in cellular properties following Individual and combined Hu gene family 




The two Neuroblastoma cell lines SH-SY5Y and SK-N-AS shared some similarities. There was 
no change in morphology following any Hu gene knockdowns. HuB gene knockdown resulted 
in a more migrative phenotype in both cell lines. 
4.7 Effect of Hu knockdown on gene regulation and translational 
networks in Neuroblastoma 
To assess the biological function of Hu proteins, the molecular targets of Hu proteins and the 
affect they have on those mRNA transcripts were determined through RT-qPCR before and 
after individual and combined Hu gene knockdowns. A collection of 91 pre-selected genes 
(Table 4.1) with appropriate controls were analysed before and after Hu gene knockdowns. 
The genes selected are thought to play a role in the development of Neuroepithelial 
neoplasms referenced by the National Library of Medicine database (NLM 2018). Gene targets 
are ranked based on frequency of gene expression changes in biomarker studies, popularity 
in overall medical research and popularity in current medical research (Biorad 2018).  
The array of genes (Table 4.1) was screened to highlight target mRNAs influenced by the 
family of Hu RNA-binding proteins regulation to establish a role of their aberrant or 





Table 4.1: Gene targets by the Neuroepithelial T1 PrimePCR™ Assay. 
 
PrimePCR™ Disease state panels (Section 2.2.8) allow for an in-depth investigation of 
differentially expressed genes within Neuroblastoma. The targets on the panel are in line with 
the National Library of Medicine database (NLM 2018). Using cDNA from Hu gene 
knockdowns in the Neuroblastoma cell lines, SH-SY5Y and SK-N-AS, RT-qPCR of these panels 
facilitated initial screening of the genes. RT-qPCR data was analysed by the PrimePCR™ data 
analysis software provided by Bio-Rad. 
4.7.1 Identification of mRNA target transcripts of Hu gene regulation 
in SH-SY5Y Neuroblastoma cells 
The gene analysis of SH-SY5Y Neuroblastoma cells following Hu gene individual and combined 
knockdowns revealed a multitude of gene expression changes when compared to the non-
target control. To identify the genes with the highest expression level changes, a set the 
threshold of 3 fold-cycle difference was applied.  
 
ABCB1 CCND1 CTNNB1 HIF1A KIT MMP9 RB1 TLR2 TBP
AKT1 CCND2 CXCL12 HLA-DRB1 KRAS MYC RRM2 TNF GAPDH
APOE CD44 CXCR4 HMOX1 MAP2K2 NFKB2 SERPINE1 TOP2A HPRT1
ATM CDK1 EGFR IFNG MAPK1 PCNA SOD2 TYMS
AURKA CDK2 EGR1 IGF1 MAPK3 PIK3CA SP1 UBB
BCL2 CDKN1A ERBB2 IGF1R MDM2 PIK3R1 SPP1 UBC
BDNF CDKN2A ESR1 IGFBP3 MKI67 PLAU STAT3 VCAM1
BIRC5 COL1A1 EZH2 IL10 MLH1 PRKCA TCF7L2 VEGFA
BRCA1 COL1A2 FN1 IL6 MMP1 PROM1 TERT VIM
CCNA2 CTBP2 GSK3B ITGB1 MMP2 PTEN TGFB1 WNT5A
CCNB1 CTGF GSTP1 KDR MMP7 RAF1 TIMP1 ZWINT
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siRNA Interference Target 
HuB HuC HuD HuR Combined Hu 
IGFBP3 IGFBP3 IGFBP3 IGFBP3 IGFBP3 
EGR1 EGR1 EGR1 EGR1 EGR1 
   IL10 IL10 
   ESR1 ESR1 
BCL2   BCL2  
CCND2    CCDN2 
 PROM1  FN1 COL1A1 
   CXCL12 SERPIN 
   MAPK3  
   IGFIK  
   SP1  
   NFKB2  
   VCAM1  
Table 4.2: Identification of targets for further gene analysis influenced by Hu gene knockdowns in 
Neuroblastoma cells SH-SY5Y. List of the 16 genes conforming to the criteria of a fold-change of at 
least 3. Highlighted genes are those consistent with two or more of the knockdown samples. 
 
Of the 91 genes analysed shown in Table 4.2, there was 16 identified alterations consisting of 
both upregulated and downregulated expression of more than a 3.0 fold-change difference 
to the control non-targeting siRNA.  
To further minimise the number of genes for analysis, targets expression that was affected by 
two or more Hu gene knockdowns were selected. Highlighted in blue in Table 4.2 are the six 
genes that conform to the criteria described above in the Neuroblastoma cell line SH-SY5Y.  
Changes in IGFBP3 and EGR1 gene expression were consistent amongst all Hu gene 
knockdowns both individually and combined. IL10 and ESR1 gene expression was affected by 
HuR and combined Hu family knockdowns. BCL2 expression changed upon HuB and HuR gene 
knockdowns whilst CCND2 gene expression was affected by HuB and combined Hu family 
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knockdowns. A custom PrimePCR™ assay was designed to specifically target these genes to 
determine the extent of the Hu gene family in regulating these targets.  
For each gene target, individual and combined Hu gene knockdown in SH-SY5Y cDNA was run 
with expression normalised to β-Actin and compared with the control non-target siRNA using 
the 2-ΔΔCt method. Statistical significance was determined by a two-tailed t-test. 
The relative fold-change in the transcript levels of B-cell lymphoma (BCL2) following 
knockdown of each Hu gene individually and in combination in the Neuroblastoma cell lines 

























































Figure 4.43: BCL2 gene expression following individual and combined Hu gene family knockdowns 
in SH-SY5Y Neuroblastoma cells. BCL2 gene expression was analysed by RT-qPCR in SH-SY5Y cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 




RT-qPCR revealed that there was statistically significant downregulation of BCL2 gene 
expression in all knockdowns tested. An average decrease of 2.1-fold was observed for the 
siRNA interference of HuB, HuC and HuR and combination Hu gene when compared to the 
control. The highest knockdown was a 3.4-fold downregulation of BCL2 mRNA level after 
knockdown of HuD gene. 
Next, the expression of Cyclin D2 (CCND2) was analysed following Hu gene knockdowns (Fig. 























































Figure 4.44: CCND2 gene expression following individual and Hu family combined Hu gene 
knockdowns in SH-SY5Y Neuroblastoma cells. CCND2 gene expression was analysed by RT-qPCR in 
SH-SY5Y cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to β-Actin and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-
tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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The relative normalised expression of CCND2 following siRNA interference of each Hu gene 
individually and in combination in the Neuroblastoma cell lines SH-SY5Y. RT-qPCR revealed a 
statistically significant downregulation of CCND2 expression in HuC knockdown by 3.5-fold 
and in HuD knockdown, a downregulation of 5.8-fold. However, a statistically significant  2.1-
fold increase of CCND2 was observed after knockdown of all Hu genes in combination. HuB 
and HuR knockdown showed little change in CCND2 gene expression. 
Next, the expression of Early Growth Receptor 1 (EGR1) following siRNA interference of each 






















































Figure 4.45: EGR1 gene expression following HuB, HuC and HuD, HuR and combined Hu gene 
knockdowns in SH-SY5Y Neuroblastoma cells. EGR1 gene expression was analysed by RT-qPCR in SH-
SY5Y cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to β-Actin and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-
tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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EGR1 gene expression was normalised to β-Actin and compared with the control non-target 
siRNA. EGR1 expression levels were downregulated in SH-SY5Y cells with siRNA interference 
of HuB, HuC and HuD genes. After HuB knockdown, EGR1 decreased by 3.7-fold, knockdown 
of HuC expression also resulted in a 2.1-fold down regulation and a HuD knockdown 
additionally showed a 3.8-fold decrease each of which was statistically significant. Little 
change was observed in EGR1 gene expression following HuR and combined Hu family 
knockdowns. 
Next, the expression of Estrogen Receptor 1 (ESR1) was analysed, the relative normalised 
























































Figure 4.46: ESR1 gene expression following individual and combined Hu gene family knockdowns 
in SH-SY5Y Neuroblastoma cells. ESR1 gene expression was analysed by RT-qPCR in SH-SY5Y cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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The relative normalised ESR1 gene expression showed that after individual Hu gene 
knockdowns there was a decrease of ESR1 expression when compared to the control. ESR1 
gene expression decreased following HuB knockdown by 3.0-fold, HuC knockdown by 4.8-fold 
and HuD knockdown by 8.7-fold, each were statistically significant. When the Hu genes were 
knocked down in combination, ESR1 expression increased by 1.1-fold. No significant change 
was observed in ESR1 expression upon HuR knockdown. 
Next, the expression of Insulin-like growth factor-binding protein 3 (IGFBP3) was analysed 




















































Figure 4.47: IGFBP3 gene expression following individual and combined Hu gene family knockdowns 
in SH-SY5Y Neuroblastoma cells. IGFBP3 gene expression was analysed by RT-qPCR in SH-SY5Y cells 
with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt 
results shown are an average of three replicates normalised to β-Actin and compared with the control 
non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-




IGFBP3 gene expression was normalised to β-Actin and compared with the control non-target 
siRNA. RT-qPCR revealed a statistically significant downregulation of 3.9-fold in IGFBP3 
expression in HuR gene knockdown of SH-SY5Y cells. There was no significant difference in 
expression in all other knockdowns. 
Next, the expression of Interleukin 10 (IL10) was analysed. The relative fold-change in the 
transcript levels of IL10 expression following siRNA interference of each Hu gene individually 
and in combination in SH-SY5Y is displayed in Fig. 4.48. Gene expression was normalised to β-






















































Figure 4.48: IL10 gene expression following individual and combined Hu gene family knockdowns in 
SH-SY5Y Neuroblastoma cells. IL10 gene expression was analysed by RT-qPCR in SH-SY5Y cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 




The relative normalised IL10 gene expression, showed that after all individual Hu gene 
knockdowns, a decrease of IL10 expression  was observed when compared to the control. 
HuB siRNA interference decreased IL10 expression by 2.8-fold, HuC siRNA interference 
showed a reduction of IL10 expression by 5.1-fold, HuD siRNA interference resulted in a 10.4-
fold decrease in IL10 expression and HuR siRNA interference reduced it by 6.3-fold. When Hu 
genes were knocked down in combination, IL10 expression increased by 1.3-fold. All changes 
to IL10 gene regulation were statistically significant. 
To summarise the expression of all the gene targets discussed above, a heat map was 
developed in Microsoft Excel using analysis from Biorad PrimePCR Analysis (Fig. 4.49). 
 
Figure 4.49: Heatmap of genes with differential expression in SH-SY5Y cells following Hu gene 
knockdowns individually and in combination. The relative gene expression data of multiple targets 
in each Hu  gene knockdown individually and combined in SH-SY5Y. Targets are clustered according 
to their similarity in the gene expression pattern. (Up regulation; Red, Down regulation; Green, no 
change; Black, as shown by the key). The lighter the shade of colour, the greater the relative 
expression difference according to the magnitude of relative gene expression). 
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The heat map concludes that the most similarity was observed in the gene expression profiles 
of CCND2, ESR1 and IL10. Knockdown of HuC, HuD and all Hu genes in combination for these 
profiles sees the same effect on the target genes expression. Of the CCND2, ESR1, IL10 
clustering, there was then a further 50% similarity to EGR1 and BCL2 with HuB, HuD and HuC 
knockdowns, which showed the same trend in the target gene expression. The least similarity 
was observed in the IGFBP3 gene expression profile compared to the other target genes.  
Interestingly, this heat map also highlights trends in the Hu knockdowns in the SH-SY5Y cells. 
Following HuC and HuD knockdown, five of the six gene targets expression decreased. HuB 
knockdown decreased its target gene expression in four of the genes. Also, all Hu genes 
knocked down in combination showed an increase in five of the target gene expression 
profiles including CCND2, ESR1, IL10, EGR1, and IGFBP3. 
4.7.2 Identification of mRNA target transcripts of Hu gene regulation 
in SK-N-AS Neuroblastoma cells 
Next, the targets displayed in Table 4.1 were screened by RT-qPCR following each Hu gene 
knockdown individually and in combination were in the second Neuroblastoma cell line, SK-
N-AS. RT-qPCR data was analysed by the PrimePCR™ data analysis software provided by Bio-
Rad. 
The gene analysis of SK-N-AS Neuroblastoma cells following Hu gene individual and combined 
knockdowns revealed many gene expression changes when compared to the non-target 
control. Therefore, a threshold of 3.6 fold-cycle difference was set to maintain a more 
manageable number of genes to target for further analysis.  
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Of 91 genes named in Table 4.1, there were 35 genes that either became amplified, over-
expressed or under-expressed and deleted by 3.6 fold-change difference in comparison to the 
control. These are summarised in Table 4.3. 
 
siRNA Interference Target 
HuB HuC HuD HuR Combined Hu 
MAPK3 MAPK3 MAPK3   
APOE APOE APOE   
FN1 FN1    
PRKCA PRKCA    
CDK1 CDK1    
TOP2A TOP2A    
CTGF CTGF    
KRAS KRAS    
GSTP1 GSTP1    
 EGR1 EGR1   
 MAP2K2 MAP2K2   
 TGFΒ1 TGFΒ1   
 BDNF SERPINE1 UBC PLAU 
STAT3 GFB1 COL1A1 HLA-DRB1  
ATM BCL2  PTEN  
RAF1 WNT5A    
VEGFA IL10    
ITGB1 BRCA1    
MMP1 AURKA    
CCNB1     
PIK3CA     
COL1A2     
Table 4.3. Identification of targets for further gene analysis influenced by Hu gene knockdowns in 
Neuroblastoma cells SK-N-AS. The 35 genes conforming to the criteria of a fold-change of at least 3.6. 




To further minimise the number of genes for analysis, targets expression that was affected by 
two or more Hu gene knockdowns were selected. Highlighted in blue in Table 4.3 are the 12 
genes that conform to the criteria described above in the Neuroblastoma cell line SK-N-AS.  
MAPK3 and APOE gene expression changes were observed following HuB, HuC and HuD gene 
knockdowns. FN1, PRKCA, CDK1, TOP2A, CTGF, KRAS and GSTP1 gene expression was affected 
by HuB and HuC knockdowns whilst, EGR1, MAP2K2 and TBFB1 expression was affected by 
HuC and HuD gene knockdowns. A custom PrimePCR™ assay was designed to specifically 
target these genes to determine the extent of the Hu gene family in regulating these targets.  
For each gene target, individual and combined Hu gene knockdown in SH-SY5Y cDNA was run 
with expression normalised to GAPDH and compared with the control non-target siRNA using 
the 2-ΔΔCt method. Statistical significance was determined by a two-tailed t-test. 
First, the effect of single and combined Hu gene knockdown was assessed for the effects on 
Apolipoprotein E (APOE) expression. The relative fold-change in the transcript levels of APOE 






























































Figure 4.50: APOE gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. APOE gene expression was analysed by RT-qPCR in SK-N-AS cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to GAPDH and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Apolipoprotein E expression decreased when all Hu genes were knocked down individually 
and combined in the SK-N-AS Neuroblastoma cell line. APOE expression decreased by 2.5-fold 
following HuB knockdown, 1.5-fold following HuC knockdown, 3.1-fold following HuD 
knockdown and 1.6-fold following HuR knockdown. Interestingly, the combined Hu family 
knockdown caused the lowest decrease expression in APOE by only 1.3-fold. 
Next, the expression of Cyclin-dependent kinase 1 (CDK1) was analysed. The relative fold-
change in the transcript levels of CDK1 expression following siRNA interference of each Hu 
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gene individually and in combination in SK-N-AS is displayed in Fig 4.51. Gene expression was 





















































Figure 4.51: CDK1 gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. CDK1 gene expression was analysed by RT-qPCR in SK-N-AS cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to GAPDH and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Kknockdown of HuC and HuR genes in SK-N-AS caused no significant change to Cyclin-
dependent Kinase 1 (CDK1) gene expression. HuB siRNA interference induced an upregulation 
of CDK1 expression by 0.8-fold, likewise HuD siRNA interference also increased CDK1 
expression by 0.5-fold. Combined Hu gene family knockdown resulted in a significant 
upregulation of CDK1 by 0.1-fold. 
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Connective Tissue Growth Factor (CTGF) gene expression was analysed following siRNA 
interference of the Hu gene family in SK-N-AS cells (Fig 4.52). Gene expression was normalised 

























































Figure 4.52: CTGF gene expression following HuB, HuC, HuD and HuR knockdowns and combined Hu 
gene family knockdowns in SK-N-AS Neuroblastoma cells. CTGF gene expression was analysed by RT-
qPCR in SK-N-AS cells with siRNA interference of HuB, HuC, HuD and HuR individually and all Hu in 
combination. The 2-ΔΔCt results shown are an average of three replicates normalised to GAPDH and 
compared with the control non-target siRNA. Error bars display ± SEM. Statistical significance was 
calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Of the statistically significant data, HuC, HuD and HuR knockdowns all decreased CTGF gene 
expression by 1.7-fold, 1.6-fold and 2.9-fold respectively. HuB and Hu family combined gene 
knockdown did not show any statistical difference. 
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The next gene to be analysed is Early Growth Receptor 1 (EGR1) was analysed. The relative 
fold-change in the transcript levels of EGR1 expression following siRNA interference of each 
Hu gene individually and combined in SK-N-AS cells is shown in Fig. 4.53. Gene expression was 



























































Figure 4.53: EGR1 gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. EGR1 gene expression was analysed by RT-qPCR in SK-N-AS cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to GAPDH and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
A reduction of EGR1 gene expression was observed in all SK-N-AS cell samples varying with 
single or combined Hu gene knockdown. Of statistical significance was the reduction in EGR1 
expression by 6.6-fold following HuC knockdown down and 5.1-fold reduction following HuD 
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knockdown, whilst Hu genes knocked down in combination saw a reduction of EGR1 
expression by 3.8-fold. 
Fibronectin 1 (FN1) gene expression was determined following siRNA interference of SK-N-AS 
























































Figure 4.54: FN1 gene expression following individual and combined Hu gene family knockdowns in 
SK-N-AS Neuroblastoma cells. FN1 gene expression was analysed by RT-qPCR in SK-N-AS cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to GAPDH and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Fibronectin 1 gene expression decreased upon Hu gene knockdowns both individually and in 
combination in the Neuroblastoma cell line SK-N-AS. Whilst none were significant most likely 
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due to SEM in the control sample, all showed a reduction of at least 1.3-fold with HuD 
knockdown causing the greatest effect on FN1 expression. 
The effect of Hu gene siRNA interference on Glutathione S-Transferase Pi 1 (GSTP1) was 
determined in SK-N-AS cells and is shown in Fig. 4.55. Gene expression was normalised to 























































Figure 4.55: GSTP1 gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. GSTP1 gene expression was analysed by RT-qPCR in SK-N-AS cells 
with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt 
results shown are an average of three replicates normalised to GAPDH and compared with the control 
non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-
test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
As seen in Fig. 4.55, a variable response was observed on Glutathione S-Transferase Pi 1 gene 
expression upon both individual and combination Hu gene knockdowns. HuB siRNA 
interference was the only knockdown to induce a decrease in GSTP1 expression. In this 
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sample, GSTP1 expression decreased by 1.4-fold. HuC, HuD and HuR siRNA interference saw 
an increased in GSTP1 expression by 0.4-fold, 0.2-fold and 0.7-fold respectively. Additionally, 
when all Hu gene were knocked down in combination, an upregulation of 0.2-fold was 
observed in GSTP1 gene expression. 
The effect of Hu gene siRNA interference on Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) was determined in SK-N-AS cells and is shown in Fig. 4.56. Gene expression 
























































Figure 4.56: KRAS gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. KRAS gene expression was analysed by RT-qPCR in SK-N-AS cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to GAPDH and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 




As seen in Fig. 4.56, a decrease in KRAS expression was observed for HuC, HuD, HuR and 
combined Hu gene knockdown. KRAS expression decreased significantly by 1.5-fold following 
HuC knockdown and 2.1-fold following HuR knockdown. HuB, HuD and combined Hu 
knockdown did not show any significant change to KRAS gene expression in the SK-N-AS cells. 
Next, two members of the mitogen-activated kinase family were analysed, Mitogen-Activated 
Protein Kinase Kinase 2 (MAP2K2 (Fig 4.57) and Mitogen-Activated Protein Kinase 3 (MAPK3) 
(Fig 4.58) for any change in gene expression following Hu gene knockdowns both individually 




























































Figure 4.57: MAP2K2 gene expression following individual and combined Hu gene family 
knockdowns in SK-N-AS Neuroblastoma cells. MAP2K2 gene expression was analysed by RT-qPCR in 
SK-N-AS cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to GAPDH and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-
tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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As seen in Fig. 4.57, the biggest reduction of Mitogen-Activated Protein Kinase Kinase 2 gene 
expression was observed in individual HuB and HuD knockdowns with a reduction of 
expression of 6.2-fold and 9.04-fold respectively. Upon HuC and HuR knockdown, MAP2K2 
expression decreased by 2.3-fold and 1.3-fold respectively. Combined Hu gene knockdown 


























































Figure 4.58: MAPK3 gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. MAPK3 gene expression was analysed by RT-qPCR in SK-N-AS cells 
with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt 
results shown are an average of three replicates normalised to GAPDH and compared with the control 
non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-
test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The expression profile of MAPK3 gene expression following Hu individual and combined 
knockdowns. Like MAP2K2, the largest reduction in Mitogen-activated Protein Kinase 3 
(MAPK3) gene expression was following HuB and HuD knockdown where expression 
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decreased by 3.6-fold and 5.7-fold respectively. HuC knockdown resulted in a 2.7-fold 
reduction in MAPK3 expression whilst HuR knockdown showed a 2.4-fold decrease. Combined 
Hu gene knockdown showed the smallest effect on MAPK3 expression although it still resulted 
in a 1.6-fold decrease. 
An overall decreased of both kinases was observed upon single and combined Hu gene 
knockdowns in SK-N-AS cell line. Within this observation is a similar pattern for each sample 
whereby HuB and HuD knockdowns showed the most decrease in MAP2K2 and MAPK3 gene 
expression followed by HuC, HuR and combined Hu siRNA knockdowns in the SK-N-AS cell 
line. 
Another member of the kinase family was analysed, Protein kinase C α (PRKCA). The relative 
fold-change in the transcript level expression following knockdowns of each Hu gene 
individually and combined shown in Fig 4.59. Gene expression was normalised to GAPDH and 


























































Figure 4.59: PRKCA gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. PRKCA gene expression was analysed by RT-qPCR in SK-N-AS cells 
with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt 
results shown are an average of three replicates normalised to GAPDH and compared with the control 
non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-
test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
An overall reduction of Protein Kinase C Alpha gene expression upon Hu gene knockdowns. 
However, only HuD siRNA interference showed a significant effect of a 2.4-fold reduction in 
PRKCA gene reduction. Of the other Hu siRNA interference-induced SK-N-AS cells, an average 
1.7-fold decrease in expression of PRKCA gene was observed. 
The gene expression profile of Transforming growth factor beta 1 (TGFΒ1) (Fig 4.60) following 
Hu gene knockdowns was analysed. Gene expression was normalised to GAPDH and 

























































Figure 4.60: TGFΒ1 gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. TGFΒ1 gene expression was analysed by RT-qPCR in SK-N-AS cells 
with siRNA interference of HuB, HuC, HuD and HuR and in combination. The 2-ΔΔCt results shown are 
an average of three replicates normalised to GAPDH and compared with the control non-target siRNA. 
Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed 
by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
There was no significant change in TGFΒ1 gene expression following Hu gene knockdowns 
although a general observation showed a large decrease when all Hu genes were knocked 
down individually. If the TGFΒ1 gene expression SEM would have been more accurate the 
results may well have represented a significant change. 
DNA Topoisomerase II Alpha (TOP2A) gene expression was analysed following Hu gene 
knockdowns and is displayed in Figure 4.61. Gene expression was normalised to GAPDH and 



























































Figure 4.61: TOP2A gene expression following individual and combined Hu gene family knockdowns 
in SK-N-AS Neuroblastoma cells. TOP2A gene expression was analysed by RT-qPCR in SK-N-AS cells 
with siRNA interference of HuB, HuC, HuD and HuR and in combination. The 2-ΔΔCt results shown are 
an average of three replicates normalised to GAPDH and compared with the control non-target siRNA. 
Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed 
by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
As seen in Fig. 4.61, there was no significant change in expression of TOP2A. Variation was 
observed in the TOP2A gene expression up on HuD and HuR RNA interference but was not 
significant. HuD knockdown resulted in a decreased TOP2A expression by 1.5-fold. HuR 
interference showed an increased expression of TOP2A by 0.6-fold. 
To summarise the expression of all the gene targets discussed above, a heat map was 




Figure 4.62: Heatmap of genes with differential expression in SK-N-AS cells following Hu gene 
knockdowns individually and in combination. The relative gene expression data of multiple target in 
each Hu gene knockdown in SK-N-AS. Targets are clustered according to their similarity in the gene 
expression pattern (Up regulation; Red, Down regulation; Green, no change; Black, as shown by the 
key). The lighter the shade of colour, the greater the relative expression difference according to the 
magnitude of relative gene expression). 
 
The heatmap concludes the most similarity was observed between the gene expression 
profiles of the protein kinases MAP2K2 and MAPK3 along with APOE and PRKCA. Their 
expression profiles for each Hu knockdown in SK-N-AS was almost identical. Likewise, TOP2A 
and FN1 shared a high similarity. EGR1 showed similar homology to TGFB1. These groups of 
targets shared about 30% similarity with CTGF, KRAS and CDK1 in their expression profiles 
following Hu gene knockdowns. Importantly, GSTP1 did not show any expression homology 
reflecting the greater divergence in the relationship to the other targets. 
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This heatmap clearly displays similarities within each Hu knockdown in that HuB and HuD 
knockdown resulted in a downregulation in 7 of the 12 genes analysed. HuC and HuR 
knockdown resulted in a downregulation in 8 of the 12 genes analysed. 
4.7.3 Genes affected by Hu gene regulation in Neuroblastoma 
To summarise the roles the genes targeting by Hu RNA-binding proteins have in cancer the 
pie chart displayed Fig. 4.63 was drawn. 
 
Figure 4.63 Map of Hu gene regulation targets identified through Hu gene knockdowns. The 
individual targets of each Hu protein individually and combined. Positive regulation is represented by 




The genes are separated into categories of the well-defined cancer hallmarks; Enhanced cell 
survival through self-sufficiency in growth signals, Enhanced cell proliferation through 
insensitivity to anti-growth signals evading apoptosis to produce limitless replication 
potential, Elevation of local angiogenesis, Evasion of immune response, Tissue invasion and 
metastasis and Reprogramming of energy metabolism. 
 
 
Figure 4.64: Categorisation of the statistically significant collective regulation of the Hu RNA-protein 
family in the Neuroblastoma cell like SH-SY5Y. mRNA targets of Hu gene regulation grouped by cancer 
hallmarks; Reprogramming of energy metabolism, tissue invasion and metastasis, evasion of the 
immune resonse, elevation of local angiongensis, enhanced cell survival and enhanced proliferation.  
 
The pie chart displayed in Fig. 4.64 showed 49% of the genes collectively controlled by the Hu 
protein family are those involved in the enchanced cell survival group. 17% of the genes 
analysed were involved in the reprogramming of energy metablism, followed by 13% of the 
targets involved in enhanced cell survival. 9% of the genes were involved in tissue invasion 
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and metastasis and elevation of local angiogenesis. 4% of the gene targets were involved in 
evading the immune response.  
4.8 Summary 
There are several conclusions that can be drawn from the results present in this chapter. Gene 
expression data showed an upregulation of all neuronal Hu genes, HuB, HuC, HuD in the 
Neuroblastoma cells lines in comparison to the control astrocyte cell line. Upregulation of the 
ubiquitously expressed HuR was observed in one of the two Neuroblastoma cells SH-SY5Y. 
Secondly, regulatory influences amongst Hu proteins was proven. This level of regulatory 
influences was variable between the two Neuroblastoma cell lines SH-SY5Y and SK-N-AS. And 
finally, to identify targets that the Hu family of RNA-binding proteins control resulting in the 
development of cancer, following Hu gene individual and combined knockdowns, several 
mRNA transcripts were found to change their expression level identifying Hu’s role at a 
genetic level. This confirms Hu genes participate in the regulation of these targets which is 
discussed in more detail below. 
With an overall higher expression of the Hu family of RNA-binding proteins, SH-SY5Y 
Neuroblastoma cells showed an upregulation of all Hu genes whilst SK-N-AS showed 
upregulation of the neuronal Hu family members HuB, HuC and HuD only. Of the neuronal Hu 
members upregulated, the SH-SY5Y showed an overall higher expression in comparison to the 





 Hu Protein 
Cell type Cell line HuB HuC HuD HuR 




  B   B      B 
Neuroblastoma SK-N-AS   N   C   C   N 
SH-SY5Y   B   C   C   C 
Table 4.4: Overall expression of HuB, HuC, HuD and HuR proteins in cell lines of normal astrocytes 
and Neuroblastoma cells. Each method of analysis including RT-qPCR (PCR), western blotting (WB) 
and immunofluorescent staining (IF) is shown. Green represents a positive result. Also shown is the 
localisation of the proteins determined through immune fluorescence cytoplasm is shown by C, the 
nucleus is represented by N, whilst B refers to both the cytoplasm and the nucleus. 
 
Whilst gene expression analysis is important, equally as valuable is the translation of these 
genes into a functional protein product. Western blot analysis confirmed HuB and HuC 
proteins were expressed in all cell lines representative of normal astrocytes and 
Neuroblastoma, whilst HuD and HuR proteins were only detected in the Neuroblastoma cell 
lines.  
The normal astrocytes cell line SVG p12 had the highest levels of HuB and HuC protein 
expression when normalised to the control GAPDH and compared to the Neuroblastoma cells. 
Based on the explanation of band sizes, HuB protein was detected as a monomer and dimer 
in the normal astrocytes and only as a dimer in the Neuroblastoma cells. Similarly, HuC protein 
was detected as a monomer and multimer in the normal astrocytes and only as a multimer in 
the Neuroblastoma cells. HuD protein was absent in normal astrocyte but present in the 
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Neuroblastoma cells. HuR protein detected by western blot at a low level in normal astrocytes 
when compared to the Neuroblastoma. 
Studies of Hu protein localisation in astrocyte cells revealed HuB, HuC and HuR proteins were 
mainly localised in the nucleus of the cells with a lower presence in the cytoplasm. There was 
no detectable expression of HuD protein confirming western blot analysis.  
In the Neuroblastoma cells, HuB protein was found predominantly localised to the nucleus 
although a faint staining revealed a low expression in the cytoplasm of the SK-N-AS cell line. 
HuC and HuD proteins were localised to the cytoplasm in both Neuroblastoma cell lines whilst 
HuR protein was found in the nucleus of the SK-N-AS cells and in the cytoplasm of SH-SY5Y 
cells. 
Optimisation experiments for siRNA transfection efficiency showed DharmaFECT I most 
suitable for SH-SY5Y cells and JETprime for SK-N-AS cells. Knockdown efficiency was 
determined through RT-qPCR whilst protein knockdown was confirmed by western blotting. 
Higher efficiency was achieved when all Hu genes were knocked down together that could be 
explained by a regulatory mechanism within the Hu family. 
Knockdown of Hu genes in Neuroblastoma cell lines, established a regulatory mechanism 
within the Hu family. The observed interplay between the different Hu proteins when 
individually or together knocked down resulted in two cell line-specific models displayed in 
Fig. 4.19 and Fig. 4.23. The described findings in Section 4.7, is in alignment with the known 
molecular heterogeneity within this disease. Of the since the only significant similarity within 
the two models is that following downregulation of HuC and HuR increases. However, the 
regulation observed by each Hu family members showed the extent of regulation that is 
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feasible. Three theories were proposed to explain the traits of regulatory influences observed; 
A compensatory effect where Hu gene family members become more expressed to 
compensate for each other’s reduced expression. A regulatory mechanism in which Hu family 
members actively bind to Hu mRNA transcripts to regulate their expression during Hu reduced 
expression, a family member may also show decreased expression or become more expressed 
dependent on the effects of the Hu’s RNA stabilisation effect on the transcript. Additionally, 
the changes observed could be due to off-target effects of Hu gene downregulation on certain 
pathways.  
The assessed motility of the cell lines prior to knockdown experiments showed the two 
Neuroblastoma cell lines had a greater migrative potential than the normal astrocytes 
highlighting the Neuroblastoma cells have a more motile, invasive phenotype.  
The knockdown of Hu genes individually and in combination showed no change to 
morphology in both Neuroblastoma cell lines. Significant changes were observed to cell 
viability only in the SH-SY5Y cell line. An increase in cell viability was observed following HuB, 
HuC, HuR and combined Hu knockdown in SH-SY5Y cells.  
SH-SY5Y cells adopted a more migrative phenotype when HuB, HuC and HuR were knocked 
down individually and when Hu genes were knocked down in combination. SK-N-AS cells also 
saw an increase in migration following HuB knockdown. 
Initial gene screening studies using pre-designed PrimePCR™ plates with genes thought to 
influence disease progression in Neuroepithelial cancers. Targets were identified for further 
analysis of gene expression change following individual and combined Hu siRNA interference. 
Due to the distinct variability in gene expression change of targets between the two 
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Neuroblastoma cell lines highlighted throughout these studies, the two cells lines were 
treated as individual models to identification of novel targets.  
The influence of Hu gene regulation can be concluded as follows. Gene expression profiling 
of the 6 selected genes in SH-SY5Y Neuroblastoma cells revealed that individual and combined 
Hu gene knockdowns resulted in a reduction of BCL2 gene expression. CCND2 gene expression 
decreased following HuC and HuD individual knockdowns but increased following combined 
Hu gene knockdown. EGR1 expression decreased following HuB, HuC and HuD individual gene 
knockdowns. ESR1 expression decreased following individual HuB, HuC and HuD gene 
knockdowns and increased following combined Hu gene knockdown. The expression of 
IGFBP3 was only affected during HuR knockdown, where its expression was reduced. 
Individual knockdowns of Hu gene observed a decrease in IL10 gene expression. An increase 
in IL10 gene expression was found following combined Hu gene knockdown. The heatmap for 
this data concluded that HuC and HuD have the largest effect on the expression of these 
chosen genes. 
Of the 12 genes analysed in SK-N-AS cells, APOE and MAP2K2 gene expression reduced 
following individual and combined Hu gene knockdowns. CDK1 gene expression increased 
following HuB and HuD gene knockdowns. CTGF gene expression reduced following HuC, HuD 
and HuR gene knockdowns. EGR1 gene expression decreased following HuB, HuC and HuD 
gene knockdowns, which is consistent with the SH-SY5Y cell lines. Combined Hu knockdown 
also resulted in an EGR1 expression decrease. GSTP1 expression decreased following HuB 
knockdown but increased following HuC and HuR gene knockdowns. KRAS gene expression 
decreased after HuC and HuR gene knockdowns. MAPK3 gene expression decreased following 
all Hu individual gene knockdowns. PRKCA showed a reduced gene expression following HuD 
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gene knockdown. The overall heat map of this data revealed HuC and HuD followed closely 
by HuB as major players in the gene regulation of these targets. 
The targets from both gene models were combined to show the extent of Hu gene regulation 
in Neuroblastoma. Their categorisation in cancer hallmarks concluded majority of the targets 
are involved in enhancing cell proliferation.  
Importantly, highlighted consistently throughout these studies is the cellular and molecular 





Part III: Expression of Hu proteins in Glioblastoma 
Glioblastoma remains the most common and most malignant brain tumour, responsible for 
2.5% of all cancer-related deaths (Hanif et al. 2017). HuR overexpression in Glioblastoma was 
initially reported by Nabors et al. (2001). Later, studies showed HuR localisation in Glioma 
cells influences its role within the cells and its function in developing the cancer. It was 
reported that HuR in Glioma is often present in the cytoplasm influencing a more malignant 
phenotype and therefore a poorer prognosis (Filippova et al. 2011).  
Whilst some molecular targets of HuR in Glioblastoma have been identified e.g. MSI1 (Vo et 
al. 2012), the extent of target transcripts of the ubiquitously expressed HuR and the neuronal 
Hu proteins, HuB, HuC and HuD are yet to be determined. These studies aim to identify the 
roles of these proteins in tumour initiation or development through their influence on 
molecular pathways.  
This experiment focussed on building an expression profile of these Hu proteins in a 
Glioblastoma multiforme cell line and using a normal astrocyte cell line as a control. 
Knockdown studies of each Hu protein in the Glioblastoma multiforme cell lines were 
established to determine any specific effects on molecular pathways. The following cell lines 
were selected as suitable models to investigate Hu proteins in Glioblastoma; SVG p12 for 
normal astrocytes and U87-MG for Glioblastoma.  
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5.1 Hu gene expression in Glioblastoma and normal astrocytes 
The gene expression level of all Hu proteins in Glioblastoma U87-MG cells and normal 
astrocytes SVG p12 were determined using quantitative RT-qPCR (described in Section 2.26). 
HuB (1), HuC (1), HuD (6), HuR (2) and β-Actin primer sequences are listed in Table 2.3 of 
Section 2.27. The fold-change of expression was analysed by comparing expression levels to 
the normal astrocyte cell line SVG p12. β-Actin was used as a housekeeping gene to normalise 
Hu expression. Statistical significance was calculated by a two-tailed t-test. 
Figure 5.1: Gene expression of all the Hu protein family members Glioblastoma compared to normal 
astrocytes. HuB, HuC, HuD and HuR gene expression was analysed by RT-qPCR in Glioblastoma cells 
U87-MG and normal astrocytes SVG p12. The 2-ΔΔCt results shown are an average of three replicates 
normalised to β-Actin. Error bars display ± SEM. Statistical significance was calculated by a two-tailed 
t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The relative fold-change in the transcript levels of all Hu genes in the Glioblastoma cell line in 
comparison to the normal astrocyte cell line is displayed in Fig. 5.1. The normal astrocytes 




































expressed a low level of HuB, HuC and HuD gene, whilst HuR was expressed at higher levels. 
The data concludes all Hu genes were upregulated in the U87-MG Glioblastoma cell lines. 
A 1.85 fold-increase of HuB gene expression was observed in U87-MG cells when compared 
to the SVG p12 normal astrocyte cell line. A similar expression increase was observed for HuC 
and for HuD by a 1.79 and 1.9 fold-change respectively. HuR gene expression showed a 
smaller 0.83 fold-increase in U87-MG cells compared to SVG p12 cells. 
5.2 Hu protein expression and localisation in Glioblastoma and normal 
astrocytes 
Gene expression studies at RNA level do not necessarily reflect the abundance of the protein 
product. Therefore, Western blot analysis (described in Section 2.3) was used to determine 
the protein expression in the Glioblastoma cell line, U87-MG and normal astrocyte cells, SVG 
p12. Astrocyte cells were also used as a control for Neuroblastoma studies in Chapter 4. 
Western blot analysis confirmed the presence of HuB and HuC proteins in the SVG p12 normal 
astrocyte cell line. Low expression of HuR was also observed with a distinct absence of HuD 
expression in the normal astrocytes. 
The Hu protein family have been shown to shuttle between the nucleus and the cytoplasm 
(Doller et al. 2008b). Its subcellular location particularly in the cytoplasm has shown 
correlation with a poorer prognosis in Glioblastoma (Filippova et al. 2011). Therefore, 
immunofluorescence staining (Section 2.4.1) and fluorescent microscopy was used to 
determine the localisation of each Hu protein in Glioblastoma cells and astrocytes.  
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5.2.1 HuB protein expression 
HuB protein expression was confirmed using western blotting (Section 2.3). Protein 
extracted from Glioblastoma cells and normal astrocytes were analysed for the presence of 
HuB protein with anti-HuB IgG. Anti-GAPDH IgG was used to detect GAPDH as a control 
protein.  
 
Figure 5.2: Representative western blot analysis of HuB protein with anti-HuB antibody. HuB and 
GAPDH protein expression in normal astrocytes SVG p12, and Glioblastoma cells U87-MG. GAPDH 
protein expression was used as a loading control. (n=3). 
 
As shown in Fig. 4.2, HuB protein was detected in the normal astrocytes SVG p12 and 
Glioblastoma cells U87-MG. There is a faint band at 38kDa for each cell line and a higher 
migrating band at 76kDa which could be explained as a HuB dimer. A signal at 76kDa was also 
observed in Neuroblastoma cells (Fig. 4.2). GAPDH protein detection was used as a loading 
control and was detected at the expected size of 37kDa.  
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The signal intensity of GAPDH was comparable in both cells as well as for HuB. This differs 
from the gene expression profile displayed of HuB at RNA level (Fig. 5.1) where HuB protein 
was upregulated in the Glioblastoma cell line. 
Subcellular localisation of HuB protein was determined for the Glioblastoma and normal 
astrocyte cell lines. Anti-HuB IgG was used with secondary Alexa green 488 FITC IgG. Cells were 
counterstained with DAPI nucleus stain.  
 
Figure 5.3: Example of the cellular localisation of HuB protein in normal astrocytes SVG p12 and 
Glioblastoma cells U87-MG. The left column displays staining of nuclei with DAPI (blue), the middle 
column is stained with anti-HuB (green) and the right column displays a merged picture of DAPI and 
anti-HuB staining. Magnification x20. (n=3). 
 
As seen in Fig. 5.3, HuB expression was confirmed in both cell lines by anti-HuB 
immunofluorescent staining. This aligns with western blot analysis where HuB protein was 
also detected (Fig 5.2).  
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In normal astrocyte cells, SVG p12, HuB was expressed in both the nucleus and the cytoplasm 
which was shown by a stronger fluorescence co-localising with DAPI nucleus stain and a 
weaker signal in the surrounding cytoplasm. HuB was localised to the cytoplasm in 
Glioblastoma cells U87-MG. 
5.2.2 HuC protein expression 
HuC protein expression in U87 Glioblastoma cells and SVG p12 normal astrocytes was 
determined by western blot analysis (Section 2.3). The primary antibodies anti-HuC IgG and 
anti-GAPDH allowed for the detection of HuC and GAPDH proteins respectively and are 
displayed in Figure 5.4. 
 
Figure 5.4: Example of western blot analysis of HuC protein with anti-HuC antibody. HuC and GAPDH 
protein expression in normal astrocytes SVG p12, and Glioblastoma cells U87-MG. GAPDH protein 




HuC was identified at its expected size of 37kDa in the SVG p12 cell line whilst a second 
stronger band was also detected at 156kDa in both cell lines which could be due to 
multimerisation of HuC. This higher molecular band was also found in Neuroblastoma Hu 
protein studies (Fig. 4.4).  
GAPDH protein was detected at its expected size of 37kDa. HuC was expressed at a very high 
level in SVG p12 cells when compared to the weak GAPDH signal. HuB protein was comparable 
to the GAPDH loading control. This suggests a high HuC protein expression in SVG p12 cells in 
comparison to U87-MG cells. This differs from the gene expression data show in Fig 5.1, where 
HuC expression was higher at RNA level in U87-MG cells than in SVG p12 cells. 
Immunofluorescent HuC protein labelling (Section 2.4.1) was performed to identify its’ 
subcellular localisation. Anti-HuC IgG was used with the secondary Alexa green 488 FITC IgG. 
Cells were counterstained with DAPI nucleus stain for nuclear localisation. HuC 





Figure 5.5: Representative cellular localisation of HuC protein in normal astrocytes SVG p12 and 
Glioblastoma cells U87-MG. The left column showed staining of nuclei with DAPI (blue), the middle 
column is stained with anti-HuC (green) and the right column displays a merged picture of DAPI and 
anti-HuC staining. Magnification x20. (n=3). 
 
As seen in Fig. 5.5, HuC protein expression was observed in SVG p12 and U87-MG cell lines, 
confirming western blot data shown in Fig. 5.4. The strongest HuC protein fluorescence was 
observed in the cytoplasm of U87-MG cells. SVG p12 cells showed a strong signal for HuC 
protein in the nucleus with a weaker stain observed in the cytoplasm.  
5.2.3 HuD protein expression 
HuD protein was detected in only in U87 cells by western blot using HuD specific antibodies. 
HuD was absent in the control cell line. A comparable amount of GASPH protein used as 
loading control was observed in SVG and U87 Cells.  Fig 5.6 showed HuD protein was 




Figure 5.6: Example of western blot analysis of HuD protein with anti-HuD antibody. HuD and GAPDH 
protein expression in normal astrocytes SVG p12, and Glioblastoma cells U87-MG. GAPDH protein 
expression was used as a loading control. (n=3). 
 
This correlates with HuD expression at an RNA-level shown in Fig. 5.1 where it was higher in 
U87-MG cells compared to the normal astrocytes SVG p12. Immunofluorescence staining 
using anti-HuD antibodies confirmed an absence of HuD in the normal astrocytes and a strong 





Figure 5.7: Representative cellular localisation of HuD protein in normal astrocytes SVG p12 and 
Glioblastoma cells U87-MG. The left column showed staining of nuclei with DAPI (blue), the middle 
column is stained with anti-HuD (green) and the right column displays a merged picture of DAPI and 
anti-HuD staining. Magnification x20. (n=3). 
 
The immunofluorescence shown in Fig. 5.7 agrees with western blot data of HuD protein 
expression (Fig. 5.6) and HuD gene expression profile (Fig. 5.1) in the U87-MG cell line. HuD 
expression is confirmed in the cytoplasm only of the Glioblastoma cells. 
5.2.4 HuR protein expression 
HuR protein expression level and its cellular localisation was analysed in Glioblastoma U87-
MG cells and normal astrocytes SVG p12. The primary antibodies anti-HuR IgG and loading 




Figure 5.8: Example of a western blot analysis of HuR with anti-HuR antibody. HuR and GAPDH 
protein expression in U87-MG Glioblastoma cells and normal astrocytes SVG p12. GAPDH protein 
expression was used as a loading control. (n=3). 
 
HuR protein was only detected in U87-MG cells at the expected size of 36kDa. GAPDH was 
detected at 37kDa in both cell lines. These results differ from the gene expression profile (Fig. 
5.1), that showed HuR to be expressed in both cell lines. This suggests that the HuR gene to 
protein translation is low in the U87-MG Glioblastoma cells and could be explained by post-
transcriptional modifications and post-translational regulatory events.  
To identify HuR protein’s subcellular location in these cells, immunofluorescence staining was 
performed (Section 2.4.1) (Fig. 5.9). Anti-HuR IgG was used with secondary Alexa 488 FITC IgG. 




Figure 5.9: Representative cellular localisation of HuR protein in Glioblastoma U87-MG and normal 
astrocytes SVG p12. The left column showed staining of nuclei with DAPI (blue), the middle column 
with anti-HuR (green) and the right column displays a merged picture of DAPI and anti-HuR. 
Magnification x20. (n=3). 
 
HuR protein expression was detected in normal astrocytes and Glioblastoma cells. The 
strongest staining in SVG p12 astrocyte cells co-localised with the DAPI stain and therefore 
showed HuR protein was predominantly in the nucleus with some weaker expression 
observed in the cytoplasm. HuR protein was also located in both the nucleus and cytoplasm 
in Glioblastoma cells U87-MG with the strongest staining observed in the nucleus of these 
cells.  
HuR was not detected during western blot analysis however its presence during 
immunofluorescence studies confirms its protein expression. Therefore, it can be assumed 




5.3 Establishing Hu gene and protein knockdowns using siRNA 
interference in Glioblastoma cells 
To determine the cellular and molecular role of the Hu family overexpression in Glioblastoma 
and its influence in the initiation and development of cancer, Hu gene knockdowns were 
established in the U87-MG cell line. U87-MG cells were tested for the most efficient 
transfection reagent, concentration of siRNA and time periods. Samples were collected and 
analysed. 2-Δ ΔCT values were calculated normalised to β-Actin. 
For each Hu gene in the U87-MG Glioblastoma cell line, a knockdown was established 
individually and in combination to knockdown the whole Hu family. Commercially available 
siRNAs were purchased to interfere with the genes HuB, HuC, HuD, HuR, GAPDH and a non-
targeting siRNA. Each siRNA contained a pool of four interfering sequences (Table 2.4). In this 
specific cell-line, siRNAs were introduced with DharmaFECT I transfection reagent over 48 
hours, for which the protocol is provided in Section 2.7.3. 
RT-qPCR was performed to confirm Hu gene knockdowns. The cycling and reactions of RT-
qPCR are described in Section 2.26. HuB (1), HuC (1), HuD (6), HuR (2) and β-Actin primer 
sequences are listed in Table 2.3 of Section 2.27. The fold-change of expression was analysed 
by comparing expression levels to the control non-targeting siRNA (Fig. 5.10). β-Actin was the 
housekeeping gene to which the data was normalised. Statistical significance was calculated 





































































































































Figure 5.10: Knockdown efficiency of Hu genes after individual Hu siRNA interference in the 
Glioblastoma cell line U87-MG. HuB (A), HuC (B), HuD (C) and HuR (D) gene expression following Hu 
gene knockdowns was analysed by RT-qPCR in the Glioblastoma cell line, U87-MG. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin gene expression and compared with 
the control set at 1.00. Error bars display ± SEM. Statistical significance was calculated by a two-tailed 
t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
As seen in Fig. 5.10, in the Glioblastoma cell line, U87-MG, the knockdown efficiency was 2.4-
fold for HuB, 1.5-fold for HuC, 1.7-fold for HuD and 4.3-fold for HuR. Whilst not as successful 
as Neuroblastoma studies, HuC and HuR knockdown were still statistically significant based 
on a two-tailed T-test. 
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Regulatory influences between the Hu protein family has previously been documented in 
research and observed in the previous chapter of this thesis. A combined Hu gene family 



















































































Figure 5.11: Combined siRNA interference of all Hu genes in the Glioblastoma cell line U87-MG. HuB, 
HuC, HuD and HuR gene expression following a full knockdown of each Hu gene in a single attempt in 
the U87-MG Glioblastoma cells. Samples were analysed by RT-qPCR. The 2-ΔΔCt results shown are an 
average of three replicates normalised to β-Actin gene expression and compared with the control set 
at 1.00. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and is 
displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
A combined knockdown of all four HuB, HuC, HuD and HuR genes was mostly successful. HuC, 
HuD and HuR knockdown increased overall. Unfortunately, HuB still proved challenging to 
knockdown in this cell line. The combined Hu family gene knockdown resulted in a decrease 
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of expression of 1.5-fold for HuB, 8-fold for HuC, 2.8-fold for HuD and 5.2-fold for HuR, of 
which the latter three were statistically significant as determined by a two-tailed t-test. 
To confirm the Hu genes knockdowns’ and the impact at protein-level, protein expression 
levels were analysed by western blot analysis 96-hour post-transfection (Section 2.3).  
Each Hu gene knockdown both individually and in combination in Glioblastoma cells U87-MG 
was blotted and analysed for Hu protein. The primary antibodies anti-HuB, anti-HuC, anti-HuD, 
anti-HuR and anti-GAPDH were used. GAPDH was used as a control protein to normalise 






Figure 5.12: Hu protein expression during single and combined Hu knockdowns in U87-MG 
Glioblastoma cells. A) HuB protein reduction following single HuB and combined Hu family siRNA 
interference. B) HuC protein reduction following single HuC and combined Hu family siRNA 
interference. C) HuD protein partial reduction expression following single HuD and combined Hu 
family siRNA interference. D) HuR protein reduction following single HuR and combined Hu family 
siRNA interference. GAPDH protein expression was used as a loading control. 
 
Western blot analysis shown in Fig. 5.12A displays the HuB protein was detected at 75 kDa, 
which is double of the expected size of 37kDa. This was earlier identified in Fig. 5.2. Due to 
the size of this band, it is most likely dimerisation of HuB. The HuB knockdown showed little 
reduction in HuB protein expressed. Following knockdown of all Hu family members in 
combination, HuB protein was absent. This trend was also observed for HuC (Fig. 5.12B) and 
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HuD (Fig. 5.12C) knockdowns. HuC protein was detected at 156kDa. This was previously 
documented in Fig 5.4 and was suspected to be HuC multimer. HuD was detected at its 
expected size of 42kDa. Shown in Fig. 5.12D, no HuR protein could be detected after the HuR 
siRNA knockdown.  
The described difference in Hu individual and combined Hu gene knockdowns could be due 
to complex interplay between the Hu family members as previously shown in Neuroblastoma 
studies (Section 4.4). Observations concluded Hu gene family members can influence 
expression or translational efficiency by targeting their own or family members mRNA 
transcripts and regulating their expression. The next section (5.4) aims to study these 
regulatory influences. 
5.4 Differential gene expression of Hu proteins following individual 
and combined Hu gene knockdowns in Glioblastoma 
Due to differences in the gene expressions of single and combined knockdowns and the 
known ability of HuR to regulate its own expression, a gene expression profile was established 
to explore the possibility of a regulatory mechanism within the Hu family of RNA-binding 
proteins in Glioblastoma. The level of all individual Hu genes expression when individual Hu 
siRNA interference was performed was analysed and compared to the non-targeting control 
siRNA transfection. 
RT-qPCR was performed to confirm Hu gene knockdowns and to determine any changes to 
the expression levels of other Hu genes. The cycling and reactions of RT-qPCR are described 
in Section 2.26. HuB (1), HuC (1), HuD (6), HuR (2) and β-Actin primer sequences are listed in 
Table 2.3 of Section 2.27. β-Actin was the housekeeping gene to which the data was 
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normalised and compared to the non-target control. Statistical significance was calculated by 






































































































































Figure 5.13: Influence of individual Hu gene knockdowns on other Hu gene family members 
expression levels in U87-MG, Glioblastoma cells. A) HuB Knockdown B) HuC Knockdown C) HuD 
Knockdown D) HuR Knockdown. The 2-2-ΔΔCt results shown are an average of three replicates 
normalised to β-Actin gene expression and compared with the non-target control. Error bars display 
± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001. (n=3). 
Here the initial Hu gene knockdown levels are those described previously in Fig. 5.10. 
Displayed in Fig. 5.13A, a 2.4-fold knockdown of HuB gene expression, resulted in a significant 
3.9-fold reduction of HuC gene. No significant change was observed for HuD or HuR 
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expression.  HuC siRNA interference is shown in Fig. 5.13B, a 1.5-fold knockdown of HuC 
showed a significant 0.3-fold increase in HuR expression. A 1.7-fold HuD siRNA knockdown 
(Fig 5.13C) did not significantly change the expression of the other genes. HuR siRNA 
knockdown (Fig. 5.13D) of 4.3-fold resulted in a significant decrease in HuC gene expression 
by 3.8-fold and HuD gene expression by 4.0-fold. 
To better visualise the key expression changes after each Hu knockdown, the data from above 
displayed in Fig. 5.10, Fig. 5.11 and Fig. 5.13 is summarised in Fig. 5.14. The data is normalised 
to the same non-target controls of the siRNA interference transfection.  











































Figure 5.14: Complete profile of Hu gene expression in Glioblastoma cell line U87-MG, after 
knockdown of each individual Hu protein individually and combined. HuB, HuC, HuD and HuR 
expression following knockdown of each Hu gene both individually and in combination was analysed 
by RT-qPCR in U87-MG cells. The 2-ΔΔCt results shown are an average of three replicates normalised to 
β-Actin gene expression and compared with the non-targeting control. Error bars display ± SEM. 
Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. (n=3). 
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The effect of the combined knockdown on individual Hu expression is displayed in Fig. 5.14. 
HuB gene knockdown results in a HuC and HuD gene expression decrease, whilst there was 
little change to HuR. Upon HuC siRNA interference, HuD expression also decreased. However, 
HuB and HuR gene expression increased.  
Following HuD siRNA interference, a decrease in HuR expression was observed along with 
increased HuC expression and no change in HuB expression. Upon HuR siRNA knockdown, 
there was a decrease in all other Hu genes. Fig. 5.14 also shows the knockdown all Hu gene in 
a single combined attempt. Since similarities are observed between HuR knockdown and 
combined Hu family knockdown, this could suggest HuR is the major player in the Hu family 
combined knockdown. 
The overall knockdown profile is summarised as percentages in a heatmap and is displayed in 
Fig. 5.15. 
 
Figure 5.15: Heatmap summarising Hu gene expression change after single and combined 
knockdown experiments in U87-MG Glioblastoma cells. Colour intensity proportional to the 
percentage change. Statistical significance was calculated by a two-tailed t-test and is displayed by *P 
≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
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In summary, a similar Hu gene expression profile is observed when all Hu genes are knocked 
down in combination and following individual HuR gene knockdown.  
The differential expression changes in different Hu family members was previously described 
in Chapter 4 of the Neuroblastoma studies. In short, three possible explanations were 
described based around compensatory action, regulatory effects or consequences of off-
target effects.  
To conclude the differential expression, change within the Hu RNA-binding protein family, a 
model was drawn summarising how the regulation occurs and is shown in Figure 5.16. 
 
Figure 5.16: A model representing the regulation of the Hu protein family in the Glioblastoma cell -
line U87-MG. Colour intensity proportional to the change in regulation.  
 
The model summarises only statistically significant data determined by a two-tailed t-test. 
The model showed that following HuR knockdown, HuD and HuC gene expression also 
decreased as did HuC expression when HuB was knocked down. Following HuC knockdown, 
HuR gene expression increased.  
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Based on the three potential explanations that are described above for compensatory 
expression or regulatory influences within the Hu family, there are several conclusions that 
can be drawn in the U87-MG Glioblastoma cell model. 
5.5 Cellular morphology of normal astrocytes and Glioblastoma cells 
The morphology in which cells grow in the human body influences their function. In cancer, 
cells adopt a more invasive phenotype in which the cells are more robust and gain function. 
Glioblastoma are typically hard to treat due to the nature of their growth. These tumours are 
not considered a defined mass with clear borders, instead considered as diffuse 
Glioblastomas, they have finger-like projections called tendrils that extend into other parts of 
the brain (Armento 2017). 
5.5.1 Cellular morphological analysis 
Microscopic analysis of Glioblastoma and normal astrocytes is shown in Fig. 5.17. Cell images 
were obtained using an Eclipse II fluorescent inverted microscope and Microtec camera as 





Figure 5.17: Microscopy images of the normal astrocytes and Neuroblastoma cell lines. Inverted light 
microscopy at x20 objective. A) Normal astrocytes cell line, SVG p12. B) Glioblastoma cell line, U87-
MG.  
 
Astrocytes form the supportive tissue of the brain. The normal astrocytes cell line SVG p12 
was established from a foetus during the first trimester. These typically grow in star-shaped 
cells called fibroblasts. In culture, U87-MG Glioblastoma Multiforme cells grow with the same 
characteristic star-shape as SVG p12 astrocytes. 
5.5.2 Cellular migrative potential 
Cancer cells are known for their ability to migrate from the localised tumour and establish a 
secondary tumour also called a metastasises. A good measure of both cellular migration and 
invasion, which replicates the ability of a cancer cell to metastasise. Astrocyte and 
Glioblastoma cell migration was calculated by the ability of the cells to invade into a 0.5% 
agarose gel matrix. It was captured through several microscopy imaging equipment. The 
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images below were achieve using time-lapse photography captured by the CytoSMART™ 
camera as described in Sections 2.5 and 2.5.1. 
First, the ability of the normal astrocytes to migrate into the gel was assessed and is shown in 
Fig. 5.18. 
 
Figure 5.18: The migration of SVG p12, normal astrocyte cells into an agarose gel matrix. During the 
observed 42-hour period, no migration into the gel matrix was detected. (n=3). Time-lapse 







As previously observed in Section 4.5.2, the normal astrocytes, SVG p12 did not migrate into 
the agarose gel during the observed 42 hours and instead proliferated and grew in a line 
surrounding the agarose. This was expected for a non-cancer cell line.  
The Glioblastoma U87-MG cells were then observed for their ability to migrate into an 
agarose gel matrix. The cells were seeded into a well and a period of 24 hours preceded to 
allow the cells to adhere for the migration was captured. Images were taken every 15 
minutes for 42 hours. 
 
Figure 5.19: The migration of U87-MG Glioblastoma cells into an agarose gel matrix. Over the 
observed 42-hour period, cells migrated into the gel matrix. (n=3). Time-lapse photography of the cell 






The migration of U87-MG cells into the agarose gel matrix is shown in Fig. 5.19. U87-Mg cells 
started to migrate into the gel matrix at around 6-hours. A key hallmark of cancer is the ability 
of cells to invade and metastasis and this was portrayed by the U87-MG Glioblastoma cells 
penetrating the agarose gel matrix and proliferating. 
The invasiveness of the Glioblastoma cell line U87-MG and the normal astrocyte cells SVG p12 
was compared and is shown in Fig. 5.20. 





















Figure 5.20: The migration of U87-MG Glioblastoma cells compared to the non-migration of SVG p12 
astrocytes. Migration into the gel matrix was calculated by the percentage surface area invaded by 
the cells. 
 
The U87-MG cells achieved a 47.82% invasion into the gel matrix over the 42-hour period 
observed through time-lapse photography. This finding highlights the greater migrative 
potential that Glioblastoma cells have compared to normal astrocytes. 
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5.6 Cellular morphology, viability and migration following Hu protein 
knockdown in Glioblastoma 
As previously discussed in Section 4.6, cancer cells can contain many genomic mutations that 
contribute to changes in cellular phenotype that may manifest through cell proliferation, 
motility and morphology (Baba and Câtoi 2007). 
To assess the effect of Hu gene expression on these features in Glioblastoma, cell morphology 
was analysed 48 hours following individual and combined Hu gene knockdowns. Cells were 
imaged to assess any changes to cell morphology through size and shape following Hu gene 
knockdowns. Images were obtained using an Eclipse II fluorescent inverted microscope and 
Microtec camera as described in Section 2.1.6. 
As shown in Fig. 5.21, the morphology of U87-MG was not influenced by the individual or 





Figure 5.21: U87-MG cell morphology 48-hours post-transfection with Hu siRNAs. U87-MG cells with 
Hu genes knocked down in combination and individually. Light microscopy at 20x objective. 
 
Some cells had died, these were removed when the media was replaced prior to imaging. It 
is also important to mention; these images do not confer the confluency of the cell lines 
following Hu knockdowns. Other methods to evaluate cell viability are described next in this 
section.  
Cell viability of U87-MG cells with individual and combined Hu gene knockdowns was 
determined by CellTiter 96® AQueous One Solution assay (Section 2.6). 48-hours post-
transfection absorbance was recorded at 24-hour intervals over 120-hours. The absorbance 
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was then converted to a percentage and compared to the control non-targeting siRNA (Fig. 
5.22). 
 
Figure 5.22: Cell viability of U87-MG cells after knockdown experiments. Mean cell viability 
normalised to the control non-target siRNA treated cells. A) Effect of HuB knockdown. B) Effect of HuC 
knockdown. C) Effect of HuD knockdown. D) Effect of HuR knockdown. E) Effect of combined Hu 
knockdown. MTS absorbance was recorded at 490nm over a 144-hour period. Data are expressed as 
mean values ± SD. n=3. Statistical significance was calculated by a two-tailed t-test and is displayed by 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 






























































































































Whilst defining the role of the Hu-family of RNA binding proteins, we observed that reduced 
expression of HuB and HuC resulted in an initial lower rate of cell viability compared to the 
control, however a conclusive increase at the 120-hour time point. At the 120-hour time 
point, U87-MG cells treated with HuB siRNA showed a reduction in cell viability in comparison 
to the control whilst HuC siRNA-treated cells showed an increase. 
 The knockdown of HuD, HuR and all Hu gene in combination, resulted in a decrease in cell 
overall viability in comparison to the non-target siRNA control. At 120 hours HuD knockdown 
resulted in a 5.38% decrease in cell viability compared to the control. Whilst HuR knockdown 
decreased cell viability by 9.11% and all Hu combined knockdown showed 6.70% decrease in 
cell viability. 
Cell motility was measured before and after individual and combination Hu gene knockdowns 
with a scratch wound assay (Section 2.5.2). Migration images are shown in Fig. 5.23, Fig. 5.24 
and Fig. 5.25. This assay measures the ability and speed of the cells to migrate into an 
artificially created cell-free gap until new cell-cell contacts are established. Cells were imaged 





Figure 5.23: Scratch wound assays in control U87-MG Glioblastoma cells following interference with 
a non-targeting siRNA. Mobility was assessed 24 hours post-transfection when cells were confluent 
for 72 hours. Wounds were generated using a needle after cell confluence following siRNA 
interference. Timepoints state the number of hours post-wound making. Yellow lines highlight the 
gap. Magnification x10. (n=3). 
 
The initial gap made by inducing a wound in the cell monolayer can be seen shrinking over 




Figure 5.24: Scratch wound assays in U87-MG Glioblastoma cells following knockdown of Hu genes individually. Mobility was assessed 24 hours post-
transfection when cells were confluent for 72 hours. A) HuB knockdown B) HuC knockdown C) HuD knockdown D) HuR knockdown. Timepoints state the 
number of hours post-wound making. Yellow lines highlight the gap. Magnification x10. (n=3).
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The scratch wound assays following individual Hu gene knockdowns are displayed in Figure 
5.24. An overall decrease in the wound can be seen over the timepoints. U87-MG cells with 
HuD knockdown detached from the flask following 24-hours so no images were taken at the 
48-hour timepoint. 
Next the effect of a combined Hu gene knockdown was determined and is displayed in Figure 
5.25. 
 
Figure 5.25: Scratch wound assays in U87-MG Glioblastoma cells following knockdown of Hu genes 
in combination. Mobility was assessed 24 hours post-transfection when cells were confluent for 72 
hours. Wounds were generated after cell confluence following siRNA interference. Timepoints state 
the number of hours post-wound making. Yellow lines highlight the gap. Magnification x10. (n=3). 
 
Percentage migration into the cell-free gap was calculated for the 24 hour timepoint using 
ImageJ pixel analysis. Two-tailed T-test determined the statistical significance. This data is 
show in Fig. 5.26  
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Figure 5.26: Cell migration of Glioblastoma cells U87-MG represented as the percentage of 
migration into the cell-free gap over 24 hours. The measure of cell motility was calculated in ImageJ 
through the measurement of pixels and conversion into a percentage to determine the rate of cell 
migration. Data showed the mean migration of cells into the cell-free gap over 24 hours. Error bars 
display ± SEM. Statistical significance was calculated by a two-tailed t-test and is displayed by *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The cell migration data in Fig. 5.25 displays that following HuB, HuC and combined Hu gene 
knockdowns, there was a significant increase in the cell migration in comparison to the non-
target siRNA control. HuB knockdown resulted in a 33.58% increase, HuC knockdown showed 
a 22.76% increase whilst all Hu gene knocked down in combination resulted in a 28.30% 
increase in migrative potential. 
A summary of changes to the cellular properties observed following Hu gene knockdowns in 




Figure 5.27: Changes in cellular properties following Individual and combined Hu gene family 
knockdown in the Glioblastoma cell line U87-MG.  
 
No visible change in morphology was observed following any of the Hu gene knockdowns. 
HuB and HuC knockdowns both caused an increase in cell viability and migrative potential. All 
Hu knockdown also increased the U87-MG cells migrative potential. 
5.7 Effect of Hu knockdown on gene regulation on translational 
networks in Glioblastoma 
To identify gene networks the Hu RBPs are impacting in the development and progression of 
cancers, many genes known to influence Glioblastoma were analysed following knockdown 
of the Hu proteins. Ultimately, this will allow a better understanding of how Hu genes are 
functioning in the cancer and how they target translational pathways when they are 
aberrantly or overexpressed in Glioblastoma. Pre-designed PrimePCR™ assays with an array 
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of 91 primer sets in addition to controls targeting genes known to influence Glioblastoma 
were screened. This was to determine how Hu impacted networks and may influence 
fundamental cell processes.  
U87-MG Glioblastoma cells were treated with siRNA and transfection reagents over a 48 
hours period. RNA was then extracted, and reverse transcribed to cDNA. The knockdown was 
confirmed by real-time PCR before the samples were then run on PrimePCR™ assays. The pre-
designed plate was run on RT-qPCR and analysed by the PrimePCR™ data analysis software 
provided by Bio-Rad.  
 
Table 5.1: Gene targets by the Glioma T1 PrimePCR™ Assay.  
 
Gene analysis of U87-MG Glioblastoma cells revealed many differential gene expression 
changes of other targets. To reduce the number of targets for further analysis, a threshold of 
2.0 fold-cycle difference in gene expression was selected.  
AKT1 CD44 CXCR4 HRAS MAPK3 PCNA SERPINE1 TNF TBP
APOE CDK1 E2F1 IFNG MDM2 PIK3CA SOD2 TOP2A GAPDH
ATM CDK2 EGFR IGF1 MKI67 PIK3R1 SP1 TYMS HPRT1
AURKA CDKN1A ERBB2 IGFBP3 MLH1 PLAUR SPP1 UBB
BCL2 CDKN2A ESR1 IL10 MMP1 PRKCA STAT3 UBC
BIRC5 COL1A1 EZH2 IL6 MMP2 PROM1 TCF7L2 VCAM1
BRCA1 COL1A2 FN1 ITGB1 MMP7 PTEN TERT VEGFA
CCNA2 CTBP2 GSK3B KDR MMP9 RAF1 TGFB1 VIM
CCNB1 CTGF GSTP1 KRAS MYC RB1 TIMP1 WNT5A
CCNB2 CTNNB1 HIF1A MAP2K2 NFKB2 RBM47 TIMP3 XPO5
CCND1 CXCL12 HMOX1 MAPK1 NOTCH1 RRM2 TLR2 ZWINT
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Of the 91 genes analysed shown in Table 5.1, there were 21 gene that conformed to this 
criterion and therefore had a differential gene expression consisting of either amplified, 
overexpressed, deleted or under expressed. These are shown in Table 5.2. 
 
siRNA Interference Target 
HuB HuC HuD HuR Combined Hu 
HMOX1 HMOX1 HMOX1 HMOX1 HMOX1 
MMP9     MMP9 MMP9 
NOTCH1 NOTCH1     NOTCH1 
VCAM1 VCAM1   VCAM1 VCAM1 
COL1A1     COL1A1   
 MMP1  MMP1 MMP1 
   IGFBP3 IGFBP3 
APOE ITGB1 IGF1 FN1 PCNA 
ERBB2 RAF1       
IL10 STAT3       
TERT MLH1       
  PCNA       
  RB1       
  TCF7L2       
  TLR2       
Table 5.2: Identification of targets for further gene analysis influenced by Hu gene knockdowns in 
Neuroblastoma cells U87-MG. List of the 21 genes conforming to the criteria of a fold-change of at 
least 2. Highlighted genes are those consistent with two or more of the knockdown samples. 
 
To limit the number of genes analysed in further studies and to identify the most important, 
genes whose expression was affected by two or more Hu gene knockdowns were selected. 
These are highlighted blue in Table 5.2. This lowered the gene selection to seven genes for 
the Glioblastoma cell line, U87-MG. A PrimePCR™ assay was designed to specifically target 
these genes to confirm their gene expression changes.  
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The relative fold-change in the transcript levels of alpha-1 type I collagen (COL1A1) following 
knockdown of each Hu gene individually and in combination in the Glioblastoma cell lines 























































Figure 5.28: COL1A1 gene expression following individual and combined Hu gene family 
knockdowns in U87-MG Glioblastoma cells. COL1A1 gene expression was analysed by RT-qPCR in 
U87-MG cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to β-Actin and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-
tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The gene expression profile of COL1A1 displays no statistical significance due to variation in 
the control. Although there was an overall general trend of decreased expression of COL1A1 
was observed when the Hu gene family were knocked down individually. A 1.3-fold decrease 
in expression was observed following HuB knockdown, a 1.6-fold decrease following HuC 
knockdown, a 2.4-fold decrease following HuD knockdown and a 3.5-fold decrease following 
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HuR knockdown. Little variation was seen when all Hu genes were knocked down in 
combination. 
Next, the expression level of Heme Oxygenase 1 (HMOX1) was analysed for any alterations 


























































Figure 5.29: HMOX1 gene expression following individual and combined Hu gene family 
knockdowns in U87-MG Glioblastoma cells. HMOX1 gene expression was analysed by RT-qPCR in 
U87-MG cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to β-Actin and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-
tailed t-test and is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
The HMOX1 gene expression profile displshowed an overall increased in HMOX1 gene 
expression following Hu gene knockdowns. HMOX1 gene expression increased by 1.4-fold 
following HuB knockdown, a 2.6-fold increase was observed following HuC knockdown, a 3.1-
fold increase was observed following HuD knockdown and a 1.9-fold increase was observed 
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following HuR knockdown. Combined Hu gene knockdown resulted in a 2.5-fold increase in 
HMOX1 gene expression. All upregulations observed were statistically significant following 
analysis by a two-tailed t-test. 
Insulin-like growth factor-binding protein 3 (IGFBP3) gene expression was determined 
























































Figure 5.30: IGFBP3 gene expression following individual and combined Hu gene family knockdowns 
in U87-MG Glioblastoma cells. IGFBP3 gene expression was analysed by RT-qPCR in U87-MG cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 
is displayed by *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (n=3). 
 
Insulin-like growth factor-binding protein 3 (IGFBP3) gene expression showed an overall 
increase following Hu gene knockdowns. IGFBP3 gene expression increased by 1.1-fold 
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following HuB knockdown, 0.6-fold following HuC knockdown, 0.6-fold following HuD 
knockdown and 2.6-fold following HuR knockdown. Combined Hu gene knockdown resulted 
in an increase of 1.9-fold in IGFBP3 gene expression. All expression changes were statistically 
significant. 
Matrix metallopeptidase 1 (MMP1) gene expression following Hu gene individual and 






















































Figure 5.31: MMP1 gene expression following individual and combined Hu gene family knockdowns 
in U87-MG Glioblastoma cells. MMP1 gene expression was analysed by RT-qPCR in U87-MG cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 




Following all Hu gene knockdowns both individually and in combination, MMP1 expression 
increased. Following HuB knockdown, MMP1 expression increased by 0.7-fold, 0.9-fold 
following HuC knockdown, 1.1-fold following HuD knockdown and 1.6-fold  following HuR 
knockdown, of which the latter three are significant. Combined Hu gene knockdowns saw an 
increase in MMP1 gene expression by 1.1-fold that was also significant.  
A further member of the Matrix metallopeptidases was analysed Matrix metallopeptidase 9 























































Figure 5.32: MMP9 gene expression following individual and combined Hu gene family knockdowns 
in U87-MG Glioblastoma cells. MMP9 gene expression was analysed by RT-qPCR in U87-MG cells with 
siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt results 
shown are an average of three replicates normalised to β-Actin and compared with the control non-
target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-test and 




The gene expression profile of MMP9 displays no statistical significance due to variation 
within samples. No obvious trend is observed, however a 1.3-fold increase in MMP9 gene 
expression was observed following HuD gene knockdown and a 2.4-fold decrease following 
HuR knockdown. 
The expression profile of Notch homolog 1 (NOTCH1) was analysed following Hu gene 























































Figure 5.33: NOTCH1 gene expression following individual and combined Hu gene family 
knockdowns in U87-MG Glioblastoma cells. NOTCH1 gene expression was analysed by RT-qPCR in 
U87-MG cells with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. 
The 2-ΔΔCt results shown are an average of three replicates normalised to β-Actin and compared with 
the control non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-




NOTCH1 gene expression showed little change following HuC, HuD and HuR gene 
knockdowns. However, upon HuB knockdown, an increase of 2.2-fold was observed and a 1.0-
fold increase following combined Hu gene knockdowns of which both were statistically 
significant. 
The vascular cell adhesion molecule 1 (VCAM1) gene expression profile was established 




















































Figure 5.34: VCAM1 gene expression following individual and combined Hu gene family knockdowns 
in U87-MG Glioblastoma cells. VCAM1 gene expression was analysed by RT-qPCR in U87-MG cells 
with siRNA interference of HuB, HuC, HuD and HuR both individually and in combination. The 2-ΔΔCt 
results shown are an average of three replicates normalised to β-Actin and compared with the control 
non-target siRNA. Error bars display ± SEM. Statistical significance was calculated by a two-tailed t-




The VCAM1 gene expression profile showed no statistical significance. There were very little 
differences observed in the gene expression. The most distinct changes observed, was an 
upregulation of VCAM1 gene expression following HuD knockdown which can be discredited 
due to its large SEM. The second largest difference is the 1.6-fold decrease in VCAM1 
expression following HuR gene knockdown. 
To summarise the expression of all the gene targets discussed above, a heat map was 
developed in Microsoft Excel using analysis from Biorad PrimePCR Analysis (Fig 5.35). 
 
 
Figure 5.35: Heatmap of genes with differential expression in U87-MG cells following Hu gene 
knockdowns individually and in combination. The relative gene expression data of multiple targets 
in each Hu gene knockdown in U87-MG. Targets are clustered according to their similarity in the 
gene expression pattern. (Up regulation; Red, Down regulation; Green, no change; Black. The lighter 
the shade of colour, the greater the relative expression difference according to the magnitude of 




The heat map displayed Fig. 5.35, concludes that the most similar expression profiles were 
that of MMP1, HMOX1 and IGFBP3. VCAM1 and COL1A1 displayed no similarity to the other 
genes. MMP9 and NOTCH shared small similarities within their expression profiles. 
The heatmap also highlighted trends between the Hu knockdowns. Following combined Hu 
gene knockdowns, 4 of the 7 genes were upregulated including NOTCH1, MMP1, IGFBP3 and 
HMOX1. HuB knockdown showed 5 of the 7 genes were downregulated which included 
NOTCH1, MMP9, MMP1, HMOX1 and IGFBP3.  
The array of genes affected by Hu RNA-binding proteins in Neuroblastoma are summarised 






Figure 5.36 Map of Hu gene regulation targets identified through Hu gene knockdowns in U87-MG 
cells. The individual targets of each Hu protein individually and combined. Negative regulation is 
shown by a red arrow. 
 
All the statistically significant regulation of genes following Hu gene individual and combined 
knockdowns are displayed in Fig. 5.36. Interestingly, all the genes were upregulated following 
the Hu gene knockdowns, showing that Hu genes play a role in negatively regulating their 
expression in that upon a downregulation of Hu gene expression, the regulatory control is 
lost, and their gene targets expression increases.  





The investigations into the Hu RNA-binding protein family and its role in Glioblastoma is 
shown in this chapter. The expression of each Hu gene and protein is summarised in Table 
5.4. 
 Hu Protein 
Cell type Cell line HuB HuC HuD HuR 




  B   B      B 
Glioblastoma U87-MG   C   C   C   N 
Table 5.3: Overall expression of HuB, HuC, HuD and HuR proteins in cell lines of normal astrocytes 
and Glioblastoma cells. Each method of analysis including RT-qPCR (PCR), western blotting (WB) and 
immunofluorescent staining (IF) is shown. Green represents a positive result. Also shown is the 
localisation of the proteins determined through immune fluorescence cytoplasm is shown by C, the 
nucleus is represented by N, whilst B refers to both the cytoplasm and the nucleus. 
 
Gene expression data showed an upregulation of HuB, HuC, HuD and HuR gene expression in 
the U87-MG Glioblastoma cell line when compared to the normal astrocytes SVG p12. 
Western blot analysis confirmed all Hu proteins were also present in the Glioblastoma cell 
line. HuD and HuR proteins were absent in the normal astrocytes. However, HuR protein was 
later confirmed present through immunofluorescent staining. 
Hu localisation studies revealed HuB, HuC and HuR proteins were localised to the nucleus with 
fainter expression present in the cytoplasm whilst HuD protein was confirmed absent. In U87-
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MG Glioblastoma cells, the neuronal Hu proteins were present in the cytoplasm whilst HuR 
protein was predominantly localised in the nucleus with weaker expression in the cytoplasm. 
A knockdown of each Hu gene individually and in combination was established in the 
Glioblastoma U87-MG cells (Fig. 5.10). Knockdown efficiency was determined through RT-
qPCR. Protein knockdowns were confirmed by western blotting (Fig. 5.12). As previously 
shown, HuB protein was detected at twice its expected size and HuC protein was detected at 
four times its expected size. HuB, HuC and HuD protein expression decreased following 
individual knockdowns and was completely absent in the combined knockdown for HuB and 
HuC proteins. HuD’s protein expression decreased following combined Hu gene knockdowns 
but was not as large as the other Hu proteins. HuR was knocked down at a protein level 
following individual and combined Hu gene knockdowns.  
A higher knockdown efficiency was observed when all Hu genes were knocked down in 
combination compared to individual knockdowns except for HuB observed in Fig. 5.10 and 
Fig. 5.11. Since this was observed, gene studies were performed to identify any changes to 
Hu gene family members upon individual Hu gene knockdowns.  
From these findings, it became apparent there was a level of regulatory control occurring 
within the Hu gene family that lead to the production of the model displayed in Fig. 5.16. 
From this model, it can be concluded that upon HuC knockdown, HuR gene expression 
increased showing HuC protein negatively regulates HuR gene expression. HuB knockdown 
resulted in a downregulation of HuC gene as did HuR knockdown on HuD and HuC gene 
expression. This indicates HuB positively regulates HuC gene expression and HuR positively 
regulates HuC and HuD gene expression. Three proposed theories are discussed for these 
regulatory influences and are discussed in Section 5.4. 
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Initial studies of the naïve cells migrative potential, U87-MG cells were able migrate into an 
agarose cell matrix whereas SVG p12 cells weren’t showing Glioblastoma cells have a more 
migrative phenotype than normal astrocytes. 
Following knockdown studies, no change in cellular morphology was observed, however 
changes in viability and migration potential were observed. Over 120 hours, HuB and HuC 
knockdown in U87-MG cells caused a significant increase in cell viability when compared to 
the control. The cells migrative potential increased following HuB, HuC and combined Hu gene 
knockdowns. 
To identify genes that the Hu-RNA binding protein family target, a pre-designed PrimePCR™ 
arrays containing genes thought to be involved in Gliomas determined through the National 
Library of Medicine. Whilst lots of genes expression level changed following individual and Hu 
gene knockdown, a criterion was set to minimise the number of targets for further study. 
Genes with a gene expression change of 2.0 fold-change cycles and consistent amongst 2 or 
more of the Hu knockdowns reduced the targets to seven genes. The genes studied were 
HMOX1, MMP9, NOTCH1, VCAM1, COL1A1, MMP1 and IGFBP3. 
In-depth gene studies on the targets described above revealed a significant upregulation in 
NOTCH1, IGFBP3 and HMOX1, following HuB gene knockdown. Upregulation was also 
observed in MMP1, IGFBP3 and HMOX1 following HuC, HuD and HuR individual knockdowns. 
NOTCH1, HMOX1, IGFBP3 and MMP1 gene expression increased following Hu family 
combined knockdown. This is suggestive of a negative regulatory effect of the Hu family on 




Chapter 6  
Discussion  
Part I: Expression of Hu proteins in Small cell lung 
cancer, Non-small cell lung cancer and normal bronchial 
epithelium 
Worldwide, lung cancer is considered one of the leading causes of cancer-related death 
(Matsumoto et al. 2012). Lung cancers are divided into two categories, Small cell lung cancer 
(SCLC) and Non-small cell lung cancer (NSCLC). SCLC represents 15-20% of all lung cancers in 
the western world (Lampaki et al. 2016).  
Since 1970, there have been over 40 clinical trials conducted on SCLC patients with no 
significant improvement. The treatment remains unchanged consisting of combinational 
chemotherapeutic drugs of etoposide and cisplatin or etoposide and carboplatin (Sundstrom 
et al. 2002, Okamoto et al. 2007).  
SCLC is diagnosed at a late stage resulting in a poor prognosis (Matsumoto et al. 2012). 
Current research into lung cancers stems the idea of identifying a set of new novel antibody 
markers. Targeting the biology and behaviour of the cancer will allow earlier diagnosis and 
could be used for a national screening program. Additionally, identifying more specific targets 
will aid the development of treatments to improve overall the survival rate.  
In many cancers including Small cell lung cancer, neuronal Hu proteins are ectopically 
expressed in tissues or HuR is found overexpressed and this is thought to have a detrimental 
effect on the cells contributing to the disease. Their role in cancer development is mainly 
thought to be related to their role in stabilising mRNA transcripts where oncogenes are 
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stabilised and tumour suppressor genes are destabilised (King 1997, López de Silanes et al. 
2003, Hostetter et al. 2008).  
Ectopic Hu expression was originally discovered due to investigations into the cause of 
paraneoplastic disorders in patients with SCLC. These patients show a higher titre of 
autoantibodies against Hu proteins (Trier et al 2012). 
Therefore, Hu proteins could be potential markers for the early detection of SCLC. This would 
impact the diagnosis and treatment of SCLC since treatment of early stage SCLC has a better 
prognosis. 
6.1 The family of Hu RNA-binding proteins and their presence in lung 
cancers 
To investigate the Hu RNA-binding proteins expression levels in lung cancers, cell lines 
representative of the normal bronchial epithelial tissue, Non-small cell lung cancer and Small 
cell lung cancer, were examined.  
HuR is the most studied gene in the Hu family and its overexpression in cancers is well 
documented and related to a more aggressive cancer. As expected, HuR mRNA was expressed 
in all tested cell lines as HuR protein is expressed ubiquitously. There was a significant 
overexpression of HuR in two of the SCLC cell lines and one of the NSCLC lines when compared 
to the normal bronchial epithelial cells supporting the idea that HuR is functionally 
upregulated in cancers (Abdelmohsen and Gorospe 2010). This has previously been 
documented in SCLC (Onganer et al. 2005) and NSCLC (Wang et al. 2009). 
294 
 
The two suspension Small cell lung cancer cell lines, NCI-H69 and NCI-H345 showed HuB, HuC 
and HuD ectopic gene expression, whilst the third semi-adherent cell line, CorL88 displayed 
HuC and HuD gene expression. The absence of the neuronal Hu family members in the control 
normal bronchial epithelial cells and NSCLC cells suggests that the expression of these genes 
could influence SCLC development. Interestingly, lung cancer cell lines NCI-H69 and NCI-H345 
represent a more severe form of SCLC with a considerably poorer prognosis. 
The ectopic expression of the neuronal Hu proteins in SCLC supports existing knowledge that 
HuB, HuC and HuD can be ectopically expressed in SCLC tumours but not in Non-small cell 
lung cancers (Manley et al. 1995). Correlation exists between SCLC patients, a high titre of 
HuB and HuD protein antibodies and the development of paraneoplastic disorders. In these 
disorders, the expression of neuronal Hu proteins by the SCLC tumour provokes an 
autoimmune response against both the tumour and nervous tissue resulting in neurological 
disorders (Trier et al 2012). The oncogenic properties of Hu proteins and how they become 
expressed and respectively overexpressed in some tumours is unknown, although it is 
suggested somatic mutations may play a key role (D’Alessandro et al 2010).  
RBPs contribution to SCLC carcinogenesis can be explained by their ability to bind to mRNA 
transcripts of oncogenes or tumour suppressor genes affecting their stability and 
consequently influencing oncogenic signalling pathways (Wang et al. 2015).  
Hu proteins bind directly to AU-rich sequences found in the introns and 3՛ untranslated 
regions of many short-lived mRNAs. They can target a large range of transcripts involved in 
cancer development including those responsible for proliferation, invasion and metastasis, 
angiogenesis and immunomodulation. This allows aberrant and over-expressed RBPs to 
provide a regulatory function specific to the cancer needs (Wurth 2012).  
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Genome-wide studies of Hu expression revealed major differences between mRNA transcript 
presence and protein expression. It also revealed that protein expression vary in different 
conditions such as during development, environmental stress and during disease (Re et al. 
2016). Therefore, protein expression studies using western blot were performed for each Hu 
protein detection. 
Western blotting interestingly revealed strong HuB protein expression in CorL88, NCI-H345 
and NCI-H69 SCLC cell lines as well as faint staining in the NSCLC cell lines, NCI-H322 and NCI-
H358. The mRNA expression of HuB was almost undetectable in NSCLC cells when compared 
to the normal bronchial epithelial cell, analysed by the ΔΔCT method. Low HuB expression at 
RNA level and high protein expression detected through western blot suggests a high 
translation rate.  
HuC and HuD protein expression was only detected in NCI-H345 and NCI-H69 SCLC cell lines 
despite the third SCLC cell line CorL88 also showed a HuC and HuD at RNA level. This could be 
explained by mRNA instability or a low translational rate of HuC and HuD in the CorL88 SCLC 
cells. 
In summary, ectopic expression of the neuronal Hu proteins, HuB, HuC and HuD proteins was 
observed in Small cell lung cancer. An upregulation of HuR was observed in all NSCLC and 
SCLC cells.  
Whilst the results have currently demonstrated the aberrant and over expression of the Hu 
RNA-binding protein family that is definite at both gene expression and protein level in SCLC, 
the subcellular localisation of the Hu proteins within cells is as important to the pathogenicity 
of the cancer.  
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HuB, HuC and HuD protein expression is in the cytoplasm of neurons whist HuR protein is 
predominantly expressed in the nucleus (Gao and Keene 1996, Kasashima et al. 1999, Good 
1995). 
HuR’s cytoplasmic overexpression is associated with a clinically poorer cancer phenotype. As 
previously discussed in Section 1.10, HuR cytoplasmic localisation in Oesophageal tumours is 
associated with lymph node metastasis, high-grade malignancy and poor survival rates (Zhang 
et al. 2014). Large tumours in Breast cancer are usually p53 positive, oestrogen and 
progesterone receptor negative, and show upregulated cytoplasmic HuR (Heinonen et al. 
2007, Calaluce et al. 2010). Chemically induced mice lung tumours expressed elevated levels 
of cytoplasmic HuR (Blaxall et al. 2000).  In NSCLC specifically, cytoplasmic HuR induced 
angiogenesis and lymph-angiogenesis through the upregulation of VEGF-C (Wang et al. 2011).  
Whilst HuR protein could not be detected by western blot in the normal bronchial epithelial 
cells, a clear localisation to the nucleus could be shown by immunofluorescence. 
Furthermore, HuR protein was also localised to the nucleus in both NSCLC cells lines.  This was 
consistent with HuR’s expected subcellular localisation. HuR’s nuclear role is in regulating the 
export of bound mRNAs to the cytoplasm protecting them from decay (Brennan and Steitz 
2001). HuR protein expression in nucleus of NSCLC cells correlates to a more treatable cancer 
diagnosis. 
In NCI-H345 and NCI-H69 SCLC cells specifically, all Hu proteins expression was confirmed by 
western blot and immunofluorescence. This shows the ectopic expression detected at RNA 
level leads to a protein product that can be identified by specific Hu antigens. Anti-Hu 
fluorescence staining revealed the Hu family of proteins resided in the nucleus of the NCI-H69 
cell line, whilst all Hu proteins were detected in the cytoplasm in the NCI-H345 cell line. This 
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data highlights the variability of SCLC and the differential localisation of Hu proteins can be 
explained by the different cell types that been found in SCLC cancer samples. Contrary to their 
normal localisation in neurons, HuB, HuC and HuD protein in NCI-H69 and HuR in NCI-H345 
were alternatively localised, a feature conserved to SCLC cells.  
There is little known about how the subcellular localisation of neuronal Hu proteins affects 
the cancerous phenotype. However, research into the posttranscriptional gene regulatory 
role of Hu proteins and their ability to influence mRNA transcript stability provides a possible 
explanation of how these cells contribute to disease (Zaharieva et al. 2015b). In the nucleus, 
Hu proteins control polyadenylation and splicing. Whilst in the cytoplasm, Hu proteins 
regulate mRNA stability by binding to AU-rich elements (AREs) of many short-lived mRNAs 
(Kim and Gorospe 2008, Zhu et al. 2007).  
The presence of HuR in  the cytoplasm of NCI-N345 SCLC cells is indicative of nucleo-
cytoplasmic shuttling, a process that is discussed in Section 1.7.3. In the cytoplasm, HuR 
mediates mRNA stabilisation through its ability to interact directly with an mRNA transcript 
by binding to AREs in their 3′UTR enabling translation into a protein (Abdelmohsen and 
Gorospe 2010). Hu proteins target an array of RNA transcripts coding for transcription factors, 
cytokines, growth factors and proto-oncogenes (Wang et al. 2015). Many of HuR’s targets are 
oncogenes therefore promoting stabilisation and translation of mRNA transcripts in SCLC will 
aid cancer initiation and progression.  
Whilst HuC gene expresison was observed in CorL88 SCLC cells, HuC protein could not be 
detected by western blot or immunofluorescence staining suggesting the expressed RNA 
detected by RT-qPCR is inactive and therefore not translated into a protein. CorL88 cells 
showed weak staining of HuD in the cytoplasm whilst HuR was observed in the nucleus 
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corresponding to their normal localisation described in the literature  (Gao and Keene 1996, 
Kasashima et al. 1999, Good 1995). HuD was previously undetected by western blot in CorL88 
cells, yet fluorescence staining showed a weak signal of HuD protein in the cytoplasm, its 
natural residing location.  
6.2 Cellular properties of normal lung and lung cancer cells 
Cell culture observations revealed similar morphology within each cell subtypes of SCLC, 
NSCLC and the normal bronchial epithelial cells separately. SCLC has impressive 
morphological features during in-vitro studies and this could be related to its pathogenicity. 
These cells are small and round with small nucleus to cytoplasm ratio. They grow in clusters 
regardless of whether they are in suspension or attach to the vessel in which they are cultured 
(Brambilla et al. 2001). 
All three SCLC cell lines grew in clusters. NCI-H345 and NCI-H69 of the SCLC cell lines grew in 
suspension while the third CorL88 is a semi adherent cell line. Interestingly, the semi adherent 
CorL88 cell line differed in its Hu protein expression at RNA and protein level compared to the 
other two SCLC cells lines and gives rise to further studies of Hu derived targets that influence 
anchorage dependence.  
The two NSCLC cell lines and the normal bronchial epithelial cells shared a similar morphology 
with adherent properties. This allowed studies of motility.  
These cells were tested for their ability to migrate into a gel matrix. Interestingly, one of the 
NSCLC cell lines, NCI-H358 was able to migrate into the gel matrix showing a more motile cell 
phenotype. This could represent the ability of the cells to metastasize into distant organs 
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forming secondary tumours. This finding highlights a difference in migrative potential within 
the NSCLC tumours but also concludes that it is possible for some NSCLC tumour to have a 
metastatic phenotype. 
In this study, the ectopic expression of the neuronal Hu genes HuB, HuC and HuD in SCLC were 
identified with an overexpression of HuR in both SCLC and NSCLC. Current diagnosis of SCLC 
relies heavily on the morphology in which the lung tumour cells present. This along with the 
developmental stage of the disease determines the course of treatment the patient is offered. 
A large degree of variability between Hu gene and protein expression was observed as well 
as differential cellular localisation even within the SCLC cells with similar morphology. This 
highlights the importance of the development of new diagnostic methods particularly 
focussed on molecular subtyping of cancers since the morphology is not sufficient. 
6.3 Concluding Remarks 
The proposition of using Hu gene and protein expression to develop a grading system could 
be beneficial to current diagnosis methods, however further studies would be required to 
support this theory. Initially, the aberrant expression of these proteins in the cells should be 
determined due to its significance but then also the sub-cellular expression of these proteins 
is indicative of their role within the cells which is essentially the most important factor. 
The expression and prognostic value of the neuronal Hu genes and proteins could initially be 
used an indicator of SCLC through detection of anti-Hu antibodies in the blood as previously 
described by D’Alessandro et al. (2008), or in very early lung tumour tissue. It was established 
that aberrant HuB, HuC, HuD and overexpression of HuR in SCLC may influence the progress 
of the cancers through their natural role as RNA-binding proteins. By regulating splicing 
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patterns and the stability of mRNA transcripts, the ectopic Hu proteins along with natural-
occurring lung-specific RNA-binding proteins, increase the number of transcripts expressed 
overall in the tumour due to their individual target transcripts, expanding the number of 
genes transcribed. The extra Hu protein action gives rise to a genetically-rich enhanced cell 
type influencing the cancers development and progression. The extent of Hu profiling can be 
used as a prognosis method in that the more of the Hu genes actively working the more 
enhanced the cancer cells are and likely to be a more aggressive phenotype.  
The subcellular Hu localisation in the SCLC cells could serve as method to better predict 
prognosis. This also gives rise to Hu proteins as therapeutic targets regardless of their role 
since by targeting cells only containing the aberrantly expressed proteins, the tumour tissue, 
and the evidence that a triple depletion of neuronal Hu genes in mice was lethal (Akamatsu 
et al. 2005).  
The ability to transfect SCLC-cell lines proved extremely difficult, this is thought to be due to 
their growth in suspension. Therefore, considering this reason and previous research on this 
cancer and Hu proteins, it was decided to focus our future studies on Glioblastoma and 
Neuroblastoma. If studies into SCLC were continued, CRISPR technology would have been 
used to knockout the Hu genes in these cell lines. 
Due to the inability to knockdown the Hu genes it was impossible to determine if using Hu 
proteins as targets to knockdown genetically within SCLC cells would impact the tumours 
growth. If this was the case, immunotherapeutic testing and therapeutic drugs could be 
applied to several different malignancies of solid tumours where Hu proteins are indicated 





Part II: Expression of Hu proteins in Neuroblastoma  
Neuroblastoma is an embryonal tumour of the peripheral sympathetic nervous system. It 
represents 15% of all childhood cancer deaths and has an average 5-year survival rate of less 
than 50% (Maris et al. 2007, Ehrlich et al. 2014). The molecular heterogeneity and phenotypic 
diversity of Neuroblastoma is responsible for a wide range of clinical presentations and 
varying response to treatments. The severity of this disease drives the need to yield 
actionable therapeutic targets for this highly fatal cancer (Louis and Shohet 2015). 
Hu proteins and their corresponding antibodies have been found in Neuroblastoma. Ball and 
King (1997) found that in primary NB tissue, samples that expressed the highest Hel-N1 (HuB) 
or HuD levels were MYCN unamplified tumours. HuB and HuD upregulated gene expression 
in this cancer provides an excellent model for Hu protein analysis.  
Whilst Hu activity is reported in many cancers and thought to have oncogenic properties, 
unfortunately, the mechanisms that modulate its ectopic and overexpression in tumours is 
largely unknown. It is suggested somatic mutations may play a key role (D’Alessandro et al 
2010). HuR specifically is localised in chromosome 19p13.2 and this particular locus has been 




7.1 The family of Hu RNA-binding proteins and their presence in 
Neuroblastoma 
The Hu gene expression profiling in Neuroblastoma focused on three cell lines; normal 
astrocytes, SVG p12, as a control and two Neuroblastoma cell lines, SH-SY5Y and SK-N-AS. 
Using relative fold change expression analysis (2-∆∆Ct) and ß-Actin as an internalised standard, 
the expression levels of each Hu gene was analysed. The RT-qPCR data of the two 
Neuroblastoma cell lines was normalised to the control cell line, SVGp12 normal astrocytes 
cell line which by itself had the lowest gene expression of HuB, HuC, HuD and HuR.  
Hu gene analysis revealed an upregulation of the neuronal Hu genes in both Neuroblastoma 
cell lines compared to the control astrocyte cell line. These genes are known to be 
differentially expressed at various stages of embryonic neuronal development. HuB 
expression occurs very early in development whilst HuC and HuD expression appear later in 
embryonic development (Marusich et al. 1994, Yano et al. 2016). Since Neuroblastoma is an 
embryonal-derived tumour, an upregulated expression of all the neuronal Hu genes in 
tumours, may induce a gain-in-function where a new molecular function or a new pattern of 
gene expression is observed.  
The ubiquitously expressed HuR was significantly upregulated in SH-SY5Y Neuroblastoma 
cells. HuR gene expression levels are often elevated in cancer cells and are reduced in 
senescent and quiescent cells (Dai et al. 2012). This upregulated expression of HuR suggests 
an additional role in this cell line compared to the second Neuroblastoma cell line, SK-N-AS 
and the control normal astrocyte cell line.  
A comparison of the two Neuroblastoma cell lines showed an overall higher gene expression 
of all Hu proteins in SH-SY5Y cells than the second Neuroblastoma cell line SK-N-AS when 
compared to the control astrocytes.  
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This variation of Hu gene expression in these two cell lines aligns with the described variation 
of HuB and HuD expression at a densitometric levels in samples of Neuroblastoma tissue as 
determined through RNase protection assay (Ball and King 1997).  
The observed gene expression profile of Hu proteins does not necessarily mean that the 
same levels of expression is detected at protein level. Additionally, a proteins intracellular 
localisation determines it functional effect (Zaharieva et al. 2015b). Previously studies have 
shown that Hu proteins can redistribute between the nucleus and cytoplasm. The neuronal 
Hu members HuB, HuC, HuD are mainly located in the cytoplasm with a small amount of 
protein detected in the nucleus (Gao and Keene 1996, Antic and Keene 1998). Hu proteins 
subcellular localisation can be quite variable depending on the cell type. A more 
cytoplasmic-defined localisation is observed in many tumour cells (Antic and Keene 1997). 
It is well established that in the nucleus, Hu proteins regulate processes such as alternative 
splicing and polyadenylation and are also involved in the export of bound mRNAs to the 
cytoplasm protecting them from decay (Brennan and Steitz 2001, Zhu et al. 2007, Izquierdo 
2008). In the cytoplasm, they continue to act on these mRNA transcripts by binding directly 
and upregulating a transcripts potential (Brennan and Steitz 2001). 
HuB was expressed at RNA level in all cell lines as confirmed by RT-qPCR gene analysis. Protein 
expression levels did not correlate with transcript mRNA levels detected by the gene analysis. 
Normal astrocytes showed the least HuB gene expression at an almost undetectable level 
when compared to the Neuroblastoma cells following 2-∆∆Ct gene quantification. However, at 
a protein level, HuB showed a four times higher expression compared to GAPDH expression 
suggesting a high translational rate for HuB in normal astrocytes, SVGp12. This could be 
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explained by the embryonic origin of this cell line when HuB is expressed during neuronal 
development as mentioned above. 
In addition to the expected Hu signal at 38kDa, a band at 76kDa was detected which could be 
a HuB dimer. This is rather a usual occurrence following the denaturation of proteins before 
the Western blot but offers an explanation. The presence of HuB could be confirmed by 
immunofluorescence and a localisation in both the cytoplasm and nucleus was found. 
The nuclear localisation of HuB in normal astrocytes is inconsistent with the regular 
localisation of HuB protein. The presence neuronal Hu family proteins in the cytoplasm and 
the nucleus of the normal astrocytes is not surprising since they share similarities with 
neurons in that both reside in cortical areas, contribute to the maintenance of the central 
nervous system and allow metabolic interplay between astrocytes and neurons.  In neurons, 
Hu proteins can appear to be distributed equally in both the nucleus and cytoplasm (Antic 
and Keene 1997). As a post-transcriptional gene regulator, HuC protein can act to influence 
splicing patterns and mRNA export when it is localised in the nucleus. 
The SK-N-AS Neuroblastoma cells showed equal expression of HuB to GAPDH expression as 
determined through band intensity. Compared to SH-SY5Y cells, SK-N-AS cells have a higher 
protein expression which is consistent with the gene expression data. In SH-SY5Y cells, HuB 
proteins shows less than half of the control GAPDH protein expression. 
In SK-N-AS and SH-SY5Y Neuroblastoma cells, only the higher band at 76 kDa could be 
detected which could be a result of HuB protein dimerisation. HuB was localised mainly in 
the nucleus, with a weaker signal in the cytoplasm in these cells. HuB protein is normally 
restricted to the cytoplasm in undifferentiated neurons where it co-localises with ribosomes 
controlling mRNA metabolism and neuronal differentiation (Gao and Keene 1996). The 
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presence of neuronal Hu proteins in the nucleus is not unusual as it is well documented that 
Hu proteins can translocate from the cytoplasm to the nucleus playing crucial roles in 
posttranscriptional gene regulation (Doller et al. 2008b).  
HuB nuclear localisation in the Neuroblastoma cell line SK-N-AS, could be explained by its 
upregulated gene expression and high protein level whereby it is proactively transported to 
the nucleus in a ratio-dependent mechanism. As previously described, in the nucleus, HuB 
can regulate alternative splicing of mRNA transcripts and can assist in the export of mRNA 
transcripts to the cytoplasm protecting them from decay (Zhu et al. 2007, Ince-Dunn et al. 
2012, Brennan and Steitz 2001). 
One feature of cancer cells is a high proliferation rate. In the cytoplasm, HuB protein can bind 
and regulate the stability and translation of many mRNA transcripts involved in proliferation. 
This increases the molecular advantage of a cell (Brennan and Steitz 2001).  
HuC protein was found to be highly expressed in the normal astrocytes, SVG p12. In this cell 
line, it was detected as a monomer at the expected size of 39kDa and around four times the 
expected size of HuC protein, suggesting HuC experiences multimerisation. HuC protein was 
predominantly localised in the nucleus of the SVG p12 astrocytes, although a lower a level of 
HuC protein was also observed in the cytoplasm.  
The nuclear localisation of HuC in normal astrocytes is inconsistent with the regular 
localisation of HuC protein and is thought to be due to similar effects described about HuB 
where there is an increased demand for mRNA regulation in the nucleus. 
Similar to the effects seen in the embryonic cell line, the stresses upon a cancer cell may result 
in HuC being recruited to the nucleus. In the nucleus, it can regulate the splice patterns of 
mRNA transcripts and assist in their translocation to the cytoplasm for additional processing. 
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In both Neuroblastoma cell lines, only the higher molecular band four times the size of the 
expected 39kDa was detected by Western blotting. This is potentially significant of HuC 
protein multimerisation. HuC was expressed equally and about half of the GADPH control 
protein expression. At RNA expression level in SH-SY5Y cells showed a HuC higher expression 
level than SK-N-AS cells highlighting again that RNA expression levels do not necessarily 
reflect on the abundance at protein level. 
HuC protein expression and localisation was also confirmed by immunofluorescence studies. 
HuC was localised in both the cytoplasm and the nucleus in the normal astrocytes and SH-
SY5Y, Neuroblastoma cells. In SK-N-AS cells, HuC protein was expressed in the cytoplasm only. 
HuC protein is reportedly expressed in the cytoplasm of differentiated neurons (Okano and 
Darnell 1997).  
The larger protein moieties detected in normal astrocytes and Neuroblastoma cells could be 
explained by a dimerization or multimerisation of HuB and HuC, respectively. It is known that 
Hu monomers can bind to each other or themselves at the third RRM and hinge region of Hu 
RNA-binding proteins structure displayed in Fig. 1.6. (Fialcowitz-White et al. 2007, Kasashima 
et al. 2002). 
Dimerisation and multimerisation of the neuronal proteins is thought to contribute to their 
ability to form large ribonucleoprotein (RNP) complexes. These form from protein-protein 
interactions that then bind RNA (Kasashima et al. 2002). RNP complexes then bind with the 
translational apparatus of the cell, upregulating transcript stability and translation (Antic and 
Keene 1998). 
Protein analysis revealed HuD was absent in normal astrocytes but present in the 
Neuroblastoma cells. HuD protein expression in the SH-SY5Y cells was comparable to the 
GAPDH control. In SK-N-AS cells, HuD protein was expressed about 20% of the control band 
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intensity. Overall, a higher HuD protein expression was observed in the SH-SY5Y cells that 
correlates with gene expression levels.  
The absence of HuD protein in normal astrocytes was confirmed by immunofluorescent 
staining. In SK-N-AS and SH-SY5Y cells, HuD protein was found in the cytoplasm only which 
aligns with the described localisation of HuD in neuronal development  (Kasashima et al. 
1999). 
Ball and King (1997) reported that upregulation of HuB and HuD gene expression correlated 
with unamplified MYCN levels in primary Neuroblastoma tissue. A upregulation of HuB and 
HuD was found in both Neuroblastoma cell lines, SH-SY5Y and SK-N-AS and their known status 
of NMYC-non-amplified cells (Peirce and Findley 2015, Veas-Perez de Tudela et al. 2010). 
Western blot analysis showed a very low expression of HuR in the normal astrocytes cell line 
SVG p12. A low abundance of HuR was confirmed by immunofluorescence with a 
predominant localisation to the nucleus. 
A slightly increased expression of HuR compared to GADPH was seen in both Neuroblastoma 
cell lines. The protein expression level aligns with the HuR RNA expression level which showed 
a upregulation in both Neuroblastoma cell lines, but not statistically significant in SK-N-AS 
cells. 
HuR protein was localised in the nucleus of the SK-N-AS cells and in the cytoplasm of SH-SY5Y 
cells. In neurons, HuR protein expression is predominantly seen in the nucleus of normal cells, 
but upon cellular signals HuR shuttles between the nucleus and the cytoplasm (Good 1995, 
Fan and Steitz 1998). 
RNA-binding proteins localisation often determines the extent of transcript stability, 
translation rate and degradation (Zhu 2009). The cytoplasmic localisation of HuR protein in 
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SH-SY5Y cells could be linked to its overexpression. Often when an upregulation of HuR 
protein in the nucleus occurs, the cells actively translocate HuR protein to the cytoplasm 
(Doller et al. 2008b). In the cytoplasm, HuR protein can participate in roles such as regulating 
mRNA translation, stability and degradation.  
HuR is the most extensively researched Hu protein in cancer related studies; it’s upregulation 
and cytoplasmic localisation has been linked to a severe phenotype of cancer resulting in a 
poor prognosis (Table 1.2).  
7.2 Regulatory interactions of Hu RNA-binding proteins in 
Neuroblastoma 
Members of the Hu family can bind their own mRNA and mRNA of other family members and 
influence their expression (Bolognani et al. 2009, Mansfield and Keene 2012). Hu proteins 
bind mRNA sequences containing a distant AU-rich elements and once bound stabilise the 
target transcripts (Pullmann et al. 2007, Al-Ahmadi et al. 2009).  
HuR protein specifically auto-regulates its’ own expression through a negative feedback loop 
maintaining HuR homeostasis in proliferating cells. This occurs in response to cellular stress 
by promoting alternative polyadenylation site usage. HuR protein residing in the nucleus 
contains a GU-rich element overlapping with the HuR major polyadenylation signal. Following 
upregulation of HuR protein, the expression of the long 2.4kb isoform of HuR containing an 
AU-rich element is destabilised, reducing its protein level. This maintains a steady expression 
of HuR in the cell (Dai et al. 2012). 
To understand the regulatory interactions of Hu RNA-binding proteins, a single and combined 
knockout of the Hu genes was established in SH-SY5Y and SK-N-AS Neuroblastoma cells using 
siRNA interference.   
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Observations in Neuroblastoma cells but particularly in the SH-SY5Y cell line, where a high 
overall expression of Hu genes was observed, were suggestive of a regulatory mechanism 
occurring between Hu family members an overall more efficient knockdown of Hu gene 
expression was achieved in a combined knockdown compared to the individual knockdowns. 
This was later confirmed by western blot where the most efficient knockdown of each 
individual Hu protein was through the combined Hu siRNA knockdown. 
In the single knockdowns of HuR and HuD, all the other Hu family members mRNA levels also 
reduced. In the combined knockdown, an increased efficiency was seen for the neuronal Hu 
genes, HuB, HuC and HuD. HuR gene expression following combined Hu gene knockdown 
correlated a combined effect of the individual knockdowns of HuD and HuR. HuR mRNA levels 
decreased by 27% following HuD knockdown, 81% following HuR knockdown and 70% 
following combined Hu family knockdown. Overall, it can be concluded that HuD and HuR the 
main players in regulating other Hu proteins expression. 
Hu family proteins are highly conserved not just within their sequence but in their roles as 
posttranscriptional regulators. ELAV is the Drosophila homolog of the human Hu genes. 
Zaharieva et al. (2015) found that Drosophila family members can regulate each other’s target 
transcripts. ELAV-related Sex-lethal regulated ELAV targets. They also described a dosage-
compensation relationship between Sex-lethal and RBP9 proteins.  
It appears familial Hu proteins are possibly able to functionally counteract the depletion of 
another. The work described in this thesis found regulatory mechanisms within the Hu family 
network. This led to the development of a hypothetical model of Hu protein interactions for 
each of the Neuroblastoma cell lines.  
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The hypothetical model describes the potential interactions and regulatory interplays as 
follows. Firstly, an auto-regulation of Hu protein family members where they can target their 
own transcripts and regulate their expression in a feedback loop. Secondly, the regulation 
could be due to a functional compensation, during which other Hu genes become upregulated 
for the decreased expression of other Hu family members after the knockdown. And finally, 
the observed effects could due to an off-target effect of Hu gene regulation, whereby a mRNA 
transcript affected by the Hu genes regulation triggers a feedback loop, affecting the 
expression of a different Hu gene family member. Since, miRNAs and other RBPs have also 
shown to influence Hu protein expression, it’s important to consider potential other upstream 
or downstream regulators of the Hu family proteins, which itself highlights the need to 
identify other signalling pathways important for Hu regulatory function (Al-ahmadi et al. 
2013).  
In the SH-SY5Y cell line, HuB is potentially a negative regulator of HuC and HuD gene 
expression. This could be explained that HuB bind to AREs of HuC and HuD mRNA transcripts 
which leads to a regular expression of their mRNA in the cells. Therefore, when HuB is 
downregulated, consequently the expression of HuC and HuD would increase. Alternatively, 
HuC and HuD genes may compensate for the decreased expression of HuB gene by 
upregulating their own expression. There is also the possibility that HuB knockdown results 
in off targets effects subsequently upregulating HuC and HuD gene expression through 
downstream activators. This could be HuB acts of a different target transcript that also affect 
HuC and HuD gene regulation and the described effects could be due to the effect on that 
different transcript initially. 
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When HuC gene expression was reduced, a significant increase of HuR gene expression was 
observed. This could be explained by HuC protein actively controlling the transcription of HuR 
mRNA or that the increase in HuR gene expression compensates for HuC gene activities.  
HuD seems to positively regulate the gene expression of the other neuronal Hu genes, HuB 
and HuC. Whilst HuR upregulated the gene expression of all the other Hu genes in this 
Neuroblastoma cell model. When HuD or HuR gene expression was decreased, the other Hu 
genes expression were also reduced. This is most likely due to HuD and HuR proteins binding 
directly to the mRNA transcripts of the other Hu genes and stabilising their expression or it 
could be due to off target effects where a different mRNA affected by HuD or HuR knockdown 
influences the other neuronal Hu proteins. HuC protein was also found to be a positive 
regulator of HuB gene expression, since HuB gene expression decreased when HuC gene was 
knocked down. This can be explained by the same possible interpretation as described for 
HuD regulation of HuB and HuC. In the SK-N-AS cell line, the following explanations are based 
on three hypothesised regulatory interactions that were previously discussed in Section 4.4.1. 
HuC and HuD are negative regulators of HuB expression. The regulatory influences of HuC and 
HuD proteins on HuB gene expression may be explained by direct binding of HuC or HuD 
proteins to the mRNA transcripts of HuB gene and stabilising its expression. Therefore, upon 
HuC and HuD siRNA knockdown, HuB mRNA transcript is no longer under this regulatory 
control and its expression increases. It is also possible that HuB compensates for the reduced 
gene expression of HuC and HuD. This level of regulation can be explained by the same 
interpretations discussed for HuC’s regulation of HuR. 
HuR knockdown appears as a positive regulator of HuC expression as a decrease in HuC 
expression occurs. This can be explained by the fact that HuR binds directly to HuC’s mRNA 
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transcript and stabilises its expression. Therefore, when HuR expression is reduced, HuC’s 
transcript becomes unstable. Additionally, this could be caused by off target effects of HuR’s 
downregulation. HuC and HuR are located on the same chromosome, 19p13.2 where HuC is 
centromeric to HuR (Van Tine et al. 1998). 
Correlation between nuclear HuR and its ability to auto-regulate its own transcript was 
documented by Dai et al. (2012). HuR autoregulates its expression by promoting alternative 
polyadenylation site usage through a negative feedback loop. This often leads to a large 
amount of cytoplasmic HuR as it’s the nuclear HuR that induces this action. In the 
Neuroblastoma cell line SH-SY5Y, overexpression of HuR gene showed a predominant protein 
presence in the cytoplasm contributing to this theory. 
These regulatory interactions observed of HuR may apply to other Hu proteins since their 
sequences and function is highly conserved. This may also explain the inability to achieve 
higher than a 50% knockdown of HuB gene in SK-N-AS cells. 
The observed higher molecular weight of HuB and HuC in western blots that could be a result 
of a dimerisation or multimerisation respectively, has been shown to allow Hu proteins to 
upregulate their own mRNA transcripts and further bind with additional Hu proteins at the 
third RRM and hinge region as previously described (Fialcowitz-White et al. 2007, Kasashima 
et al. 2002). 
In Neuroblastoma, HuB and HuC proteins were revealed as major players in only the negative 
regulation of other Hu genes. In SK-N-AS cells, HuB protein was a negative regulator of HuR 
gene expression. This was shown by HuB gene knockdown and a resulting increase in HuR 
gene expression. Also, HuC protein negatively regulated HuB gene expression. In SH-SY5Y 
cells, HuB protein was a negative regulator of HuC and HuD gene expression, since following 
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HuB knockdown, HuC and HuD gene expression increased significantly. Additionally, HuC 
protein was a negative regulator of HuR gene expression.  
Of the two cell regulatory models, the only similarity is that HuC is a negative regulator of HuR 
gene expression. However, if these models were combined, HuB and HuR protein can regulate 
each other’s expression, as can HuB and HuD, HuC and HuR. 
This presented study on gene expression and the regulatory network of Hu proteins highlights 
the compensatory effects of which is important to be considered for gene therapies. Further 
study would require complete knockouts of the Hu genes that could be achieved by CRISPR. 
Also, miRNA analysis would help understand the extended regulation of Hu genes.  
7.3 Hu proteins and their influence on Neuroblastoma cell phenotype 
The knockdown studies of single and combined Hu genes were assessed for their effect on 
cellular properties. No clear changes of the cell morphology were observed following 
individual or combined Hu gene knockdowns.  
MTS studies revealed HuB, HuC and combined Hu gene knockdowns increased cell viability in 
SH-SY5Y cells but not in SK-N-AS cells. This suggests that in the cell, HuB and HuC proteins can 
act in manner to maintain a steady rate of cell viability and without this control, a possible 
upregulation in cell viability could occur. This would suggest HuB and HuC proteins have 
tumour suppressor properties. This may be occurring through direct regulation of transcripts 
involved in cell viability or through regulating transcripts whose downstream targets affecting 
cell viability. In Glioblastoma, HuB protein has previously been described as a tumour 
suppressor (Tarter 2013). 
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Cell migration, invasion and chemotaxis are typically involved in diverse processes from 
embryonic development and differentiation to angiogenesis, immune response, wound 
healing and cancer cell metastasis (Khabar 2017).  
Cell mobility and cell invasiveness was measured through cell migration into an agarose gel 
matrix. When compared, SK-N-AS cells had an overall more invasive phenotype than SH-SY5Y 
cells before any knockdown experiments. In a wound healing assay, HuB gene knockdown 
increased the migrative potential of both Neuroblastoma cell lines, as did individual HuC and 
HuR knockdown and combined Hu gene knockdown in the SH-SY5Y cell lines. Differences 
observed between the cell lines may be related to the higher overall expression of Hu genes 
in SH-SY5Y cells compared to the SK-N-AS cells. Interestingly, HuB gene expression was 
highest in the SK-N-AS cells which was the only effective gene knockdown in producing 
cellular effects.  
The increased motility after Hu gene knockdowns suggests that Hu gene play a role in the 
relative migration rate of these cells. The described effects of HuB, HuC and HuR inducing a 
more migrative phenotype, suggests that the Hu genes role in the cell, is to maintain a relative 
rate of migration. 
7.4 Gene targets regulated by Hu proteins in Neuroblastoma 
The influence of Hu gene expression on potential mRNA targets was analysed. Gene 
amplifications of Hu genes and consequential increases in their protein expression are likely 
to impact translational networks and change fundamental cellular processes. Hu proteins can 
modulate the stability of ARE-containing mRNAs in vitro positively as well as negatively 
(Brennan and Steitz 2001). 
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A commercially available array consisting of 91 mRNA targets described in the National Library 
of Medicine database and thought to contribute to the development Neuroepithelial 
disorders was used. Gene expression levels were analysed following single and combined Hu 
gene knockdowns in both Neuroblastoma cell lines SH-SY5Y and SK-N-AS. In each 
Neuroblastoma cell line, a unique alteration in target gene expression was observed.  
Considering each cell line as an individual model and to reduce the number of target genes 
for analysis, several parameters were set. A 3.0 cycle fold-change difference in gene 
expression compared to the control non-targeting siRNA expression was selected for the SH-
SY5Y samples following individual and combined gene knockdowns when compared to the 
non-targeting knockdown control. A fold-change of 3.6 cycles was selected for SK-N-AS 
Neuroblastoma cells. An additional selection for the genes were ones that were consistent in 
two or more of the knockdowns observed within each cell line. For the SH-SY5Y cell line, 6 
genes were identified to meet these criteria and 12 genes for the cell line SK-N-AS. 
A knockdown of Hu genes individually and combined in SH-SY5Y cells revealed that B-cell 
lymphoma (BCL2) mRNA transcript levels were affected, showing a lower expression. This 
shows that in the Neuroblastoma cell model SH-SY5Y, Hu proteins regulate the expression of 
BCL2 transcript probably by stabilising its mRNA. Ishimaru et al. (2009) identified HuR as a 
component of Bcl-2 messenger ribonucleoprotein (mRNP) complexes in in HL60 Leukaemia 
cells and A431 Carcinoma cells. BCL2 mRNA contains AU-rich elements in the 3′-untranslated 
region to which Hu proteins can bind to and regulate (Schiavone et al. 2000). A schematic 




Bcl-2 is an anti-apoptotic protein and mediator of cell survival and cell death,  by regulating 
caspase-dependent and caspase-independent cell death pathways (Nunez and Clarke, M. F. 
1994). Bcl-2 is known to affect the progression of diseases such as cancer, autoimmune 
diseases and neurological conditions such as stroke and neurodegenerative diseases (Hughes 
et al. 2006, Akhtar et al. 2004, Kirkin et al. 2004). The potential influence of Hu genes in 
neurodegenerative disorders and its ability to regulate BCL2 transcript has previously been 
discussed in Section 1.8.  
Cyclin D2 (CCND2) gene was shown to be regulated by HuC and HuD proteins in SH-SY5Y 
cells. Following knockdown of these Hu genes, CCND2 expression also decreased suggesting 
HuC and HuD positively regulate the stability of CCND2 mRNA transcript promoting its’ 
expression. Cyclins are involved in controlling the cell cycle progression for which their 
expression is tightly regulated (Johnson and Walker 1999). HuR protein was documented in 
Colorectal carcinoma cells, RKO, to regulate cell division and checkpoint responses by 
stabilising the transcripts of key cell cycles regulators, namely cyclin A and cyclin B1 (Wang 
et al. 2000)  Therefore, it is not surprisingly that HuC and HuD show this effect on CCND2.  
Following a combined Hu gene knockdown, a large upregulation of CCND2 was observed. 
This is unusual but can be described by genetic compensation. This is a widespread 
phenomenon, where the reduced or loss of expression of one gene is compensated by 
another with a similar function and expression pattern. There are multiple RBPs in the 
human genome that co-regulate mRNA targets. Keene (2007) described a model in which 
mRNAs encoding for proteins with similar functions are co-ordinately regulated as post-
transcriptional RNA operons or regulons, through a ribonucleoprotein-driven mechanism 
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(Keene 2007). This co-regulation of mRNA transcripts has also been described for the 
Drosophila Hu homolog, ELAV, and its family members (Zaharieva et al. 2015b) 
The decrease of Hu protein expression could induce the expression of other RNA binding 
proteins to compensate for Hu’s cell vital functions in posttranscriptional gene regulation of 
target RNAs, here acting on Cyclin D2 expression (El-Brolosy and Stainier 2017). HuR protein 
and the eukaryotic translation initiation factor 4E (eIF4E) are RNA regulons sharing targets 
that regulate survival and proliferation-related genes such as c-myc, cyclin D1 and VEGF 
(Wurth 2012, Topisirovic et al. 2009).  
Importantly, this shows how targeting HuB or HuC protein individually could be beneficial in 
the reducing CCND2 expression whilst a knockdown of all Hu proteins seems to have the 
contrary effect. The influence of Hu proteins on target RNAs in Neuroblastoma that are 
involved in cell proliferation, and the compensatory aspects when Hu proteins are 
downregulated, highlight the underlying molecular complexity of the disease and a concept 
that must be considered for therapeutic approaches. 
Early Growth Receptor 1 (EGR1) gene encodes a transcription factor required for programmed 
cell death or apoptosis in both normal and tumour cells (Adamson and Mercola 2002). Here 
it was shown that following HuB, HuC and HuD gene knockdowns in SH-SY5Y cells, EGR1 gene 
expression also decreased. This shows that the neuronal Hu proteins act as positive regulators 
of EGR1 mRNA expression. The same effect on EGR1 was also observed in the second 
Neuroblastoma cell line, SK-N-AS. In this cell line, the combined Hu gene knockdown also 
significantly decreased EGR1 gene expression. In addition, in SK-N-AS cells, the combined 
knockdown of all Hu proteins showed a significant decrease of EGR1 expression while in SH-
SY5Y cells, only a moderate decrease was observed. 
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These findings suggest that in Neuroblastoma cells, the neuronal Hu genes actively regulate 
EGR1 gene expression either directly or indirectly and consequently stimulating tumour 
growth (Adamson and Mercola 2002). In Prostate cancer, EGR1 is overexpressed. EGR1 was 
linked to several target genes including cyclin D2 (Virolle et al. 2003).  
As mentioned in SH-SY5Y cell line, the combined Hu gene knockdown did not reduce the EGR1 
expression much, therefore EGR1 could upregulate CCND2 expression. However, in SK-N-AS 
cell, the expression of CCND2 was not selected as a target following the criteria described 
above, therefore this interpretation cannot proved. 
Neuroblastomas are often defined by a poor outcome if an amplified state of proto-oncogene 
MYCN is found (Cohn et al. 2009). MYCN is a member of the MYC family of transcription 
factors regulating cellular processes including survival, proliferation, and differentiation 
(Westermark et al. 2011). Lovén et al. (2010) shows an array of MYCN-induced miRNAs 
including the micro RNAs, miR-18a and miR-19a, that target and repress Estrogen Receptor 1 
(ESR1) gene expression. ESR1 encodes the protein estrogen receptor α. ESR1 expression in 
Neuroblastoma tumours has been shown to induce a favourable disease outcome.  
Individual knockdowns of HuB, HuC and HuD genes showed their proteins are positive 
regulators of ESR1 gene expression, as when HuB, HuC and HuD gene expression decreases, 
ESR1 also does. In the SH-SY5Y cells, HuB, HuC and HuD proteins must be acting on the ESR1 
gene transcript to maintain a steady regulation, potentially demonstrating a tumour 
suppressor role. SH-SY5Y cells do not show MYCN amplification and no interference with ESR1 
regulation by MYCN must be considered. However, it has been shown that MYCN becomes 
upregulated in SH-SY5Y cells when treated with nutlin-3 and doxorubicin, due to cellular 
stress (Peirce and Findley 2015). Upon knockdown of the Hu family in combination, ESR1 gene 
319 
 
expression increased, suggesting that a downregulation of the Hu family could be a potential 
target for gene therapy  leading to higher ESR1 gene expression. Lovén et al. (2010) showed 
higher ESR1 expression induced growth arrest and neuronal differentiation in Neuroblastoma 
cells.  
Insulin-Like Growth Factors play a crucial role in the regulation of cell proliferation, 
differentiation, apoptosis and transformation (Clemmons and Jones 1995). Insulin-like 
growth factor-binding protein 3 (IGFBP3) was shown to be positively regulated by HuR RNA-
binding protein. This was shown in mouse embryonic stem cells where a knockdown of HuR 
decreased IGFBP3 expression. It showed IGFBP3 contains a HuR binding motif in its 3′-UTR 
that upon HuR binding, increased stability of the transcript (Wang et al. 2014). This suggests 
HuR as a novel target to reduce IGFBP3 since a HuR knockdown resulted in a decrease in 
IGFBP3 expression in the SH-SY5Y cells.  
The anti-inflammatory cytokine Interleukin-10 (IL10) has previously been reported to regulate 
the expression of HuR (Prasanna et al. 2009). To maintain normal physiology, IL10 balances 
anti-inflammatory regulatory T-cells and proinflammatory IL17-expressing T-cells. Mice 
deficient in IL10 have increased inflammatory responses often causing cancer, demonstrating 
a tumour suppressive effect of IL10 (Oft 2014). The data presented shows that after the 
individual knockdown of Hu genes in SH-SY5Y, IL10 expression was decreased. Therefore, Hu 
genes may post-transcriptionally regulate IL10 expression or IL10 expression may decrease 
because of down-stream effects following Hu gene depletion. A combined knockdown of all 
Hu genes leads to a significant increase in IL10 expression. This is most certainly an off-target 
effect, where different genes compensate for Hu gene expression decrease.  
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It could be hypothesised that a combined Hu family knockdown may provide a good 
therapeutic target since there is a large increase in IL10 expression, that would induce an anti-
tumour effect. Overexpression of a synthetic IL10  has shown to induce anti-tumour immunity 
(Oft 2014). However, this must be confirmed by further experiments looking at the interaction 
of Hu proteins on multiple levels.  
An upregulation of Apolipoprotein E (APOE) is commonly associated with the Alzheimer’s 
disease pathology (Diedrich et al. 1991). Likewise, Hu genes have been implicated in 
Alzheimer’s pathology and regulation of genes implicated in AβPP processing (Amadio et al. 
2010). 
ApoE proteins function in lipid metabolism and neuronal homeostasis (Huang, Yadong and 
Mahley 2014). There are three variants isoforms of ApoE proteins of which the ApoE3 variant 
has previously been identified in SH-SY5Y Neuroblastoma cells (Dupont-Wallois et al. 1997). 
In Neuroblastoma, ApoE has also been shown to affect cell viability when oxidised by a 
phospholipid (Hoy et al. 2000). 
In Ovarian cancer, ApoE was shown to be a tumour-associated marker required for increased 
proliferation and cell survival. Knockdown experiments in ovarian cells, OVCAR3, resulted in 
cell-cycle arrest and apoptosis (Chen et al. 2005).  
In the presented study, APOE gene expression was downregulated following all individual and 
combined Hu gene knockdowns in SK-N-AS cells. This highlights that the APOE gene is 
targeted directly or indirectly by the Hu gene family maintaining its regulation in these cells. 
Further experiments would be required to prove that the knockdown of Hu protein results in 
a decrease of APOE inducing cell death in a vivo model.  
As previously mentioned, Neuroblastoma has a poor prognosis if proto-oncogene MYCN is 
amplified (Cohn et al. 2009). A study in Neuroblastoma cells showed that cells treated with 
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CDK1 inhibitors showed a reduced expression of MYCN and survivin expression. They 
concluded CDK1 inhibition induced cell cycle arrest and apoptosis through interruption of the 
miR-34a–MYCN–survivin pathway (Chen et al. 2013).  
A knockdown of HuB and HuD genes individually in SH-SY5Y cells, resulted in an increased 
CDK1 gene expression. This shows HuB and HuD proteins have a repressive regulatory effect 
on CDK1, either through direct or indirect effect on the CDK1 gene transcript.  
Studies into Connective Tissue Growth Factor (CTGF) expression in breast carcinoma revealed 
CTGF contains five HuR binding motifs and is therefore regulated by HuR protein (Heinonen 
et al. 2011). The data presented in this study confirms HuR protein as a regulator of CTGF in 
SK-N-AS cells. The downregulation of HuR lead to a decreased CTFG expression. CTGF 
expression was also downregulated when HuC and HuD genes were knocked down 
individually. This potentially shows that these Hu proteins also regulate CTGF. These results 
suggest that in the SK-N-AS Neuroblastoma cells, Hu proteins modulate CTGF mRNA levels 
during post-transcriptional events ensuring its expression is maintained. CTGF is a matrix-
associated protein and its functions in cancer is related to angiogenesis and tumour growth 
and even cancer cell migration and invasion (Chu et al. 2008). This highlights the potential 
oncogenic effects of HuR, HuC and HuD in relation to the CTGF transcript in these cells. 
High expression levels of Glutathione S-Transferase Pi 1 (GSTP1) mRNA that encodes a 
detoxifying enzyme expression have been associated with decreased survival in 
Neuroblastoma patients. Further investigation revealed N-Myc as a transcriptional regulator 
of GSTP1. N-Myc also regulates the expression of several ATP-binding cassette (ABC) 
transporters, further increasing the level of regulatory control in drug metabolism. This could 
explain the high multi-drug resistance observed in Neuroblastoma (Fletcher et al. 2012). SK-
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N-AS cells are typically MYCN-non-amplified cells, although MYCN expression can be induced 
through treatment induced cellular stress as previously described (Prochazka et al. 2013).  
GSTP1 gene expression was reduced following HuB gene knockdown. This shows that HuB 
protein is a positive regulator of GSTP1 expression. In contrast, HuC and HuR proteins were 
revealed as negative regulator of GSTP1 gene expression since their knockdown resulted in 
increased GSTP1 expression levels. This is suggestive of a tumour-suppressor function to 
maintain low/moderate GSTP1 expression in the SK-N-AS Neuroblastoma cells. These 
observed differences in the effect of single Hu proteins on the expression of certain genes 
highlights molecular heterogeneity of this type of cancer and the difficulty of establishing an 
effective treatment. 
Transforming growth factor beta (TGF-β1) mRNA has previously been reported in 
Neuroblastoma and normally plays a role in the homeostasis of proliferation and 
differentiation (Lolascon et al. 2000). TGF-β normally functions in cell growth inhibition, 
however it is documented that several cancers develop resistance to TGF-β (Polyak 1996). 
TGF-β1 mRNA levels decreased in SK-N-AS cells following all Hu gene individual and combined 
knockdowns. Although this downregulation was not significant, it forms an intricate part in 
the Neuroblastoma network. The observed regulation suggests that Hu proteins upregulate 
TGF-β1 expression in the SK-N-AS cells. 
TGF -β1 binds to one of three cell surface receptors namely TGF-βR1, TGF-βR2. and TGF-βR3. 
Lolascon et al. (2000) reports TGF-βR3 is extensively reduced in the later stages of 
Neuroblastoma development. 
Protein kinase C α (PKCα), belongs to a family of proteins that emit signals inducing lipid 
hydrolysis. These signals stimulate other factors such as G protein-coupled receptors and 
tyrosine kinase receptors, which lead to activation of pathways ultimately activating protein 
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kinase C (Newton 1995). In Breast cancer, Protein kinase C α induces a more migrative 
phenotype of breast cancer cells through FOXC2-mediated repression of p120-catenin (Pham 
et al. 2017). 
Following HuD gene knockdown in SK-N-AS cells, PKCα was also reduced suggesting a positive 
regulation of HuD protein on PKCα mRNA transcript. In these cells, HuD protein would 
maintain the expression of PKCα, which may have the same effect as in Breast cancer cells, 
inducing a more migrative phenotype. 
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) forms part of a group of GTP-
binding proteins called the RAS family that are characterised by a catalytic G domain 
(Wennerberg et al. 2005). K-Ras protein is involved in signalling pathways intracellularly, 
transporting signals from the cell surface to the nucleus. Their signalling cascade is initiated 
by molecules like TGF-β1 binding to cell surface receptors. Overall K-Ras can modulate normal 
cellular functions such as cell differentiation, growth, chemotaxis, migration and apoptosis 
through activation of downstream targets such as cytoplasmic kinases. In cancer, K-Ras can 
therefore influence transformation, angiogenesis, invasion and metastasis (Zuber et al. 
2000).  
A screening of relapsed Neuroblastomas revealed 29 somatic mutations of which eighteen 
were forecast to initiate the RAS-MAPK signalling pathway. 61% of activating mutations in the 
RAS-MAPK pathway were detected in Neuroblastoma cell lines. KRAS particularly has shown 
to have a activating somatic mutation in Neuroblastoma (Eleveld et al. 2015).  
In SK-N-AS cells, HuC and HuR individual gene knockdowns resulted in a decrease in KRAS 
gene expression, suggestive of a positive regulatory effect of HuC and HuR proteins on KRAS 
mRNA. This is most likely due to an indirect effect, since there is no evidence to suggest KRAS 
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mRNA contains an AU-rich element in its 3′UTR region for Hu proteins to bind directly to. Only 
10% of all mRNA transcripts are thought to contain AREs in their 3′UTR (Halees et al. 2008). 
Mitogen-activated protein (MAP) kinases are downstream effectors in the RAS-MAPK 
signalling pathway. They aid in the relaying extracellular signals to implement intracellular 
responses. The combined effects of MAPKs function to modulate cell growth, cell 
differentiation and cell death (Schaeffer and Weber 1999).  
Mitogen-activated protein kinase 2 (MAP2K2) gene expression was reduced following 
individual and combined Hu gene knockdowns in SK-N-AS Neuroblastoma cells. Mitogen-
activated protein kinase 3 (MAPK3) serves downstream of MAP2K2 and showed a significant 
decrease in expression following all individual Hu gene knockdowns. A decrease also occurred 
following combined Hu gene knockdown but was not statistically significant. MAPK mRNA are 
not reported to have ARE in their 3′ untranslated regions therefore concluding Hu gene 
regulation occurs due to an indirect effect. This is most likely an upstream regulator of MAPK.  
7.5 Concluding remarks 
Hu gene analysis revealed its upregulated expression in all Neuroblastoma cells lines when 
compared to the control normal astrocytes. Hu protein was observed in its natural location 
except for HuD in SH-SY5Y cell where it is located in the nucleus. This was most interesting 
since this cell line showed the most Hu protein expression overall. Whilst this aberrant 
localisation of HuD protein is usually associated with a poorer diagnosis, HuD knockdowns did 
not reveal any in vitro cell phenotypic gain of migration or viability. 
The HuB protein dimerisation and HuC protein multimerisation described in Section 7.1, are 
thought to increase the binding potential of their proteins in binding to themselves and other 
proteins. Further correlating this theory was that HuB and HuC proteins were seen to be major 
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players in the expression of mRNA targets discussed in Section 7.4. HuB knockdown 
influenced changes in RNA levels of four of the six transcripts analysed. Whilst HuC 
knockdown influenced the expression of five of the six transcripts. Additionally, HuB 
knockdown induced a more migrative phenotype in both Neuroblastoma cell lines whilst in 
the SH-SY5Y cell line, HuB knockdown also saw an increase in cell viability. Also observed in 
the SH-SY5Y cells was a more migrative phenotype following HuC and HuR knockdowns and 
greater viability following HuC knockdown. Further highlighting HuB and HuC as large 
influencers in the cellular phenotype. 
The regulatory interactions described in both Neuroblastoma cell lines showed that through 
either direct effect on each other or off-target effects of Hu gene regulation, the regulation 
loops back to affect the expression of a different member of the Hu RNA-binding protein 
family. Despite either mechanism, a high level of regulation is observed if the two models 
were combined. This highlights the need for genome wide studies when considering targets 
for personalised targeted therapies, especially where genes are as highly conserved as the Hu 
family of RNA-binding proteins are. 
Gene expression studies identified targets of Hu genes at RNA level. Of these genes, Hu 
generally displayed a positive regulatory effect on their transcripts upregulating their 
expression or a negative regulatory effect maintaining a steady expression in the cell  through 
direct binding of the mRNA transcript or in-directly through cascade effects. Either way this 
revealed Hu genes collectively as major players in regulating the transcripts of BCL2, EGR1, 
IL10, APOE, CDK1, GSTP1, MAP2K2, MAPK3, ESR1, CTGF, PRKCA, KRAS IGFBP3 and CCND2 in 
the Neuroblastoma cell models. Following generalised classification of the function of these 
genes, it was found the targets contribute to a pathogenic phenotype of many cancer 
hallmarks including energy metabolism, cell survival and proliferation, invasion and 
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metastasis, immune response and angiogenesis. HuB and HuC were on numerous occasions 
found to be potentially acting in a tumour suppressive function. However, overall, the 
regulation of these transcripts contributed to an oncogenic phenotype.  
Interestingly, some of these targets fall into the RAS-MAPK signalling pathway adding a 











Part III: Expression of Hu proteins in Glioblastoma 
Glioblastoma multiforme is an astrocytoma that is challenging to treat because of their 
proliferative and metastatic ability (Ware et al. 2003). With a two-year survival rate for adults 
aged 46-64 of just 7.7% and 2.1% for patients over 65, this highlights the aggressiveness of 
the disease and the need for further research (Bolognani et al. 2012). 
HuR is known to be over-expressed in human gliomas (Bolognani et al. 2012). Its expression 
is often seen localised to the cytoplasm where it’s thought to bind and upregulate cancer-
related mRNA targets such as TNF-α, VEGF and IL-8. Stabilisation of these oncogenes 
promotes a higher grade tumour and poorer prognosis (Nabors et al. 2003). 
Reports highlighting the significance of HuR expression in Glioblastoma were established in 
2001, where the tumours were reported to overexpress HuR in the nucleus of the cells by 
Nabors et al. (2001). HuB has previously been reported to have tumour suppressor properties 
in Glioblastomas (Tarter 2013). 
8.1 The family of Hu RNA-binding protein and their presence in 
Glioblastoma 
The Hu gene expression profiling in Neuroblastoma focused on two cell lines; normal 
astrocytes, SVG p12, as a control and the Glioblastoma cell line, U87-MG. Using relative fold 
change express when analysed (2-∆∆Ct) and ß-Actin as an internalised standard, the expression 
levels of each Hu gene was analysed. The RT-qPCR data of the Glioblastoma cell line was 
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normalised to the control cell line, SVGp12 normal astrocytes cell line which by itself had the 
lowest gene expression of HuB, HuC, HuD and HuR. The upregulated expression of the Hu 
genes in the Glioblastoma cells suggests an additional role in this cell line compared to the 
normal astrocytes. 
HuB gene expression was detected in the cell lines for normal astrocytes and Glioblastoma, 
however a significant upregulation of HuB expression was observed in the U87-MG 
Glioblastoma cells. This observation was also seen in the expression profiles of HuC, HuD and 
HuR gene expression.  
Despite the upregulation of HuB at RNA level in U87-MG cells, HuB protein detection through 
western blotting revealed an almost equal expression of HuB protein in the normal astrocytes 
and Glioblastoma cells.  
HuB protein was detected at its expected size of 38kDa and an additional band at 76kDa that 
could be a dimer. The higher molecular weight band could be indicative of a HuB dimer and 
had a stronger signal then the monomer. The higher molecular weight band in HuB protein 
analysis was also detected in protein analysis of Neuroblastoma cell lines SH-SY5Y and SK-N-
AS (Section 7.1). 
The presence of HuB was confirmed by immunofluorescence. HuB localisation was 
determined as both the nucleus and cytoplasm in normal astrocytes, but only in the cytoplasm 
of the Glioblastoma cells. HuB protein resides in the cytoplasm of undifferentiated neurons 
where it co-localises to the ribosomes controlling mRNA metabolism and neuronal 
differentiation (Gao and Keene 1996). Whilst the cytoplasm is the normal location for HuB, 
an upregulation of cytoplasmic Hu expression is often seen in tumour cells (Antic and Keene 
1997), consistent with the localisation described here. 
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HuC protein showed a much higher expression in the normal astrocytes than in U87-MG cells. 
HuC was detected at the expected size of 39kDa and around four times the expected size at 
156kDa, that could represent a multimer of HuC protein. This was also detected previously in 
Neuroblastoma studies (Section 7.1). Both the monomer and suggested multimer were 
detected in the SVG p12 astrocyte cell line, however only the multimer was found in U87-Mg 
Glioblastoma cells. 
Like HuB, HuC protein was localised to both the nucleus and cytoplasm in normal astrocytes 
but only in the cytoplasm of the Glioblastoma cells, which is described as the normal 
localisation in differentiated neurons (Okano and Darnell 1997).  
The subcellular distribution of Hu proteins is reported to vary amongst tumour cell lines, 
whereby expression of Hu proteins is mostly seen in the cytoplasm. However, in neurons from 
the hippocampus and neocortex, Hu proteins can be equally distributed in both cellular 
compartments (Antic and Keene 1997). The equal distribution between the cytoplasm and 
the nucleus is seen for HuC and HuD proteins in normal astrocytes. The nuclear presence of 
neuronal Hu proteins, observed in the normal astrocytes is known due to their involvement 
in functional regulatory processes such as alternative splicing, polyadenylation and mRNA 
decay. 
The larger protein moieties detected in normal astrocytes and Glioblastoma cells are 
consistent with homo-dimerisation and homo-multimerisation of HuB and HuC proteins, 
respectively. This was also found in the Neuroblastoma cell lines SH-SY5Y and SK-N-AS 
(Section 7.1). Multimerisation as described above is a structural feature that ensures 
specificity for RNA target recognition (Soller and White, Kalpana 2004).  
330 
 
Western blot and immunostaining revealed an absence of HuD protein in normal astrocytes, 
despite a low expression at mRNA level. HuD protein expression in U87-MG cells revealed a 
similar expression level to that of GAPDH protein and immunofluorescence showed HuD 
protein was localised to the cytoplasm. 
HuR protein expression was not detected in SVG p12 astrocytes and showed only a weak 
protein expression in U87-MG Glioblastoma cells, despite a high RNA expression level seen 
with qPCR. HuR protein expression was confirmed Immunofluorescence in both cell lines and 
is mostly located in the nucleus with a weaker signal in the cytoplasm. A nuclear location of 
HuR has been described for many cell types (Hinman and Lou 2008). HuR protein has a 
nuclear-cytoplasmic shuttling sequence (HNS) in the hinge region of the protein which allows 
it to translocate between the two cellular compartments (Fan and Steitz 1998). The 
cytoplasmic localisation of HuR is often correlated to a more aggressive cancer phenotype. 
The localisation of HuR is related to its subcellular function. In the nucleus Hu proteins 
regulate processes such as alternative splicing and preparing mRNA for export in the 
cytoplasm whilst in the cytoplasm, they regulate transcript stability and mRNA decay. HuR 
overexpression and its localisation in the cytoplasm has been described in Glioblastoma.  In 
the cytoplasm it stabilises factors such as VEGF, BCL-2 and IL8. When HuR was silenced, cells 
showed a  decrease in anchorage-independent growth and cell proliferation (Filippova et al. 
2017). A summary of known mRNA targets stabilised by Hu proteins are listed in Table 1.1. 
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8.2 Regulatory interactions of Hu RNA-binding proteins in 
Glioblastoma  
Regulatory interactions between different Hu proteins have been described for 
Neuroblastoma in Section 7.2. The influence of individual and combined Hu knockdowns on 
the expression of the other Hu protein members was analysed in U87-MG cells as well. 
A more efficient knockdown of Hu gene expression was achieved in the combined approach 
in U87-MG cells compared to individual knockdowns for the Hu genes HuC, HuD and HuR. HuB 
knockdown decreased in efficiency following combined Hu gene knockdowns compared to 
the single Hu gene knockdown. 
Western blot analysis confirmed a more efficient knock down was also seen at protein level 
in the combined Hu siRNA transfection. 
Details of the knockdown data and the influences of gene expression between the different 
Hu proteins is summarised in a hypothetical model (Fig. 5.16) of interaction for U87-MG 
Glioblastoma cells. As previously described for Neuroblastoma cell lines, there are three 
potential explanations to interpret the up or down regulation of different Hu proteins after 
an individual or combined Hu gene knockdowns. Firstly as a result of an individual knockdown 
other Hu protein family members become more expressed to compensate for the reduced 
expression of a different Hu family member (Zaharieva et al. 2015b). A second interpretation 
is a regulatory effect, whereby Hu family members target each other’s transcripts stabilising 
and controlling their expression. A third interpretation is that the observed effects could due 




Overall, RNA and protein expression showed that there is a statistically significant change in 
gene expression following a HuB knockdown resulting in a decreased expression of HuC. A 
HuD siRNA knockdown did not significantly change the expression of the other Hu genes. 
When HuR was knocked down a significant decrease in HuC and HuD mRNA levels was 
observed. 
HuR is potentially a positive regulator of HuC and HuD mRNA transcripts since following HuR 
knockdown a significant decrease in HuC and HuD mRNA was also observed. Therefore, upon 
HuR depletion, the control is no longer there so HuC and HuD expression also decreases. 
Alternatively, different HuR targets that influence the expression of HuC and HuD are less 
expressed after HuR knockdown which the leads to a down regulation of HuC and HuD gene 
expression as well. 
HuB was also found to be a positive regulator of HuC, since a knockdown of HuB lead to a 
decreased expression of HuC. This can be explained by the same mechanism described above. 
The decrease of HuB can either directly or indirectly by other HuB targets, influence the 
expression level of HuC mRNA. 
HuC itself negatively regulates HuR expression leading to an increase in HuR mRNA expression 
following HuC knockdown. Utilising its role as an RNA-binding protein enables HuC proteins 
to regulate HuR mRNA transcripts by binding directly to ARE in its 3′-UTR regions, destabilising 
the transcript. Alternatively, HuR gene may compensate for the decreased expression of HuC 
by upregulating its own expression. There is also a possibility that HuC knockdown results in 
off-target effects subsequently upregulating HuR expression. 
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The regulatory effects of HuB and HuC may be linked to the HuB protein dimerisation and 
HuC protein multimerisation in the Glioblastoma cells (Kasashima et al. 2002). These actions 
allow Hu proteins to upregulate mRNA transcripts and further bind with additional Hu 
proteins through the action of forming ribonucleoprotein complexes (Kasashima et al. 2002, 
Hinman et al. 2013). 
Whilst further clarification is required to fully understand the interaction between different 
Hu proteins, a first insight into the complex regulatory network of Hu proteins is described 
above. The interplay and compensatory of the Hu family members could potentially apply to 
other highly conserved RBP members and may need to be considered in targeted therapy 
approaches. 
8.3 Hu proteins and their influence on Glioblastoma cell phenotype 
To understand the contribution of Hu proteins on cellular properties, cell viability, 
morphology and migrative potential were assessed after the described individual or 
combined Hu gene knockdowns. There were no clear changes to the U87-MG cell morphology 
following individual or combined Hu gene knockdowns.  
MTS assays showed that HuB and HuC individual gene knockdowns significantly increased the 
U87-MG cell viability compared to the control non-targeting siRNA cells. This suggests that in 
U87-MG cells, HuB and HuC proteins are potentially functioning to maintain a steady rate of 
cell viability. Without the regulatory control of HuB and HuC proteins in the cells, a possible 
upregulation in cell viability could occur. This would indicate a tumour suppressive effect of 
HuB and HuC knockdown on cell viability and is consistent with effects observed in 
Neuroblastoma (Section 7.3). This tumour suppressive function of HuB particularly, is 
documented in Glioblastoma studies (Tarter 2013). An interpretation of this regulation is that 
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HuB and HuC proteins modulate cell viability by binding to an array of mRNA transcripts, that 
can directly or indirectly affect cell survival and cell death pathways. 
The general cell mobility and invasiveness was measured through a cell migration into an 
agarose gel matrix. When compared to the normal astrocyte cells, SVGp12, the U87-MG cells 
had a more invasive phenotype. This is typical of Glioblastoma cells and present issues during 
treatment since surgery to remove the tumour sees a high re-occurrence rate since the 
tumour cells have already invaded normal brain tissue  (Demuth and Berens 2004).  
In a wound healing assay of U87-MG cells, individual HuB and HuC gene knockdowns along 
with a combined Hu gene knockdown generated an increased directional migratory cell 
response. The increased motility following HuB and HuC gene knockdowns suggests that Hu 
proteins play a role to maintain a relative migratory rate. This is possibly through influencing 
the stability of mRNA transcripts that function directly or indirectly lead into cell migratory 
pathways. The described findings may support genetic studies or give rise to networks in 
which Hu proteins influence. It is also suggestive of HuB and HuC proteins functioning with 
tumour suppressor properties also observed in the cell viability assays in this cell line. 
8.4 Gene targets regulated by Hu RNA-binding proteins 
It is well established that Hu proteins function as post-transcriptional gene regulators 
(Hinman and Lou 2008). To gain a better understanding of the molecular role and function of 
Hu proteins in Glioblastoma, an array of 91 genes were screened following individual and 
combined Hu gene knockdowns. The genes are documented in the National Library of 
Medicine database as key players in the development of Glioblastoma tumours.  
Several parameters were set to identify key target genes of Hu protein regulation. A minimum 
of a 2.0 cycle fold-change difference from the control non-targeting siRNA was required. An 
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additional criterion was set that the expression changes must be consistent between two or 
more of the Hu gene knockdowns. This identified seven genes for further analysis. 
HMOX1, a cell-surface marker was seen upregulated by 54% glioma tissue compared to 
normal brain tissue. Following cell injury or stress, Glioblastoma cell lines showed an 
increased expression of HMOX1 by 81% and the protein was located in the cytoplasm. High 
HMOX1 expression is associated with a decreased survival time. HMOX1 protein was also 
shown to regulate Glioblastoma cell proliferation (Gandini et al. 2014). An additional study 
found HMOX1 expression in pseudopalisading cells that reside in the hypoxic region of 
Glioblastoma tumour. Increased HMOX1 expression correlates with increased invasion in 
Glioblastoma tumours (Ghosh et al. 2016). 
In U87-MG cells, a knockdown of Hu genes individually and combined revealed Heme 
Oxygenase 1 (HMOX1) mRNA transcript was affected by Hu genes showing an increase in its 
expression. This defines Hu genes as negative regulators of HOMX1 expression, however this 
is likely through indirect effects since the HMOX1 transcript does not contain an AU-rich 
sequence in its 3′ prime UTR.  
Insulin-like growth factor-binding protein 3 (IGFBP3) was previously identified to be affected 
by HuR protein regulation in the Neuroblastoma studies (Section 7.4). In Glioblastoma cells, 
it was shown that following all Hu gene knockdowns both individually and combined, IGFBP3 
expression increased. This probably through Hu proteins binding to a Hu binding motif in the 
3′-UTR of IGFBP3 mRNA transcript. This increased expression was observed at the highest 
level following both HuR individual knockdown and the Hu family combined knockdown. It is 
important to consider the effect seen in the combined knockdown is potentially only caused 
by the observed effect on IGFBP3 by the HuR knockdown.  
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The observed regulation suggests that in the U87-MG cells, the Hu genes are regulating the 
IGFBP3 expression in a negative manner to maintain a steady level in the cells. Without Hu 
proteins control and more specifically Hu’s regulatory control, an upregulation in IGFBP3 gene 
expression. 
Since IGFBP3 regulates cell proliferation, differentiation, apoptosis and transformation 
(Clemmons and Jones 1995), maintaining a steady expression level of IGFBP3 in the cells 
ensuring it is not upregulated is suggestive of a tumour suppressor effect. On the contrary, 
HuR in Neuroblastoma SH-SY5Y cells was shown to have a positive regulatory effect inducing 
a potential oncogenic effect and further highlighting variability with Hu gene regulation 
(Section 7.4).  
One of the most important hallmarks of malignant gliomas is their invasive behaviour 
(Demuth and Berens 2004). Matrix metallopeptidases exhibit proteolytic activity towards 
extracellular matrix molecules, which induce a more invasive motile phenotype in cells  
(Fillmore et al. 2001). Matrix metallopeptidase 1 (MMP1) and Matrix metallopeptidase 
(MMP9) gene expression was analysed following individual and combined Hu gene 
knockdowns. MMP1 expression increased significantly following HuC, HuD, HuR individual 
gene knockdowns and a combined Hu gene knockdown in U87-MG cells.  
Whilst the profile of MMP9 expression showed no statistically significant changes due to 
variation in the control, it could still be observed that HuB and HuD gene knockdowns increase 
MMP9 expression. In contrast, HuR gene knockdown decreased MMP9 expression. MMP9 
specifically has been shown to have an AU-rich element in its 3′-UTR to which HuR is known 
to bind providing protection against degradation (Akool et al. 2003). These studies confirm 
findings by Akool et al. (2003), that HuR binds to MMP9. This is also consistent with 
downregulation of MMP1 and MMP9 expression following HuR knockdown and confirms HuR 
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is acting on their mRNA transcripts to maintain their expression in the cell in a positive 
manner. Since MMP expression is correlated with a more motile phenotype, it explains the 
increased invasive phenotype of Glioblastoma cells when compared to normal astrocytes. 
The observed differences in the effect of single Hu proteins on the expression of a single gene, 
and the fact that HuD protein can have both positive and negative effects on MMP expression 
highlights the heterogeneity of Glioblastoma and provides and explanation in the difficulty of 
creating an effective treatment. 
Interestingly, the Ras-dependent MAPK/ERK signalling pathway, that it is consitently 
highlighted in these Hu gene target studies, maintains increased MMP9 levels in immortalised 
keratinocytes through cooperation with α3β1 integrin that stabilises the MMP9 transcript 
(Iyer 2005). 
The Notch signalling pathway is involved in cellular processes such as stem cell proliferation 
and maintenance (Stockhausen et al. 2010). It was established that NOTCH1 is expressed in 
71% of Glioblastoma tumours (Han et al. 2017). Furthermore, knockdown of NOTCH1 mRNA 
in Glioblastoma cells, both in vitro and in vivo induced apoptosis. It was found that Notch 
binds with NF-κB (p65), that plays a key role in the proliferation of Glioblastoma cells (Hai 
et al. 2018). 
Individual HuB knockdown and combined Hu gene knockdown showed that NOTCH1 
expression increased. There was no change in NOTCH1 expression following the other Hu 
genes individual knockdowns, HuB protein could be major player in the combined 
knockdown, and HuB’s reduced expression results in an increase in NOTCH1 expression. The 
observed upregulated expression of NOTCH1 mRNA is suggestive of HuB’s role to maintain a 
steady state of NOTCH1 protein abundance in the U87-MG cells. Without HuBs regulatory 
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control, NOTCH1 expression would be even higher in the cells which is indicative of tumour 
suppressor role of HuB on the NOTCH1 transcript.  
The gene expression profile of alpha-1 type I collagen (COL1A1) and Vascular cell adhesion 
protein 1 (VCAM1) did not produce any statistically significant data due to large unfortunate 
variation in the control. There was an observable progressive decrease in expression in 
COL1A1 from HuB to HuC to HuD to HuR knockdown, suggesting there may be a regulatory 
mechanism of HuR on COL1A1, but this would need repeating to clarify. 
8.5 Concluding remarks 
Gene analysis showed an upregulated expression of all Hu genes in the U87-MG 
Glioblastoma cells when compared to the control normal astrocytes. Neuronal Hu proteins 
showed their normal cytoplasmic localisation. HuR protein was found in both the cytoplasm 
and the nucleus. HuR is normally localised in the nucleus and a cytoplasmic HuR localisation 
has been associated with a more aggressive cancer and poor survival rate. This is thought to 
be due to HuR’s ability to stabilise transcripts encoding for oncogenes and transcripts 
involved in cancer progression. On a cellular level, in vitro studies did not show any changes 
in the viability or migration of U87-MG cells after the HuR knockdown. 
The HuB protein dimerisation and HuC protein multimerisation are thought to contribute to 
a greater binding potential of the Hu proteins (Kasashima et al. 2002). HuB and HuC were 
shown to influence the same number of targets as were HuD and HuR. Interesting, on the 
initial gene array HuB and HuC Knockdown did affect more target genes but this would need 
further analysis to confirm this observation. In the Glioblastoma cells, HuB and HuC were 
revealed as major players in modulating cell viability and motility determined by MTS and 
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wound healing assay, respectively. When HuB and HuC were knocked down, an increase in 
the viability and migration was observed suggesting their targets on a molecular level may 
influence cell anchorage and adhesion pathways as well as cell survival and cell death 
pathways.  
From the collected data, a regulatory Hu network was hypothesised within the Glioblastoma 
U87-MG cells. The described regulations correspond to similar interaction found in the 
Neuroblastoma cell lines. The main findings of the regulatory mechanisms are that HuB is a 
positively regulator of HuC and HuR positively regulates HuC and HuD mRNA transcripts. 
Whilst HuC is a negative regulator of HuR, this shows the complex compensatory interactions 
of this highly conserved protein family members which has to be considered in target specific 
therapies.  
Gene expression studies in the U87-MG Glioblastoma cell line identified targets of Hu genes 
at RNA level. Mainly a negative regulatory effect was observed that maintained a steady 
expression of target transcripts. The transcripts regulated by Hu proteins were NOTCH1, 
HMOX1, IGFBP3, MMP1. A knockdown of all Hu proteins resulted in an increase in HMOX1 
expression. Maintaining a low HMOX1 expression in cells is associated with an increased 
survival rate suggesting a tumour suppressive effect of Hu proteins (Gandini et al. 2014). The 
same effect was observed for IGFBP3 mRNA levels which increased after Hu knockdowns. 
Since IGFBP3 is responsible for cell proliferation and differentiation, a coordinated regulation 
prevents cells from uncontrolled growth (Clemmons and Jones 1995).  
Also, MMP1 expression was negatively controlled by Hu proteins and after Hu knockdown an 
increase in expression was observed. HuB knockdown resulted in an increase in NOTCH1 
mRNA again showing the negative regulatory control of the Hu proteins on this set of targets.  
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The negative control of this set of target genes by Hu proteins suggest a role for Hu proteins 
as tumour suppressors. To elucidate the role of Hu proteins in tumorigenesis of Glioblastoma 
a genome wide expression analysis to look at the influence of Hu proteins on cancer related 


























Conclusions and future work 
Part IV: Overall effect of Hu proteins in cancers 
In this thesis, it has been shown that Hu proteins show varied expression profiles between 
Non-small cell lung cancer, Small cell lung cancer, Neuroblastoma and Glioblastoma. 
Knockdown studies in Neuroblastoma and Glioblastoma cell lines allowed an insight in the 
role of these proteins at a cellular level but also on a molecular level. Regulatory interactions 
were observed with the Hu family of RNA-binding proteins. And finally, an abundance of gene 
targets were identified to which Hu genes had a positive or negatively regulatory effect on. 
9.1 Influence of Hu proteins on cellular properties in cancer 
An increased cell motility could be observed after a HuB knockdown in both Neuroblastoma 
and Glioblastoma cell lines, SH-SY5Y, SK-N-AS and U87-MG. This suggests that in these cells, 
HuB is acting on transcripts to maintain a moderate level of migration control that results in 
a high mobility of these cell after HuB knockdown. These findings supports research 
presented by Tarter (2013) where HuB is described as a potential tumour suppressor. Their 
study found that HuB controls the expression of genes involved in cell adhesion and motility 
and that a loss of HuB expression increases the degree of stemness in glioma cells. 
HuB and HuC gene knockdowns increased cell viability in SH-SY5Y Neuroblastoma cells and 
U87-MG Glioblastoma. If HuB and HuC protein expression is downregulated, cell viability 
increases again highlighting a potential tumour suppressor mechanism of these two Hu 
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proteins. None of the Hu gene knockdowns resulted in a cell morphology change in the 
Neuroblastoma and Glioblastoma cell models used. 
9.2 Regulatory interactions of Hu proteins in cancer 
Assessing the effect of regulatory influences of different Hu family proteins on each other’s 
gene expression in Neuroblastoma and Glioblastoma showed some similarities. HuR was 
found to positively regulate the expression of HuC in all cell models. 
In the SH-SY5Y Neuroblastoma cell line and U87-MG Glioblastoma cell line, additional 
similarities in the gene expression of other Hu proteins regulation were observed. HuR 
positively regulated HuD and HuC negatively regulated HuR. The HuR and HuC interactions 
reveal they can both regulate each other’s proteins levels ensuring an abundance of each 
protein in the cells. A summary of the Hu protein regulation in regard to the gene expression 
of other family members in in Neuroblastoma and Glioblastoma is displayed in Fig. 9.1. 
 
 
Figure 9.1: Hypothesised regulatory interactions achieved by the Hu family of RNA-binding 
proteins in Neuroblastoma and Glioblastoma cell models. Overlay of the regulatory pattern 
observed in Neuroblastoma and Glioblastoma cell lines.  
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9.3 Gene targets regulated by Hu proteins 
Hu proteins have been shown to regulate the expression of an array of different mRNA 
transcripts. When analysed, some of the Hu proteins showed oncogenic as well as tumour 
suppressive effects depending on the knocked down Hu protein. Analysis of effected target 
genes after Hu gene knockdowns showed that many of the target genes are members of the 
MAPK signalling pathway. Some targets were upstream regulators of the pathways and others 
were downstream effectors. In addition, some of the other targets have been closely linked 
to the MAPK signalling pathway. 
The evolutionary conserved family of mitogen-activated protein kinases (MAPKs) includes 
extracellular signal-regulated kinase (ERK), p38 isoforms, and c-Jun N-terminal kinase (JNK) 
(Schaeffer and Weber 1999, Chakraborti et al. 2003). The MAPK pathways are activated by 
diverse extracellular and intracellular stimuli controls fundamental cellular processes such 
as growth, proliferation, differentiation, migration and apoptosis through a series of 
phosphorylation events (Dhillon et al. 2007). Interestingly, deregulation of the MAPK 
signalling pathway has been implicated in many neurodegenerative diseases including 
Alzheimer's disease and Parkinson's disease (Kim and Choi 2010). These disorders are also 
linked to the paraneoplastic Hu syndrome. 
Doller et al. (2008) previously identified a link between Hu proteins and MAPK showing that 
cytoplasmic shuttling of HuR is potentially regulated by MAPK and its downstream kinases 
MK2, AMPK PKC family. AMPK phosphorylates and acetylates importin-a1, a nuclear 
transportation protein resulting in nuclear accumulation of HuR (Kim et al 2008). This nuclear 
HuR is then transported to the cytoplasm in a ratio-driven exchange.  They concluded MAP 
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kinases increase cytoplasmic HuR and therefore may participate in stabilisation or translation 
or both of TNFa, IL6, IL8, COX-2 GMCSF, uPa and UPAR (Doller et al 2008).  
 
Summarised in Fig. 9.2. is an extended version of the MAPK signalling pathway showing the 
interactions between signalling pathway components from the cell surface to gene 
transcription. Hu proteins seem to influence the regulation of different targets of the network 
however the underlying mechanism and the interplay of these targets must be determined. 
In relapsed Neuroblastomas, eighteen somatic mutations were identified that initiated  the 
RAS-MAPK signalling pathway (Eleveld et al. 2015).  
Further gene profiling would be required to confirm the influence of Hu proteins on other 
MAPK signalling pathways targets and if the knockdown would influence upstream or 




Figure 9.2: Extended MAPK signalling pathway. MAPK signalling pathway with genes highlighted in black that are affected by Hu gene regulation. 
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9.4 Therapeutic intervention: Hu proteins as potential targets in 
screening, diagnosis, monitoring and treatment of cancers 
The identification of RBPs, mRNA targets and underlying molecular mechanism can give rise 
to new targets for cancer therapy and a need for the development of RNA-based therapeutics 
to treat human diseases (Wurth 2012, Cooper. et al. 2009).  
The aberrant expression of Hu protein observed in SCLC, Neuroblastoma and Glioblastoma 
could define Hu expression as biomarker in diagnosing cancer.  
Pagliarini et al. (2015) concluded future treatments for cancer will include screening individual 
patients for specific splicing-alterations and developing anti-cancer treatments in response to 
these findings. Personalised, targeted treatments based on the molecular genetics of tumours 
provides the key to future treatment (Dietel and Sers 2006).  
In this thesis, an individual pattern of Hu gene targets was established and have been 
implicated in the pathogenicity of cancers. Within the Hu family, differential Hu protein 
members showed an upregulation of targets whilst others downregulated the same target 
depending on the transcripts role but also highlighting the different regulatory effect Hu 
proteins can have on mRNA transcripts’ for example, HuR and HuB seemed to show both 
oncogenic and tumour suppressive regulation within on cell line. This results in HuB and HuC 
showing both oncogenic and tumour suppressive phenotypes within one cell line. A more in 
depth study of individual Hu genes and their effects would therefore be required before 
conclusively understanding the role of Hu proteins in Small cell lung cancer, Neuroblastoma 
and Glioblastoma. 
RBPs were considered relatively ‘undruggable’ targets due to their structure and deficiency 
in well-defined binding pockets (Wu et al. 2015). Treatment with systemic immunotoxin 
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therapy in patients with solid tumours has been unsuccessful due to poor penetration into 
the tumour (Ehrlich et al. 2014). However, the development of RNA interference (RNAi) to 
silence any gene gives rise to a new approach of therapeutic intervention. Current research 
stems the idea of developing methods to deliver siRNAs to the site of action in cells of target 
tissues (Kanasty et al. 2013). A recent strategy suggested by Jimbo et al. (2015), uses lipidoid 
nanoparticles to deliver siRNA to target tumour sites. Other mechanisms to target RNA in cells 
include the use of antisense oligonucleotides, antisense snRNA and RNA interference (Cooper 
et al. 2009). 
9.5 Future Research 
siRNA used in this thesis for knocking down the expression of target genes isn’t as efficient as 
‘Clustered regularly interspaced in between short palindromic repeats’ (CRISPR). This 
technology allows editing of the genome with great specificity, precision and efficiency.  
The inability to knockdown Hu proteins in lung cancer using siRNA interference proved a huge 
limitation therefore further experiment could be performed using CRISPR. It is a natural 
defence mechanism found in many of bacteria. This new method would allow a complete 
knockout of the Hu genes, guaranteeing to reveal the extent of its effects. 
This CRISPR technology would enable 100% knockouts in all the studies rather than a 
knockdown that leaves some functioning gene. Since, the Hu proteins can also auto-regulate 
themselves and a small amount of remaining protein can be sufficient to influence its own 
expression and target other mRNAs for regulation. This technology along with RNA-seq and 
ribosomal profiling can allow a more in-depth quantifiable level of mRNA and protein levels 
following knockout experiments. 
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As advances in medical science move towards personalised targeted treatments, core 
signalling pathways will need to be established to ensure these treatments will be 100% 
effective. Here, genetic compensation was observed following knockdown of the Hu gene in 
combination that could have adverse effect in a targeted therapy. Additionally, miRNA 
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